var title_f1_25_1424="Paradigm of gender and sexuality";
var content_f1_25_1424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Paradigm of gender and sexuality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 386px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1424=[""].join("\n");
var outline_f1_25_1424=null;
var title_f1_25_1425="Lithotomy position";
var content_f1_25_1425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Lithotomy position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 235px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADrAcYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poopCcUALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJk0c0ALRWfq+taZo0aPq+oWlkrnCG4lVN544GTz1HT1rHtPH/hS6aNY9f09TJuCebKIwxXqAWxzSuth8ravY6iiore4huYhLbTRzRno0bBgfxFSEkUxbC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZozQAtFJmjNAC0UmaM0ALRSZpQc0AFFFFABSN1paRutACUUUUAFFFFABRRRQAVHcTw2sLTXMscMS9XkYKB9Saz/E2uWfhzRbjU9RZhDEOFRSzOx4VVA6knAr5o8V63rnjbU7Y67cPZQBmmGm203yRwjAUP/fctnLA4GcehrKpVUPU6KGHlVfkd/47+L92142l+CII3KhvtGqTqWS2Cnnan8TkdFJ784rjrTxL4qe1gmvfE2qpczIN6bo1QOwOAFCAjqOM5B71z92vm3MGmokaWDEoYo2GGVQGbd1wM7VweuWyelP1p2NxA6OSbEreSRKGDOu4g8jg8B/lIPQVxyqzl1PThh6cE9LmHrCeJLS+inEenXVtLMomlUGS5lZmwGJmJyxz1J+pq/bW0eoC48i+u59QAKzW9+gUjPQCMjCcDh1Bz3J5rW1RFl02R0Yt5YFxEyY5K/MpGeOcd/WqmvWgnjj1KK1We4giIaFiR5kLYLoCP4hgEHpke5qOa+5ryct7bf1sN0q0exdX0Zjp93GyhmtJGs5YlKjcWCZVj6cFa9W+HnxNvoNRt9H8Xl5IbhvLt9TcIoVuipLt4+bHD4HJAPJryIro99LBK9xqEchHmQhp5YwoIzlf4QuPfHFWJrWVtOljtrptRtmQxsksgLjHGUcD7wPODnkdqqFRwdzKpQhVVvyPr0iiuX+F+tS+Ifh9oeqXDSNLPbjc8gwzkEqWIycE4zXUV6S1PFas7BRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACig4VSzEADkk9qxG8WeHFLhte0oFDtYfa4+D6HmgDboqtY31nqEKzWF3b3UTch4ZFdT+INWaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKVelJSr0oAWiiigApG60tI3WgBKMUorxvwl/bniWdb/WNf1vS7fU7qd7FLeeIR+WjOogwUyGwvmAjqoPTBoA9jxS4rzLWtJ8Q6SqHVfFGrXfh5FxJcWixw3VtyRvchT5iAEZIwRgnB7aNn8NvC0gju7lLrWZGhCrcX19Jcbl6hhlsc5zkDvQJux2t9d22n2c13fTx29rCheSWVgqoo6kk9K4tPFWseJvLbwPZ240l+f7Z1EMIpMNg+TEMPJwDhiVX0JqaX4c+DWjYT+H7BosZYSAlce4JxiuTs459Zu9R1Pwrf65Z+F7YSBpraVp31FgCGS1ibIWNRwrrj5gNoIFOxPNdaGR8W5r5PEmmaZdapdXRS3a9njIWOL5nKxAIB/CRKdxOeF5NcDpjCfUNUnAbaJltgcYBEa84z/tO4z0+UVqapHpkOsXFxorSS6NNbQ3EE0jF5ZgEPmM7N8xfeGBDcg5GBWboRZ9Kt5pY1jluAZ3Vem5yWP8682u7zZ72DjalH7yvYQuNalkkEUbrb7njRSG3SSEktknnCKPqD7VbRY/7ZlfzMzG1RTFt6LvfDZ9zkY9qztOgeyv9IjuFPnNpvkPIp3BnTacFu/BJB+tP1qeW31aw+zhvtFxDNbwnaSokLRkFj0wFDtz6H1rPdm6dlcs6aVhuriwRg0EfMR6hM8mP/gORj2Iz71L6WODT9IfUPtM8Md0iT/8spJRhlJH90nqDVjUljtINPSBgrLdRBexbLYc475DHP1qK7niutVnWSIXVlp0W+WJXwXlY425xgMqZbuQWXiiOrFPSLRo6joWreCrhdKvQ11bciB14E6g9Y88Fum6M4wckcHFU2uILxWNi5gv0XEQkjMTEk5C7WAyGIx+de8a4LZ7MaVNpkutMIgRBIobcF4DPI+FDHB5zkn61zcXhxdb1CPTdU8GRWOmuGLXj6pHJMpP3SqJuJOSRknjH4Vo6d9UcsMTZKMjrfgpZx2Hwr8P20UyS7IDuKEEKxdiy5HXBJH4V29eb/AaWZvCepQSrceXbatdwwSSrw8avhSp/i6cn1zXpFehHbU8qVruwUUUUyQooooAKKKKACiiigAooooAKKKKACiiigApsjpFG8krKsaAszE8ADuadXmfxZvZtdvrDwHpFw8U+oYuNUmiJDW9ip+bkdDIcIOe5pN21AyGe9+Kl9dzXly0Hw8SQJa20OY5NWKHmR2wGEO7ooxu2g11Fp4Z8PWdulvaaBpMcKDaqi0Q8e5IyfxrThhhtbaG2tYlhtoUEcUacKigYAH0FOrmlJyZg5NnG6p8ONEmnF74da48MawoOy70l/KHPZovuMvtgdav6D491DSdXttB+IlvbWV1cbltNXgO2zvCP4fm/wBXJjnaT9K2muGl3JZpvYHBlP3F/wAfoKjvdJsNS0mfTNWto76yn/10c43Bz6+x9COlEajQ4zZ2ZFFeRabqOrfDO6WHV7u41XwI2I4ryUb7jSewWUgZeHoN/Ve/FetQTRXEEc9vIssMih0dDlWUjIIPcV0ppq6NU7j6KKKYwooooAKKKKACiiigAooooAKKKKACiiigApV6UlKvSgBaKKKACkbrS0jdaAI55kt7eWeY7Y41LsfQAZNeaeDIVHwl0LUIIJjJbP8A2hEqyLbsytKxO5pB8qlGJPTK5GRmuu+Il1LY+AfEVzbsqzR6fOyFhkBthwSO/wBKp67o00Hwuu9Ftv8ASZ4dLNqnRfMKxbe5wM4oEzp3ljEBlaRPICli5I27cZyT0xiuJ0bVtJ0vUjDo1/Y3Ph+5cAmC8SRLKdicJtGdqOenOA2egIrpdLt4L7wvaW04SW2nskikUNlWUoARkdsZ6Vzei+HPCviHSd1/4a0Nr2FfsV1H9nWRoWQbfLLsoY4GMH3BHrTJ01uU/EN2fGHiyPwrYgy6JZ5l1y4RvkZsYSzJ7ls7mAPAABxmum1vWtP8L2ls97GbTSkHltcJHiG1UAbd+PuqegOMDvirujaVp+iadFYaRZwWVnEMJFCgVR6n3J7k8mrUgDKyuoZWGCCMgj0NUkYykvkePfE/wzaxwNr+jbZLPUHIuZY3Qwwl1IEq4HKsx+Y5PJBHevNtBk8zSrZSjo8I+zyK4wVZDsYfmK9o1f4cCG0v4fCN+NLtr4sbrS5086xnLFdxCdYmIB5Q8ZzivFJtI1Twv4glttc0+SxkvCOIw0tvK4HEscuMElcK4ODkA45zXDiaTvzI9jL8TG3s2/6/r8yqpEenaTMkRgS2uRAEySwjLNCBzyc/uyfarV4gk8QaZnd+6huJVwSOfkTkdDw5/wA5qrqE6st5bAnfDfWjEM+4kPIhyB2GRgD6103hjw7Z+KPGKW2orem1s7F55DbzmEFmlQIrMOSDsfgenXpXMldnozlyRv6fnY53W3uZ7u0sdOEX2oH7S0kvKQIpwHKj7x3HKrxkr14rovhv4cm1PWrEQxv/AMI7pkhuZrudNwvrgMSEU8BvmO9mGRkACvRP+Fb+EN03maOZllYMUlvJ3QAADaFL428Zwc8k+uK6qCKK3gjgtoo4II1CRxRIERFHQKBwB7CrSUTCUpVLq1r/ANWG3stzHayyWdut1cgZSF5RGHOehY5A4rgfCWoxzfE/VIooNaDwWTWk8t9OZo0nWVZGjiYn7oDDGABXodR3E8drbXFzM2yGJGllbH8KjJPHXAFVGVk0ZVKd2pX2Mfw02o6T4/ubKbVSNE1FTcWNk9spVZQCZY0kGCuDh9pBGDwcg16KeteY62LTxPp0djp98ltrixRatZRmQLPCQwMbsoPCMTtOeMNXc+FdYTxB4a07Vol2LdwrLt9CeoHtnNddKTa1OCtFRldbGrRRRWhkFFFFABRRRQAUUUUAFFFFABRRRQAUUUyaVLeCSaZwkUal3Y9AAMk0AY3jXxLZ+EfDd3q9+rSLEAsUEZHmXEpOEjQHqzHjFcf4G0e/s47/AFvxCQ3iPWpBPdLwRaxjPl2yn+6gOPc5NZnhh5/H2tweNdXgEel2pdNBs2JOFzhrtweNzYwvHA5ruiSTzWFSd9EZTl0EpsqGSKRA20spUN6ZFOorEzK1nKAiW7J5U0a42diB3U9xVmq+oL/o/mqB5kJEin6dR+IqwCGAYdCMigEBwysjqrxsCrKwyGB6gg9RXJ6Def8ACu9bg0i5YjwfqMuzT5nPy6dcMc/Z2PaNj9wnocr6V1lVdY02z1rSbrTNTi82zuUMcig4PsQezA4IPYirjLldyoyszsDRXnnw28Q6hDql34M8TSSz6tp8XnW2oSbQNQtS2FkwP414VvcZ716HXSnc3CiiimAUUUUAFFFFABRRRQAUUUUAFFFFABSr0pKVelAC0UUUAFI3WlpG60Ac18Qnc+GTbReW0l5dW1r5T4IlR5kEiYPXMfmcdcZrc1CF7ixuoIWCySRMisTjBIIB4rlfiVbi5fwnG3AGvWz52q33VkPQgjt17dsHBrsv4qBM5v4eSrL4H0bZObjy7cQNKd3zshKMfm56qeTUWuTWnhWa68QTNImnzeXHeRxRKQHLhVnP8RxkKQM5BBxxS+CfKsk1bQ4VVV0q7ZFCBsBJQJlBLElmxJyeBnpUvj+Fp/BmrCOBZ5IovtEcbMVDPGRIuSCDjKg9aZD3NmCaK4gSa3kSWGQbkdGDKw9QR1px61wWtRaxa6DY654DaMWzxi6udLjtVYXKOi/PEDgh1GCEDKG6cHr03h7VJdWsYLzy4WtZ4RNFPE5w+ScKUI3KQNuQehyO1UmYzhpdGtVTVNPs9W0+ax1O2iurOYYeKVcq3OR+R5zVukqjG9tj5/8AiJ4MPhWX+0VIm0D92m7Zl7UR5KCU/wASdMN1BAz1zW58KbFrHQtU1ia0m/trUE+1LBMjRkWqKfJRWwevzMevzMeK9VuJbC+mutJuGhmdoMzWr87omypyO6nkGvnjxnokvhnVr3w7BfanBpU6rNHEbyR0niY7RvG4fdYBT6jHrmuKtTjC8+57GExE66VJ7rX1/wCGPbtLvY9S0uzv7fPlXMSyqCQSuRypx3B4PuKsV5V8ILvVTealDa2s50cSbpo58Rrb3BYBxE2PnGMswGQT0OTivViMHFczPRT1t2ErnvH5t/8AhF549RuIrXS5ZI47+eV9gS3LjzMHruIG0AAnLDtk10VQ3Vpb3iRpdwpMiSJMquMgOjBkb6hgD+FNOzuKa5otI8/8MaXovi3xHPB4Zt7y38OPayJqGqW6lDqLjYqQecx8zYqsxwAMgLyQK9osLO306xt7KyiWG2t41ijjUYCqBgCvNvCDmL4q3T6ppx0u7vdKAtUjvVlhn2TEzMVXA8zDwc4ztB5r1A9a7obHky3CiiiqJCiiigAooooAKKKMUAFFLikx70AFFLikIoAK85+OEr32g6Z4Wt2xceI76OyYDqIB88zeoARcZHdh616MOteWpKniL4wapfq3m2fhuzGnQYbKi5mw8pxjhgiopxnr6ipk7K4m7K51ixxQxRwW0Yjt4lEcaKMBVAwB+QooorlOcKKKBz0oAgv222FwfVCo+p4FTIpVFU9VABqs7C7uFjQ5hibdIw6Mw6L/AFNWqQCjmsbWfFGgaJceRq2sWdtcY3eSz7pAPdVyR+VbcRw4PGe2fWuC+Fpsbawn06e1Ft4qtneXVFuIgLiRnckS7jkvGQQAwOO3FPpc1o0vaS5bld/Edrd/EHwzrzw3mnaFbCaxGpXMZiW7llA2RbW5EeRkOwALYAr2gEMAwOQea5HULaDUrO4s9ShS7tLhDHNDMNyyKeoP+eKpeD9XvtL1P/hHvEU8Um/c2l3hbBuohyUYH/lrGMbv7ww3rWlOotjrqYf2a0O7oooroMAooooAKKKKACiiigAooooAKKKKAClXpSUq9KAFooooAKz9c1a00TT3vb+QrGCEVVGXkc8KiDuxPAFaFeZfE201i38WaHrluNLuNOtUMMKX4k8u1unJxOxU4AI2oGI+XcT3oAwPidPrun3nhLxNrAt0hj1uBI7VmAj06KT5HeQ9ZJNpbnIVMng8Gvaj1rxH47ajql98LdWt9c0SXTruBY7qC4gnWeB2RgWTeF3KSm/qB6Z5r1vw1rFv4g8P6dq9mQYL2BJ1w27G4Zxnvg5H4UImRkXsI07x7Z34YpFqdubOUZVVMqHfGxJOS23eoAHrnpXTMAVIOCD2PesDx5pk2peHpGsgTqFk63tpgZJljO4LjvnBXHvWlouoxaxo1lqNvgRXUKygZzjI5GfY8U0RLuc94F/4lD33hiZiH09/NtCx5ltZCSp9yrbkP0Hris2WP/hBvFCy20KL4Y1y6AuArN/oV4+cSAdBHIQA2MYcg9Ca0PFf3dN8U6QVujppdpvIYOZ7Uj96q4+8VxuA9QQOTW/cR2muaNJEWEtjfQFdyYOUdeo6joaaJb69GXDxSVyngG/nS3u/DupyiXVNEKQPIXBaeAj9zMR2LKOfcGurq07nPOPK7HNeMYYbZLLXnYRSaTKJHlLbR5DkJKG4ORtO7AGSUAGMmuI/aFsYv7J0rUZmEaJNJYysMKSsyEAbv4QGUHjuBXpfiDT4tW0LUdOnVGiureSEhxlfmUjJHtnNeea0w1n4I6XPqECSzKLNsMNw3pOibufXBPPrWdSPNFxN8NUcJRmuhqfD/Sf7G8KWCyPLJeXUSXV00i7T5rouRt6KAABj2qxFYXulD/iWTSXtqWybS7mJZBzxFIckckcOSODg1q6nf2dpdul1d20DM7BVklVCcemT6YqQ8H3rz7tHuqKkt9Sjpeq2epGVbd3W4hbbLbTKY5Yz7qecejDIPY1xPjbxXd+ErhbSPWE1PWLvEkFlNYxxRwxlsbpJQyhQSQAWPOOASRXbalpdrqJWSZWjuo1KxXUJ2zRA/wB1v6HIPpUEeh2i6xq9/MFuBqawLNbzxh48xAgEBsjnI4xgEU4uKInGpLT8SXwTo2o3GpweIPEF/pdxfRW0lokGmKWhi3sjsd7EsW+QDsMfWu5x6V5bcfD7wpMsgj0WKzaSTzWexlktmL5zn5GA/Sq+trb+FDFOnjbV9KaVgY7a7kF+JsAghYmBkJP+ycAgV0Rqx2RyVKE170j1qjFeT2viv4iavdsNL0TSbTTWzsu9USWB9p6ERbix4x1xU9t4U1eRZZtY8deIpb+Y7mNi0dvBGfRI9p4HucnvVupFHO5JHqOKK8zbSfGNpB/xKvHBnlX7qanp0bo3+8yEN+VOj8b+KtGmx4q8J/aLLe26+0Kb7QI0wMFoWw/XOSM496FOLBSTPSutZPiXxLovhiy+16/qdtYwZwvmv8zn0VerH2AJrhr/AOJ0mu24sfh9pt5d6vOv/HxfWrwWtkMkFpSwBJGMhFyTkdKXQvBlpZaiNZ12dtd8TNy+oXS5ERznbBGeIkGeAOfeiU1ETkkIfGPjHxG5/wCEW8PQ6Vpjj93qWuMUdhz8yW6/NjoRuI9xTx4b1q6JbXPG2t3JbBMenhLGMHAHBUFsfjXUMxY8kk03vWLqSZm5tnI/8K/8KW0bzT2Esx6vJPe3EjOffMmCT9KfB4A8LuiyS6DbRysuCFkkzjsCd3JroU/0ucSH/j2ib5P9tv730HarVRzPuTzM5UeA9It5DLo9zq2jXDAAyWGoSrux03K5ZWx6EVHd3fjvwqVvYLtPF+kRLieze3SC+A/vIynbIR6YBrpIiLi7Mw5iiGxD2LH7xH8qtgkHg1UZtDU2Lb+NdGu/BFz4psrkSabb28k8m4ENGUBLI69VYEYIxkVyfwu0240/wVaz6gGGp6o76pebiCfMmO/BI64UqPwrnviH4civPFOl6fpUzW48STD+27SNsLcW0BWQzkfwvlRGW/iDYOa9NkILHAAHYAcAelVOfMkVOV0NopsjpGjPIwVFGST2quPOuhnLW9uemP8AWP7/AOyP1rIzJZ7mKE7XbMh6Ig3MfwqIpcXAxL+4hPVFOXYe57VPDDHAu2FAo746n6mn0AJGixoqRqFReAB2qO6kMNrLIOqqSM+vb9cVLVaf9/dJAOUjIklPv/Cv9aAZYXIVd3LYGT71yHxOjlstKtfE2mwh9W0WZGjAO0zwyMEkgJ7hgRweMgGuw71yvxCc3sOk+HIWP2nV7tC4GMpbRESSufQDCjPqwFUty4X5lY3NL1Gy1exjvtMmE1rISAR1VgcMjDsyngioNf0Wz17T/sl+rDY4lhniO2W3lH3ZI26qw9fwOQap3mmnS9au9c0a2dzd4/tGyiP/AB8Y6TRr084Dg/3xx1xnYs7mC9tYrq0lWa3lXcki9GH+eMdQeDzWb01R7cXzLknuV/BniO7hvh4c8VyRJrCgm0uEG2PUolAzIg6K4yNydQQSPlrt+lcLr+j2mu6cbS9MqYYSwzwttlt5R92SNuzD9eh4NL4e8VXOm3un6B4wljOo3ClbXU408u3vWH8GCfklxzs6Hkr6V00ql9GcNai4O/Q7mig0VsYBRRRQAUUUUAFFFFABRRRQAUq9KSlXpQAtFFFABUF9awX1ncWl3GJbaeNopUPRlYEEH6gmp6Q9RQBzPgm8+16dqGl3SKx0q6k08hju8yJQCjHPXKMASepDHpWX8PozoGpat4TlEaRW7tfaaqPkGzkb7oH8Ox9y49xjirOneVD8R/EFjNAP+JhZwXPmFz+8VQYyoB9M9R61i6jp9xbiO5063e68Q+GHb7PEhCyXdk+N0XJwcqMDPRkXgUAz0gnmuejiTw3PdT3F9MdLup18uF0Z/s8rk5wwzhCSODwCeozitTR9TttZ0m11GxYtbXMYkTIwR6gjsQcgjsQamvLaG8s57a5TfBMhjkXJG5SMEZHNUZbPUw4F/sTxAIEYLp+pFnjjwqrDcDlgoGOHHzY5+YE8ZrMtG/4RPxFDphDDQtUlYWRCki2uTl2iZv4Vfkrn+LI7itvV9JM+gfYrA7biBFa0aSRvlkQfIWbk4yACeuCe9FrJZ+JfDyG7gjmtrqMpNCeQHBIdQf8AZdSAR3GQehoIck1qZPjGeXRdU0jXY5fLso5PseooEU+ZFIcRuTjd+7k5AHZ345rqiMHmvPrCSbVbDXfAuvXRl1eGEi3uJiEa8gYZjmGO6nCsRzlc966jwdfjU/CulXYlEpkt1DSBSoZl+ViAecZBppkVI2RoWN1Fe20VzbsWikGRkYI9iDyCDwQeQQQa8j8MrqviPT73R/tV5p/h6w1C7trieOci4vG8xv3Ub8lIlDDLdSeBgDNb/jzXx4G0fxHcafaOZ5bcXNqiHCGd3WHpgAHc6scEkgE4HfV8N6a+jeHNM02V2kmtbdY5XbBLSdXJxwTuLcisa9RxWh1YKgpy12LENhZwEtDaQByqKzlAXYKu1cseTgcZJqW4MwgkNsIzPj5BKSEJ9yOcfSn0tcNz2uVJWQUqgswAGSeAKSua8by3M8Wl6HYXEltca1dfZnmi+/FbqpeZlPY7QFB9XFNK7sTUmoRcmQ3viS61W8uNK8FRw3d5ETHcalMCbOybODkj/WyD+4v4kVp+HPDNjoUsl4JJ7/WZwBcandnfPJ7A9EXr8q4H1rV0+ztdM0620/ToI7aytkEcMMYwqqP6+p6k1NWm2iPFq15VXqKSTSUUUjEKUMQRg0lKCM8nApgRW1xJNCxkdmIkdRk9MGpKrabzZIx6uWf8yas0kCCq94zELbxnEk2Rn+6vc/0qx9TgDkmqUMojie8myXmOI1HUr/Co+vWhiZbxHDD1VIkAHPAAqsS94MJujtT1fGGkHoPQe9OS3aVlkvMM45WMfcT/ABPvVk8nJoARVVVCqoVQMADoBT4xuYD1OKbXPeP9Rm07wxNHYn/iaai66fYqOSZpPlyP91dzE9ttNalJX0Kvgk/2xqut+KXyY7uX7Dp+c8WsJI3D/fk3N74FdX656DnntVbS9Pg0nSbHTLMAW1nAkEfuFAGfx6/jRe5k8q2UkecSGI7IOT/QUNg2NhH2t1nkH7leYkI6/wC2f6VcJz1pBgAADAHAHpRSEFFFNlkSGJpJDhF6/wCFAEdzN5KDYN0znbGnqf8AAUtrD5MYXO5ydzt/eY96bbRPl7m5ASQrnDHiJPQnt6k1zM/iq51iaWy8DW8d80ZKS6tcZFjA3opHMzD+6vHHJprUcYubsjW8S+IbPw/DCJklutQuTttNPtxunuW9FHYerHgVR8M6Pew3t1rniGSKTXbxBGUhYtFZQA5WCM9xnlm/ibnoBU/h3w7b6PLcXss0uoa1dgC61G55lkH91R0RB2RePrW3Uyl0R6uHwvs/eluFc5PZyeH9VvtXs2nm0u9PnX9mCX8mXvcxjryB86j03AEgiujoUlSCDgj0qU7HVOHN6jIpEmhjmhdZIZFDpIhyrKehB7imXdtBe2stteQpPbyrteNxkEf0PoRyO1Yf9nv4dubu90a3abT7lzPdWEYyyPjmSHLALnGWQA5P3QCa34JUngjnhbfDINytjGf8D6jqDwaGraoUZc3uy3Muy1K48F2MUd5Jc6h4fgyDO+6W5s0wAu/qZEBz833hkZyOa7u1uIby2iuLWVJoJVDJIhyrA9wa5xWKkFSQRyCKxU0q40m5e78LTRWbyMWmsZc/ZZyerbRzG54+ZePVT0reFbpI5auGtrA9CormbLxLdzWFybrRbm1v4Bjy2dXjlJHVJAcMPyI6EA1VsfFWo3ksccGm2uEdRPJLdFPlOclFCsSRgcNtHPBrfnja5y8kr2sdhRiuIv8AxN4lkgVNO8MrBM8uwy3N7C6RJ/z0KK4LDr8oII9+lZWpxeIRFIkHiIWAE7TC+vXU73IOxEjBCiMd1Y5OOMdal1IlKnLsemYorzf4X3NzNrusLHqN1qlrFHFHd3bMxtWuxkN9n3ZJ+Xbvw20NjHU49Iq07mb0CiiimAUq9KSlXpQAtFFFABSN1paRutAHJeL2bS/EPh7Wljj8gTmwupCg3Kk3CHceVXzAo46lgKueKZG0ua01qCCSXyGEN0IyB/o7HljkgYQ4bvxu6ZJq54q0v+2vDeo6cCVknhZY2BAKSdUYHsQwBB7EA1T8M38XinwlBLfwxu08RgvLdhwsg+WRCOwyD15xigTMTULtfBOsm/ZVTwhfjfcTK37uwn5IkI7RyZwSOA2D/ETXbK6yRh42DIwyrKcgg9CDXM6S6aVKfDWstbvaSIU09p3LG4h6GJ9wwWXIGM8qRxwazL651PwIxk8i41XwkAM+X81xpiDA6feliGc/3lC96aJkrncVzmlSLYeKdU0volyBqMW6TLEsdsmASTgED0HOAO9bWm39nqthBfabdQ3dnOu6OaFw6OPUEVzvjaP7Jf6BrakA2V8kEue8NwRE3sMM0bZPQK3rVeZgv5WTeNNAl1m1tbrTLlrPXNNkNxYXKgEBsENG4PVHHykfQ9RWP8INZtdZ0DVHsoLm3W31W4ilguAFaGRtsrxADoqGQoPXbnvXdHg1ytjaW2k/EPVJFCxvrtvFNksq75YAUIAJyzbGUkgYAQetPrcSleLiyj8UYEltfDrzeesEet2hmkhXJVdx2huD8jSiEH8K2O9QfEaSO38G6jdyqzrZGK9CK23e0MqSKpPYEqAfarMi7JHTrtYrn6HFcmKWqZ6WWSvBoZS0lLXKemZUGoXbeJrnTbiwEFolss9vdGUH7Q27DKF6jaOv1HrWfcL5vxS0zofs2izy/QvOFz7ZC/pTvHcUkWlQazbOEuNEm+3DPR4QMTofrHuI91HrSTkJ8VLAqpKy6HKAx4PFwCMj6GtIpbo4MU2oOLOnooopnlhRRRwASSAB3PSgAqteuXH2WLPmyjk/3E7k/wAqT7Q8/wAtkuR0MzfcH09alt4FgDbSWdjlnbqxpbi3JQAqhVGFAwB7UUUUDIb0lbK4I6+W38qhs181xMcbIh5UQ9MD5m/p+FO1OQJYSj+JxtUep/8A1U+wXZYwAf3Af60dRdSeiiimMUDPJOAOpJ4rj/Drf8JT4jbxO/OkWQktNGUg4lJOJbrns2Ni/wCyCe9S+OJZtTuNO8KWEzQy6rve9mQkNDZJ/rCCOhckRg+5rqIYYra3it7WJYreFBHHGo4RQMAD6CnsVshx5pnlr5/m879uwegGc0+ipJCiioZ7hImCAGSY/djXqf8AAe9AEksiQxl5W2oO9YOt65BpdzapcwTXmrXOTYaRb4aaTH8bdlHq7cD61D4m1a406S0s7JYrzxLfZ+xWjf6qBR96eT/YX17nAFXfCvh6DRLiS4knkv8AWLtlN5qM4/eTnPAA/gQfwoOAPfmi9tWb0cPKrq9jyzRPFlr4ukiuviWt3pOmXU7w2FnK/l6c7oxUpK4IZ5MgnD4XFezwRxRW8MdqkSW6oPKWIAIF6jaBxj6V5J4d06G/h0q5ucyfZ/HV6gjYBkdXLqQwPbFdhF4Yn0NUHgm8i022TJbSrlGls5MtklTnfEx/2SV6cCtZU+ZaHVSqqk7WOsorDs/Etq12bPVYJtIvt20R3f8AqpTjP7qb7knHoQfb13iCDg8H3rncXHRnoQnGavFjaKWkpFC1g6ppt3ZSXWq+Go4W1GTLz2czlIr0+5/gk64fvnDcHI3aWmnYmcFNalLRtTg1ez8+BJoXU7Jraddstu+OUdexH5HqKVjDqdtILS9lTy5WjMlu+GjkXIKkEYOM52sCDwcEYrP8RaC2pOt7pd4+l63CpEN5EoIcdRHMuP3keR909MkjBrJTVLu81FLDUceH/E0Dt5LANJZX8ZxkoxwHyMfKSJFYDqKpRT1RjKco+7Jf8E620ieC2jiknluHRcGaUKHf3O0Bc/QCsjUE+watDdRjEcpw4H6/40+W7122uQ0ul2V1ZEhW+yXDeenP3trgKwHoCD71yt/e6nfePtXRrO5j0izto7S2keX5J5t5aR0jHX+Fd57JgD5jV0otvyIrVFy+aO41LU9P0uNX1K+tbRXzs86UKZMdQik5c+ygmqMfh+58YyWkmv6eLTQra4W6is5xme4kTO0yjoqDOdvUnrx16HQvCml6bIt40Ml3qTAbru+bzph32hj90DgYUAcDPPNdCTWsKSjqznq15T06EdvDDbQJBbRJDCg2qkahVUegAqSiitjAKKKKAClXpSUq9KAFooooAKRutLSN1oAQda420WTw94/mtFhkGk66puIpAQUjvEBLpjORvRd+cY+RuldlisfxbplxqmiyR2E7wahCy3Fq6tgeahyoYd1JGCDwRQBPruj6frtgbLVrWO5tywcK4+6wOVZT1DA8gjkVy1x4hvfBrLb+J4ri60Rflj1yMbzGOcLcIPmBGMeYAQeM4Oa3/CWuw+I9Ct7+HCy8xXEWCDDMpxJGc+jAitg9DTM27aM4iHS49kms/Du+sSZiZZbMSbrK6ZjksduTHIeu4d+oPNMl1zSfGVhq3hbUVl0rVri3eGTT74+XLhgQHQg4kXP8SE/hVy++H3hq5umu7fT/AOzr0lW+06bK1q4KnIPyEDueo71neKvh9HrOkR2UeoyyPGGKTagv2mZSSGDJNkSRspAIKtx6GnZk80Xuanw81a41jwlZyairx6nbg2t4kn3xNGdrEjJI3YDc8/NT/GWkT6jbWV5pqRtq2mXC3VqHOA56PHntuUkZ45xyBXAQPrvw38TQ6n4lurS78PaskVtqWoICrw3IDCOWQYA242xl8Dd8pIB6+wdKa1VjKfuy5kYrXMPiPwnNPpjAx31q/kmVcFGKkAMOcFW4I7EEdqxvCt5/aPhfSLss7tLax7mc5ZmUbGJ9yysfxou9D1bQdaudV8IC2lt71/NvtJuZDHG8pIzNC+CI5CM7gRtbAPXmsvwGJ7SLV9Iu7RbOayvWlECOJFSOf94o3gAE/e6AY4rDEq8TtwDUZ2T0Z09FLSVxHsDZYRcwywNjbKhjORkYIxyO/WvP/CEty2r+BZLzAkbRLuxLAECRoJFXPJJyQu7k969EU4YGvOIVNhrGmEOwksfFU9s0bsW2w3UTbQCfqpx2rSns0cWMV0elHrSUp60lM8kOgySAB1Jqmi/bf3so/wBG/wCWcZ/j/wBpv6Cn3/zRJCDjznCHHp1P6CrPA6DA6ACkADtRRRTAKKKKQDZF3xuNuSVYDjuRiorFg1lbkf3AKnBxzVa0/cyyWzcYJeP3Un+hoAs0UUUwIVtLZb971YIxePEIWmx8xjBLBc+mSTU1FFABRRVactPN9nRiqAZmZTg4PRR7mkAjTSTs0dpgKDhpjyB7KO5/SqWvanbeF9Dnv2hkuJSyxQwqcyXU7HCRg+pP5DJ7VsRRgBI41AUYCqO1cbo4HijxVPr0/wA+laTJJZ6ShHyySj5Zrn35zGp9A1PzZpRpOpKxf8JaFJpcdxf6rILrxDqOJL65zkDH3YY/SJOgA6nJ710dvzPH/vDNR1X1K6NhpV/eKgka2tpZwhOAxVC2P0rNttntqKpwsjy6ztxeeAPD9xpCGY6l4tW+xKSgO65l3HqCPlTIGevr0r1OQguxHTNcGNLuok+E1mkqN9kmNzcbSVV1S1LHA7kbuM12t9dQWFpJd3snlwIQCcZLMeiqByzHoAOtdtPY8ye464jhubd7e6jimgl4aKUBlfHPKnrjr7e1ZaWF3o8Sjw+ySWwYs1heSsVxxxFJyU6Hg7l57cGofDdxcam11qVzCY54r+W0+z3JB+zRoACsezje2V3EnnBHYVswK8abZJnlbJO9gAcE8DgAcdKppSVmSpOLuiOw1WG6kjt5kezv2H/HpcEB88/dI4ccZypPGD3rQ6UkGk2GuQTWerWsd1bgBlV+qN6qRyp9wRWNrFtP4aQLpmrNqR35ay1KYvJtxzsmAyp/38r9O/PKh/KdlPF9JmzRXNy+M9Osgra1FdaZAxIW6miL25IGT+9XIGOfvY6V0kDpcW6z20kc9uw3LLEwdCPUEcYrCUXHc6o1Iy2YtVNX02z1jTZ9P1OBbiznGHRuOezAjkMDyGHINW6KRTSaszzzxVc+M/Ceg3q6Uf7dsyCIb+U5vdPUkDfIgGLgKCTlQG459av2M+krDpZ8M6v/AGnFCiLLeCbzJGk3clz1DEHOD612qkqQQSCOhFYeseGNO1F5p4lk07UJSrNe2DeTMWUkgkgYY5J6g571vTqpbo5KuGb+FnoppK4i01jXtGVxqUba7aKBtltYwl0BnndGMK+BzlcE/wB3pXUaNq1jrNmtzp84kQjLKeHQ+jKeVPsa6IyUtjjlFxdmX6KMUYqiQooooAKVelJSr0oAWiiigApD1FLSN1oA888VWnjeXWLubSJvLsFA8pI5VywA5OCOpOapW2qfEKyhj87TVu1x/GgLfjtI5r1BaWgDxuDxLreh67f6re6HNBBeIguINpSMzA7RKGIOCVwpHQ4B65ztp8UbVCVvNIvIGHBwQcfnivQ7y1gvbWW2u4kmt5VKPG4yGB7GuSsX/sHUotC1d2udPmB/s67uVDAf9O7uer9SpPUDHJoE0ivb/Enw9Njc91Ef9uLI/Q1ow+MvDs5GzVYQT/fDL/MVfufD+kXGfP0uzf8A7YqP5Vl3Hgbw5NnOmqhPeORlx+uKtXMJcnU0Z7vRtWsprSa6sLu1nQxyRNKrK6nqCM1xlrdar4CvYLG6S51bwYw2W98imWfTeeEmOcvEOzgEgfe6ZN64+GehyAmKS8ib2kDD9RVNvhsYTusdcuomHTK4x+INGolybXO9hmiuIlmt5UlicZV42DKw9QRwa5HX2msvH+kyCSX7JqVlPbPGFBQTRYlVic5BMZlGefuqKxrLwP4i0e3MGi61HDAGZxEhaNNxOSdvTk1leIrLxo8SJqKzTRWUwu4ri3KZDRgvkEYYAgEEH72cd6U1zRsx0EqdRSiz0PpRXCWHibxHdafbX8GmQXllcxiaKWFcqykZBG0mpv8AhNLyDi90OZP90sv8xXB7KXQ9tYiHU7WvOPGIltfiJoNsiM0GtX1lOm1DgTWr7pMnPeLDZx261sRePtNbia1uoj7ANWf4p8T2FzHpF/pbyvfabqEVx5RjCmSI5jmTcenyOx46lAKqEJRexlXqQnD3Xqeht1pKzk1/RpnIh1O1bnAy23+eKdPrej28Ze41fTYkBALSXcagE9BktSszybMnvAQIpVUsYnDEDqQeDj86sVkjxNoBDGLXNMmZVLFILpJnIAycIhLHjngGoF8V6ZNEz6fHqOo7CA62dhKzJnOCQwXjg9M0JMahLsbtKAa5p9b8RXAcaZ4VEfyErJqV+kYLdvlQMcdznB7daP7O8TXr51LxFb2MW8MIdIsxnaF6ebNuPJyT8voKNtzWOHqS2R0jlUiaWRlSJfvOxCqv1J4FZza7pAuYbb+07Rp5mCRRxybzIx6BduQT+NZSeC9EaWKbUYrrV7iPbtm1S6e5IKnIIUnaOeeBj2rV87TtNmsbBfs9o90zrbQRxbA7Ku5goUbQcZPOM84zSuuhusE95OxTh8WaXdSmLT11C+lAY4gs5MEDrhmAHt1qxBqt1dKskWh30a7ip+1MkLjpztJPH88VplmPBJxSUuddEbRwEerIJ5bs26NawQ+cVyyTSEBTjplQc85FZPiK71OwiNxFqekWsP8ADFPbSSyyNwNqBZAWOSBgDuOlWNQ1OdL6TTtLtRcaisInJm3RwRqWwNzY+Y9TtXnC84yKq6N4YtbO/j1bUpH1PxBsIa+nYsIs53JAnSKPk4AGcdSaadtWH1ane0EZen+IvE94LqC20zTJL+2I3W99JLYzOpx84Qq4289Q55GODgVrJ4rtbRoYPE0L6FdyEKpuGD27seyTr8ncD5scnHrWrfWa3QjLPLDLGwZJYSFcDOSuccqccr0P4CqK63pN7qVxo07D7UHMb2t1AQJAADkbgVZSDkeuDgcHBzJ7ImeEitG7Gu0qC3M6srxbd4ZWDBh7EcH8Kiso2jt1Mn+tk/eP9TXLQaQND8SwQaWrx+H9WD+dbo5MVtdKd4ZFPCCQZBC4G5c4rsScsfzpnBUpuEuVnN+PdQurbR4NN0p9mrazOLC2bOPKDDMkv/AUDH64rW0vT7XSdMtNO09BHaWsSwxL6KBj8+/1NYNlnWPiJqN8ebTQ4Bp0HXBuJAHmb/gKlE/E11FTPsengqfLHmfUSub+I7t/whWo20Ymae+8uxiSEkMzSyKm3IIIBBIJ9K6SuM8eastt4j8J6asX2qWa6e8NoM7pfKXEfOMAeY4JZuF259ioK8kdFeVoMm8Salpmj+Lba6vrsW2maFp0rLGZAqmWYiKJFzyzFEkAXPGQe9WtCglur6fVtbjIvrdwsMUkTKLIbAzCPPDHDKDIADuVh0AqjrHhWzl0++udVsG1jV711WZoDgxb2VGMO7IVUXoSNxVe2cDrJDzjO4dM+tdsY8qseZJ3dyhopt30yO6s1g8q+Zr7dCzMkhl5EgLc/Mu09Bg9qu0iqqIqIqoigKqqMAAdgBwB7VLbQSXMwjiGSep7D3NUSUbltUeYW+lK4EgG54+D9Cf4RV/R/CEcTCbVHEz9fKX7ufc9TXS2drHaQ7I+WPLN6mp6AIxDEIDCIk8kjaY9o2kemPSuT1T4daDdTvd6bHPo2pNyLvTZTAwPUZUfKw9iDXYUUAeejwx4y0yKNdP8Q2GtKCoYavbGKTGTuPmw9TyOqHpVV/EOpaaIx4l8ManYqVXdc2eL2BWJwc7PmUe5XvXplANZypRfQ1jWnHZnGabqFnqlmt1p1zFc25JXfG2cMPvKR1DDuDyKtVF4q0yLSTN4g0y2mMq/NfW1qo/0qPPLle8i53BhyQCp4IwWtxBeWsdzZzR3FtKMxzRNuRx6g1zVKfIzuo1lUWu4XMhit5JFAJRSwB9qw7nR7DxNZrc38UkF4dyLdWczQToPaRTn065HFbV//wAeNx/1zb+VVPD/APyC4+P4m/nSWkbrcJ+9UUXtYz4NA1SylU6Z4x12GEReX5N2Ir0E5+9l1BB7Vp/bvF9vcTmOfQ7632gQpKksEmc8l2G5fu+g6nsKv0lNVZrqDw1NlM694uht5pJNG0a6lA/dw2+oMpc89WeMAc4/Wqeo+M/E+nz209x4UgfTpvKifytTjM0U0kqxKpUjDDcy8g9D6jFa0k0MJj8+aOLzG2JvcLuPXAz1OMnFcXqNh4ok0m/l1HUbWZr+YrbaPFYLcRgHiOITEqcHbuZyMLyQeBWkasnuc9WjCOxseFviBqV3qTDX9NtLfSbrUZNN0+9s5mlDSqzKFlUqCu7acN0zgHGRXpQrx3wh4c1XxENFu4pNK0fwnYXgvbaz09ZHe7lRjlpGfG1SxY7cE5CnNexCuiN+pyu3QKKKKYgpD1paMc0AcH4h8ZavpGs3Fumgyz2UZASYBhvGBkg4x1NUo/irbKcXek3cPqQwP8wK9JqOaCGcYmijkHo6g/zoA4y3+J3h6UgO11D7vF/gTVnUPEng/X9NuNO1G9tLiyuUMcsU6sqsD9QMeueo61s3Ph3Rrn/X6XZt7+Uo/lWVeeAPDlzG6iwEDMCBJC7Ky+45xn8KAOcstU1bw0scFlPB4r0KJdsZiuU/tGJR6gkLNgcDBDH3NdTofinRdcVP7O1CFpmYr9nlzFMrDqpjbDAjB7Vhy/C/QWXEU18jD+IyBv5is+9+E1pcujrqkjSINqNNCrsg9A2QQPYU07ESpqR6Lg4z1HqKSvMh4C1zSlt1sPEUcEUb7YUaV413E9AOQSeeKbdWnjzTLmG4l1RJFLiNEeZNjs3AG0gZPpVcxk6HZnpvejOCCO1eef2345tOLjQ0nx1KxE/+gmmjx/qVtkaj4dnQjupZf0Kn+dNSRi6E1sQ+EIJ/DniTW/CkrSSWUZ/tPTJH5/cSt88We5STP4N2rr9x9TXnOveK7HUdf0DWYLSe21DTpmjl3gES20g2yJkEHI4YAjGRXRxeNNElPNxLH/vxH+lcNam+a8T2sLWXJaejNq9tkuIJQI7czFCEeaESBWxwSD1GccVjQeE9Pac3GpJHd3BXaAsYhiQcE7UTGec4JycHHarsPiHR5v8AV6lb8/3m2/zq9FdW03+quYH/AN2QGsryidDVObuYk/g3Q5f+XaSM/wCxKR/OqE3gDTG/1VxcIfcKw/lXYhSRkDI9RzSYOaaqSXUbo030OJXwTc2rh9P1h4mHQ7CpH4g09tJ8XxYEWtrOB0EkhP8A6EDXZ0U/ay6k/V4dDi/O8bW4y0VvcAegQ5/UGg+I/EduM3WglgOpVHA/TNdp0pQG+lHOnukTKHIr89jil8dhDi70m4jP+y3+IqSTxnoN9AYb6C42Eg7XQEAjoQQcgjsRyO1dkw3rtf5vrzVP+ydNIYPYWzljli0YJJ9zVLlfSxxzxTWid/kYtl4v0ia4aES+RbxoAkspPzEcYC4JxjHzE/h3rQj8Q6S02yO9SQg/wKzA/Q4om8MaHNnfpsIJ/uEr/I1nz+BdEl+6lxGf9mXI/Wjlg+4ljZIt+Fb2a5sJ4LmzWza1uJIo0WVpBLFnKyru+YBsnhucj0xVa58QzWPj3T9BvLe1Sz1G2eWyuRK3mPKmN0RQjbnBJGCMge1LpHhK30jUEvLS9ujtBUxMV2sCO/06/hXK/FrVLRdW8MWC3bJezm6e0FtseZptiLEEUsBuMgXBb5eoPWlypysjeFbmp3T1RvXccng+/utXk1CWTwzcyGXUEu5DIbKVjgSxE9IiSFZOdvBHernjrQv7f8N3kdnIY78wF7aeDaXfAJCZPBVjxzwCQw5Fc38V7+8g+Gr2GvWkFzqOr3ENl9ksWbLjcHfBxy2EYkDA5wDxkvn0ePwb4Wg0/QrXzvEetE2ceHZdu8FpCvZI4gSVHGCFppbPqOU7XVtB0y2cl78J20ezaHTzJNLDCny+VGbTPzDnPJ59Sc5r0iABp4wehYcevNea6Fqq6bq2k2et2rWMOnWv2S1XaQqZAUu2f9lQMivR0O1ldSD0YEcj2NOSscFZpyujkPhjmTwil5I26e/urm7lYnJLtM3X3wAPwrqa5TwhjRda1fwvLlVjkfUdOz/y0tZWyyg9zHIWU+xWusrKe56+HkpU1YK5vTS91441+8+fyrOCDTYTvypOPNmwAP7zRjknlWHFafiDUzo+j3F6kDXVwuEt7ZPvXEzcJGB1JJ9O2T2qvp1sPD/h12vpPMmijlv7+VOd0pzJKyj2wQPXb71rQjrzGGLntEvzTi1hkuSGIhHmfLjPB7biB+ZAqO1toLK1htbOJYbaFdsca5woyTjkk9SayvGDifwBrs0EH2oSaY08cBTd5q7Q4Xb3yO1b+jRNqtvbTxK0cMsMcxyOVDKGA+vNdRxDrS2ku5vLj6fxN2UV0trbR2seyJfqx6mnQQx28YjiUKo/X61JQAUUUUAFFFFABRRRQAA15R8QfCU/h918R+DbnUtOhSfztVsdPUSJPGSxaVYW4LqSWIXG4Z74r1egGhq4bHEadEDoFtHHfS6ir2w23cxG+cFeHbAAyc+lV/DT5sXj/iRzn8atp4NuNGWZPCd5BbW0spl+x30TzQwljlvKCurICeduSuScCsaWHUtE1DyZWtJ7uYbitvE6xnJ4AVmZs/8AAjXP7J2aOtV480X2OkpGKojySMqxoCzMxAAHuTwKoWZ1+dJ5xpMDWqIxRftBjnlcDhQjJtAzxuL/AIVk6tJaazpQGteFNdurZJgrWclmTvYqeSobDIORnpkisvZST1Ru8RBr3XqZeo3Gn6hPpmpeOPDlzbRRSywW32ow3FpGJG2q8ihj+8ZVByAQoPUckU/Cem3HiTxhqMdteuvhWQuJrTTp2SBFUKkaFgB8zru3IuAq7cc81b0LwFq+prLHJKNK8OmIQQ21xbBrpyS5ebGdsLFZGixhjtyeDivYbeGO2t4oIF2RRKERfRQMAflXTGFtzhnO5Dptha6Xp9vYadbx21nboI4oY1wqKOgAq0vSkpV6VoZi0UUUAFFFFAFPTbqa6W4M9nLamOd4lEhB8xVOA4x2PbvTLDV7DULi4t7S5R57d2SSIgqykHBODgkZ4yOPer9N2Lv37RvxjdjnHpQAoIIyCCPalrMXQdMjhhhgtI7eKK5+1qkBMQ83JJYhSM5JJIOQe9Ra5pd5erI2navdadO4RdyKsiqFJJwjDGTnBPsKANAferN0vR10++ubz7fqd1NPnctzdM8a85+WPhFx04A4/Gs+/wBP8Ti3sotK12yUxxbZ5buy3tK+fvfKwA47VZ1EeJEisV0z+x53EYF1JdNJHufjJQKDx16mgCxp2iaXploLaxsoo4BMbkIcsBKTneM5wa0GwwAYAgHIyM4NZ+p399Z3n7rSJbuwWB5ZJ4ZVMgZQSEWM8sTgY5HWsR/F13BMgvPDl6qXA32cUM8T3Ey4ySYiVK4BGRk4PFAHWFyATUIlcfxH86zF8RWT6hBp8kGowXk8auEks5NqZXdtaQAoCOh+brxVu0uYby3juLWVJYJBuR1PDDp/SgBt/YWepW09ve28bxzI0bnaA2CMHDDkHnqK858GadYXeky6bq1pDNq2kTNZXRkQCRtp/dyHB6Om07u5DV6PL9r+12/2ZbY23zeeZGYOPl+XYAMHnrnt0rlPGHh7XJoY9e8Mm0i8WRwrBLAzk2l7Hu+4+cH5cllbgjkdDUTi5LQunJQldrQrT+DtDl/5dDGfVJGH9aozeAtMbmGe6iP+8GH8hV3+1/EdpPaw6n4K1Jg8eZLiwuoZ1VgOm0lTyffvU0uuXwC/Z/CXiOWRmVcPFDGACcElvNPQc9KwtVR181CXQxT4HuIjmz1mZP8AeUj+Rpy6D4rh4ttaEuOitI38iK1ZE8XG0N5c21hZxoSTZWYN7cuucAbiUQMBg9xyfTnJ1Hwzdatbwwav4w12yF3EoFu1pFBtZj8o3JwJQc4w3H0q1Go9zGU6S+FMo6nrXiLQlc6pqGmKIkErrLLFuCZA3lRhtuSBuxj1NVbD4j3VxP5UVrb3kgbYRAkhG4dRuXK5+hrvLvwzZjTceHINJt5pbkXomurb7TGWI5ZRngnIOVwOp710Fj5ttZQwu0XmIoDmCPy0Zu5C9s+lX7OPVEe1ktmeMPq+o3cqXOtah4jt5ApCLpcgs4VBOQShVi7D1Y4/2RU8PjHWLML9m1aDU0A5j1OyELn6SwnB+pUV6zqmqQWkTfaGkllCNIlvEhkllAxkIvc5Zfz54ya5/UNNvvECgSwQaLZh1JPlRy3c6bSSM8rCckf3jwfaq5I7WMpe9qzC0f4iW1w/k6zplzp0g4EsbieF/cEYIH1FdRBrekznEOpWjfWQL/PFVrLwX4dtLRLZNOEgUAGSWWR5GIHUsW6/kPaoZ/AugTZ2wXER9Um/oRUOkuhDpo3YnjmH7mWKX/ccN/Kn7G9DXC6r4Bs7fyzY32oeY24rGtsJScc8EFQOD/ERnHHPFQWfg3xKkSONVisic5ia4dmXnH8OVORg/jS9l5k+zO/IyCCAR0INU59J0242efp9pIyMrqxiXcrK25SDjIwQDXMf2R4ztuINWhnA6BpBz/30KT7T44txmSyguAOu1VOfyNS6TGoyi7o6GbSBNqi6nJcO+oW8ciWbsoKWxcYZggI3EgAEk+uNuTVix0+O1kNxIzXF66BZLmQDcwHYAcKOeg/HPWuLvPEni6FedJih/wBp7aRh/OsmTxr4pEuGfS4Ex3spCc/99ij2chy55bs9H13SYNbsHtrlAXAPlSd0btz6e1YHw8vpvIutHvARcWLELn+7nBH4H+dc9aeKdWnwbrxTa2pySRDogfHpgtJ/SmaNby6l4teC18RXoe4Rnkv7SFIHkIG4rtIIUcfpVKm7WYlB2sztPF2iXmpQ2eo6H5Y17S5DNaeYSEmUjEkDkfwuvGexwa4u6+Kc93Fpseg6Ht1G/mSOK21KVkYgyeWzYjDHCt1JIwBz1FV/E1lKyLdQar4qufD9vNEt3qkmpsplRm2N9mSNRnDbQXOF5OCetdXd+H9O8MN4fg0O0+zf8TxDLIGZ5H8yKXzC8hyx3bVzk4OBTVJfaNacpU1ZMd9jv9LvdP1bW7xNTuzObaR0H2e30+KUY3Rx55+YKGkcltrEDHSujuFDFkkQFSCrI4yCOhBH9KW7jM9tPEgkLsjBRGwVi2OADg4OcYPan+GIm1nTLK/uFEayRK0iK+7EmMMu7vgggnuc1olbRA3fVi22mPqFrcQo5gieF4RIg+5uQqNv0zn8K1/DMSweHtOhUT4jgSMm4j8uRtqhcsvYnGfxrSVVRQqKFUdgMUvWmIKKR2WNC8jKiDqWOAK5zVPF1laqVs/9Kl6AjhB+Pf8ACgDpMVjal4k02wIVpTM/dYfmx9T0rm1Gv+I+GJhtCTkkbE/xatvSvCdjZNvuSbqQcjeMKP8AgP8AjQBH/wAJrpv/ADxuf++B/jR/wmunf88bn/vgf41t/wBm2H/Plbf9+l/wo/s3T/8Anytv+/K/4UAYn/Ca6d/zxuf++B/jR/wmunf88bn/AL4H+Nbf9m6f/wA+Vt/35X/Cj+zdP/58rb/vyv8AhQBif8Jrp3/PG5/74H+NH/Ca6d/zxuf++B/jW3/Zun/8+Vt/35X/AAo/s3T/APnytv8Avyv+FAGJ/wAJrp3/ADyuf++B/jWLPqcGq+LtOuLYOqB0TDjBzk/412v9m2H/AD5W3/flf8Kcmn2Ubq8dnbq6nKssSgg/lQBazSfQCiigAooooAKVelJSr0oAWiiigAooooAKKKKACg9DRSN90/SgCvRRRQANIkUbySuqRopZmY4Cgckk1zmltoVvrem6Tp9mHe3sGvLS53+YqxO4UhXJJOSc/St2+tY76wubSYsI7iJ4mK9QGBBx+dUNK8OWGly2U8CytPaWK6ekjt1iUg8jpnIHNAGs7HDfSq31yfrU0n3DUNAEP2O3IvAF8s3efPeMlWbK7d2exwByPSvP/BHh9tYtb2fxLqus3mq2V9LZuwvGhjCwkBAqxkA5XaSTyWLV6OBnj14rI8NQadFb31zpF39qhvb2a5dwwYCQsFdRx0BQj86AG2mj3tldRSW/iLUZoPNMk0V6kc3mLjhFYAFB+Zp2onxJ9tm/s+fRFsCh8sXEErS79vG4qwBG70HStamSdB9aAMG21ie2utVt9dkslks7eK7D2quqmJ9y87z97fG4AB6Y9aih1TV9SjaPT10uxv47eN7myvVkmaB5MlQWQqCCoPHr1pZYnv8AxJugha2WB0We8ilDfaY4wW8htuQoEkzAo2CRkirGhahcXt74hhuJA8dlqTW0ACgbIxBA+Djr8zscn1oAgtINds7We4mh0e6vkjSC1t7VpraAR55DBiwBHYgdOKyb68+JLXWdO0bwjHaYHyXN9O8mcc8qgH0rss0uTQBhJqPiFYrl7/QbRVSMtHHaajveV8jC/OiqO5yT2ptjq99Ml0994ev7RYYvMULNDcvKc/dVEbOe/Nbcp6UwknINAGPZa79qBP8AY2vQYkRMT2JT7xxu+990dz2rQjut8d0/2W8X7OzJtaHDS7RnMYz8wPY8ZqfA9B+VKOvagDkrXx/pV7e3Nnpun+IL25tGKXKQaXIfIcHBRySAG6HHPBBrVn16zii09rxLyzlvWKxQXFrIJAd2MMFDBe3Ujgg1lX/mQJ4xEF/DFPe3drDGyo0xhZreFMSKBkZGefRgciunihSwt4rS0DRW8KCNUDkgAcAZJyfxzQBR1bVtO0dIn1W/tbJZSVjNxKqByOoGTzjIp1pqum3cavbalYyKyCQFbhPukkBuvQkHn2q3wcbkRv8AfQNj8657WvC+j6x4n03UNR0O2uHtIZHFw0cRRnOEVJEIy5C5ZT0GCO9AHRW0guC32SVJtv3vJcPj646UrqZDtkTzCOMOu7H51h3XhPw3chQ2hWEQXP8Ax7IbfP18srn8c0niAw2UejB28nTftH2KcNdGKMRyRlFDc5fJwoBOQTn3oAXXm0OzIGo2lpJO52JbpArTSseiqgwSx/zgc1w+lW9lrPjC5j+xzadp6o5kthJtJRV+ZWYdFbuAemRmvQ5bQ2NvKdGs4ku/LS3SQJllA+RSzH5iFB7knAPXoeM8L6fAvi3VrS3aWK2tojCjQvsbhlGcjpnByBxyR0oA2fFkq3PgrVy0NulmBGluROAksQli2vlRhAeyjsB610d/ciHUYYD9+5aQAlwpG0bj8p5br0GcdTWR4xtH1Lw1f2UMlvDLc+XHGZXEabvNRtufopwK35dEa91/SNUfAWye4YKxIJEiBemMHpQBY0yw80iWcfu/4V/vf/WraAAUADAHQCqt/qNnp8Za7nSPH8OeT9B1rlbzxdcXT/Z9HtW8wnAZhub8FHT8aAOvuriG1hMtzKkSDuxxXL6l4yjGYtMgaWUnAdxgfgOpqrbeF9R1CUTaxdMoPOC29/8AAV1GmaPY6ZzawAP/AM9G5b86AOUj0nW9ddW1KZ4YOuHGPfhB/Wui0zw5p+nkOkfnTD+OX5sfQdBWxRQAZooooAKKKKACiiigAooooAKKKKACiiigAooooAKVelJSr0oAWiiigApCaWkbrQAmTS5pKKAFzSE5BFFFAEfl+9Gw+1SUUARhD7VlWWnXsPiPVb6a5D2V1DbpBBuJ8tk8zecdBncvT0rZooAheNipA61D5T/3TVyigCmI3ByFNQ2tnFaQ+TaWyQRZLbI1wMkkk49ySfxrSooApbH/ALp/Ko34xkZwelaNFAHK6Rps1pqGoXVybeWSfYkc0cZSRoxubEgHy5DO2CBkjqc1fjiihaZoo0jeZ/MlIGC74A3H1OFUfgK26TA9B+VAGRkeopa1sD0H5UwxRk5Mak/SgDJk7VHWyYIT/wAsk/KmtaQE58sD6HFAGRSg85Nav2OD/nn+ppDZQk8Bl+hoA8zvGe28TQXdnf8A7q+8RwW8iRF0IMVqInjfIG4bkJ4yCMV2knUfSrt1pPn31jMtyVht2dnhaNX8wlcKdx5UqeQRU0umxu2Vdl/WgDJorU/stP8Ans35U19L6bJvzFAGbWH46s5tQ8IanbWsXmzOsZVCQPuyoxPPHAUn8K6z+y2/57D/AL5qG80MXdpPa3BSW3uI3hlU5GUZSrDI55BIoAwJJzeeNbkKW+yabECzYBSSSX5uCGzwgHBGOcg1zfw6Vri71q8wT5soUfiSf8K6XRtDvv7J1eeKFYLq7llESTII3WNF8qFWIzuwFOGPJDDNY3hzw34h0vSltPJEMk8jNIUkU4GABlh04z0oA6e6fSbWEHV/KnkSRZEt8ByrryrY7EevaqE/iLVdWlMGk25jUngqMsB7t0FaGmeDraFlkv5TcP1KDhc/zNdNDHHBGI4UWONeAqjAFAHIaf4Od5fO1a4LMeSkZJJ+rH+ldVZWVrYpstII4hjHyjk/U9TViigAzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSr0pKVelAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    If the woman cannot be placed in lithotomy position because a suitable bed with stirrups is not available, a stack of towels or an upside down bedpan is placed under the mother's hips and back to raise the perineum above the surface of the bed/stretcher. This provides additional room to maneuver when guiding the infant posteriorly to ease his/her shoulder under the symphysis pubis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1425=[""].join("\n");
var outline_f1_25_1425=null;
var title_f1_25_1426="Photo birth 6";
var content_f1_25_1426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Delivery sequence from crowning through birth of the newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The body easily follows the shoulders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy;2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1426=[""].join("\n");
var outline_f1_25_1426=null;
var title_f1_25_1427="Mitral valve endocarditis healed parasternal long axis echo";
var content_f1_25_1427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/53844/palaxend_conv.mp4?title=Mitral+valve+endocarditis+healed+parasternal+long+axis+echo\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 417px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGhAQADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooruvBHgqLXPD17rFx/aFylvOIBZ6dGrzk4B3ncfu844BJOfSsq1aFGPNN6GlKlKrLlhucLRXS6v4aZV1K80aO7l02xeOOf7WgjniZ+AHTP97IyKsDwDraXF5FdCytFtGSOaW5uo441dlDKm4nBbBBxU/WaVruVv6X+a+8r6vUvZR/rX/JnJUV2o8BXX/CH3OsNd2q3FvfSWkkDTxhdqKSxD7uWyCAo5I5HFU7rwJrltpst5LDb5hgF1LbC4QzxQn+No85ApLF0XpzLew3hqq15X3OWoruNZ8DSDVLK10Us0T6XDqFzNdzIkcO8cksQAFzjHeub8QaHe6BepbagkYaSNZonikDpLG3RlYcEHBqqeIp1LKL1fQVShUp3clojLooorYxCiiigAooooAKKUAsQACSeABXXaRoaW983mtvK7SkjjYAcDOQc9Dx/+ugL9CPSPDk02mT/AGiJVknCmIlMtHgk56jGcY/Kt3VfDOk6d4M8Ny38H2W51BbjzdRDNIdyXKooEZYKAEJJyAT17V0UMghgLKJGAIjcoc4IOc5HTsa5TxU5u7J0Z5o4t25QSdoI6kr0/GgAtPDWmReHrp2kg1C7bTWvmKb0ksjthZAcOVYN5jrgrn5c/TgcHHSrk0t5DDJatPN5DH5oxIdjYxgkZxwAPpgVU455HXrQAbTnGDnOPxpMHGcUvGO1Bxz05+vFACYPofWjB54PBxS8e3HHfn3o49ufrx70AJg+h9aMH0PrS8D0OOe/PtRx7ccfWgBMHjg89KMH0PrSnHTj680cZ6D1xz+VACYOPal2nOMHOcfjQMdMj680cH0FACYowQOhpeOvHrjmjjpx6Z5/OgBtdX4R13S9ItXF1HrEN95pdbvTL3yGZMAeWwIIIyCc/wC1XKUVnUpqpHllsXTqOnLmieu+FfHlvqPj7V9X1lba00yay/eW8smS5i2mMDpvfI9O5rG8K/EMaZeald6gNRee9ujcyJbzR+VKD/A6OjDHbIwcfQV53RXL/Z9HVNaNJW9P6/A6fr1bR31Tb+87eTxbpl94e1bS9Q0uWKO51F9TthZyqixSMm0IQV5Ue2Pwq/feP7C4m1LVo9LuE8Q6jZfYp5WuAYFBVVMiptzkhRwTgfz85orR4Kk+n4vy/wAkR9bq9/wXn/mz0qy+JawahuaxmW0k0yDT5RFMFlBiziRGKkdzwRXMeNtfi1+9tpIDftHBD5Qa9mWR25J/hVQBz0ArnKKdPCUqc+eK1FPFVakeST0Ciiiuk5wooooAKKUDJwOtbugyHTme5RwzSRmJgqhsIwwwyQcHHAIwR2NAPyNnwv4XkFkdTvrSV4sAptbbsz0Y/XmuvtZYYJHkntB5m0hQxHB9eB6fyrnIfEz/AGN4IQ6RsrKVZhgKTk/4U3X75oreFpQFJTHycheuD7f1oA6S71JGcJJMfPYkyMi4PI/w29cetZ0uni5slllvI1aUDbG4+fjjn0rjjctEPlcLngMeh7H69B60lxfTtFGqOwIX5c5yRj69aALmraW86OkdwsioRtBXle2M9Mf55rmru1ltZfLmGCBwRyCPrV+K+mVivmmUEHhSP5npVe5m+0QoshG9RncDn8P0oAo9u3p9aMjHb6UE8kcelBzkjHPcYoAD26Gjv2PbpxQM9u3tQCTnj68UAA/D1yaB07f40cgA9vpRyMcfTigA4x/9bmg9B0oPp/SjndjHOemO9AASPQfSjjOOPTNA6H0xzxRyR7fSgAz9Mn2o4wen5c0E9/6UHp7EelADa9o0vw7pOq/B7w3OdBs7fU9S1+PR5dSQTGRYTtPmAF9m4k7c4xg8AHmvF66q31fxsfDSi31DxIfD9sy7RHPP9liKMGXGDsUqwBHoQDQB654f+E/g1vE1ijXWr39pb+JpfDt9b3KLEJZFjkdWRo2yEzHg85PXA6Vj+G/hX4a1axv9WvtV1PT9L/tVtMt1eNBJARGrb5RznJbhBgkDOe1ebSS+MIjbvJJr6G9uv7RhLGYefcYJ89f70mCfnGTz1rY8Pr8SL3W706PdeJE1W5tTfXLi7lhlngVfvszMC4wOOTnoM0Ab8nw68L6de+D7HWNb1RLzXghLRWyeTCGleLcWZg3VRxt6Zya07P4K2kGvLpGs6pPHqFnpM2rajbwhcqom2RohOcZXDsxBwCOOa8nvjr19JaR3/wDady8MbLbrN5jlEViWCA9ADuJxwDmr6T+MrnU119JfEMuosYwupBpmlJb5UxL15xtHPOMCgD0OX4ZeErIazqF3rmrXGi2c9lHCbSBPNcXAbIYsQMqykbhkHHTnjU1n4V+GdM8Py2LNqU2rp4t/sQahGvHllY2AZd20KFfO7Gd3H3a8e1jXfEclzeW+s6pq7XEkim6ju7iQs0kedu8McllycZ5FIvivxEpuyuv6sDdyrPcEXkn76RSCrvz8zAgEE8jAoA9IvPAuiW2n/EOw0a+muJtEntbOSfUbONMSm9MJMbhmKrjGW4J54Aq1P8JdHk8T6v4dsZPEh1DSoZzJcTWiiC6kjhZ1EYHI3FeAckryK8hfWNTddRD6jeMNRYPegzsftTBt4MvPznd82Wzzz1q9/wAJh4m/0L/iotZ/0E5tf9Ol/wBH4x+7+b5eOOMcUAeoad8PrLRPCOr3WowNPe3XhP8AtRUuoQGtJjcqny55B2jr15rTk+BumGHT4mv9Rs9RGpWdhf283lyGPzx1BUbQw643NweSK8cbxB4l1WdoW1fWL2a4iNs0ZuZZGkjLbjGRk5Xd823pnmpG8aeKGjt438S600duY2gQ30pWMp9wqN3G3tjp2oAd4v03RNN1mS00O+v7pLdmima8t0iPmKxHyhXYFeO+DWfbfuwjHcm48jBwcY9elVPNeSd5ZZJGkkYs8hbczE9Se/OetTEkIqI5KE5wcDB5P+eKALbuGl8yJVIUYJz8w/xNJGRc5RJnWMHI3DJ/Dn/OPyWGMQqwKvuwGJVd2PfNCmBVlM6TQzH7q7cBvfFAGpa2qy2zGYF48Eg9On8hUF3aqLdGEgLD5XVj8oB9KhtLrMaI8g2lSHAwOh9akvboiKNjn5SdhULyPUgdKAK13bS26qJQ4jbnk4B75H5VSkBCtmQuCMZA9f8APSrTXaPGBcEyAAbcnjPse1UZ9pYsowpHUjH6UARSZb5jnnk89femlSDghsDrx0oJ3bdxPT9Pal5ZfmPzA45/z9aAG8nGQc+vtS4JOTuz1JpDj0PPTmjHQd/rQAAd1zk8D39aMHHGee3tRgHoPbrRjPb6c0AB6dG2/wAqMHoQ3oPrRgdcHH1pMcfy5oAXHXrgdDRz947geufejAzyD9M0Y9u3Y0ABGOxBHFH4Nt649qMdRjke9HBOcHH1oAbXs1h8UtEt/hlbaFeWmoahqNrbCC3V4xDHGfM3nMqSAyR/7DR892rxmigD6k8P/GHQPEPxB0Jnu7rTrWTU/t8yajHDHBbMLeVCROZCT94KPlTjrmuP0v4vaRpl1oVnFN4juNOstNv7OfUZigvJHuSCCF8wgrGVBUF88k8V4XRQB7loXxP8J2lnokt/F4im1TSbPULCOQJEyTpcGQrI+X3b/n+Yc+uT3hT4xRW/hxdNsbjXLfy/CsOjxrG4REvFlLNMAH4BTC7gN3bGK8TooA7n4oeMrfxR481PW9MtyLW7WDC3sEZk3JBHGxP3urIT15znrXLf2ip+/YWTf8AK/wAiKz6KlxTNo4ipFWT0+/8AM0Pttofv6Zbj/ckkH82NHn6cfvWM4/3LnH81NZ9Wc2wsFCpN9tEhLMWHl+XgYG3Gd2c5OcYxxRyL+mP6zPsv/AY/5FjOln/lnep/20R//ZRS+XpZ6XN7H6Zt1bP/AI+Kz/XqR0BpyghtxA+pxj/PWjl7Mft0/ign8rfk0aEdrYvxHqBDdt8JB/Qmu+0HQLCfQoPOjillbcxnQYJ59x7dDXmU3L79m0NzitCLVLxLeO3SaXy0P+rMmAcnnjP1/wA8VlVpTmkoysd+XZhh8NUlKtRUk1a2vdd2/wArnb3lu+jWs0dlPFK0v/LNgAT26AcVFLp0eo2AkuxNHLANu6MrtAPOcf5/XnO0y9kmiMUzGJSAd23ccep/Culso9OS3khl1SV4nIZWhixj14J/r/8AW1gmlZu55+JqU6tRypQ5F2u3+Zx+seHza7Ql7bsmQARkFfY+nQVhSKI2KyYKZxlTnP1/z/SvWzDbWpkZjFd28wxukQls+wPANYd/4TtL24lfTbp3CrlojEetUYHnckkaOGhQAe5yf0/z+tMkl35bA3cdq6GXQWXMc21JeiqOCB3J/wAKralokkEay26O6k/PvIyD/T8TQBhjGCMZPrSquWAA3HpjPWrSWErgAFT6BeTWs3h27i09JXtXEmf4xjPXHHU0AUdPsFuoiCSpI+Xjvj+VUbq3ltpfLmUK3XHt/kVu21w1jLtmjGVwBFjkfWqOo3wv0d5AGlzkMTgIPQD/APXQBl9+x7UevTn9KDlTjjjjpTkVncIo3M2AABnNAJXPZ/h98I7fxL8Lb7WrhNQ/ty6jup9JEKZgdbcLuV/lPzOxZVGR90+lc5F8Lp38Mre/2tbLqz6M2vrpxibmyViC/m/dD4UnbjoOtVLbxr4t0V9Juf8AhIJLC40iAW9hbRInyIM8PGBtP3jkyZY571nSfEHxRJoM2jNquLCVGhZFgiVvLZ97RiQLuEZbnYCF9qSaexpUpTpu01Z/1v2+Z3uifCDRl1+50rxB4riF1HpL6l5Fnby74x5IlVnZkKkYblVJJA7E1keH/hNJrvhW81qy1hFMMNzcwRTWjxpcxwlslHYgkkLnhSB0JBzjlovHviWLxKviBNSH9rLbi080wRENEIxGEZCuxhtwOQc4yeeauWvxP8XWmmNYQapEtqyTxbTZQEqkxJkRWKblUkk7QQB2A4pmZxnp0o65J6HqQOlHoMj60cjk5GO4H5UANor0P4AaFpviX4uaDpOuWq3enXHn+bCzFQ223kYcgg8FQfwq98NfhpBrlhreoeKZr3TbXTPs4aFUEcrCVmAclxwo2HtyeMigDy6ivonRfCXgvRvCv2W7gfVpr3xYmi/bmtgGeHEbgLuYGMFHyWX5txI6YNeZ+NdC8Pad8X73RIDfafoMeptayNKoLQIJSrFMk7kUdCxyQOeaAOCor3U/A62s/FNloOp6tPHftDf308KIu42sEhSIp/tShSwz0HOD0qnffDTwhp9presXGuatPounwWE+20hjabNxJLG0ZZtqna0Wdw4wemRQB4tTlUswUYyTjk4H517t4j+GPhnw/wCG/F9tP/aV3quma1DZW95Eo+WOSHeoZd23HPzNjPAx1IqjqngPQdEvvH2laXfXd5daHpskk73tlEAGEsQXyiGJBwxy2FPbHNAHi4x3/wDrijqc/mBX0J4W+G/h3RvinY6De2+q6tdW8bm6nubVDp85ayllGw9eGC7Sc52k8Yrmz8LNGg+HdtrN9rU66rd6TJqtsqoGgbbk+RgDduwpy2QFJ5HegDx/0J5/rT0ZRGQ4/wB0/wA/alRB8rZOeDSSx+WeGz3Vh3oAQsxOSST97Oe/rTlZQS2eeg/zmmBcgY/OgAbcnOcHqOKAL+nahNayhg5Yddpzhu1dHo13ZzxEzyW8ezokiHH14rjnJP3n3Y70pckd+P4hnr1oA79b+6aVhFMrqeP3ZJ4ra0q1H2aSeTVIrSRvmIkjLBvTGf615ba3txaMrQTNEy5HB/H+daia65m33QaRiMBienv70Adt5od4YkkhvLnlc5CBfXnjn6VNqV1Fb2RtgsMmzB8sHcW/HoP51wkmp2ygPFvSYD0GBn2x/n2qjPqDO7Mksgyfm3HLNQB0TXKNeLOsUVqSd2erDjtmtPV/FVubeKGxYAqvBC8H3J6n/wCsK4WAhkZpJHaRhkYzx7/zpLpY1HyY7H5+p/r/APqoA0Ly6SdQsSMXIOSO2e+fz/z0bb6JqF3p011Bbkww8bc/M3rgeg9Kr6ZJBJdxrd3Bt7YcuwUszewwDz7/AI123/Ca6TZwJDZ29wyIMKAoUY/E5rCtUnGypxuz2cqwWErqVTGVVCK2V9W/TsvxONOmx2p3apOIGA/1EQ3Sn6jov4nPsajfUzEjR6dF9jjIwzrzI3sX/oMD2qncMJbmWSJMRlyyqTnAJyATUXHH61oo31kcEsRyNxoqy79X8/8AK3mKc85znrjH50fnge3QUmOcYOT0FAAJ6H6e1WcoYPTBz2GKOc5BYt1zRgY96McdDz37UAHQg9vfjIpB9BR2pe+Rgc8CgCzpWpX2kX8V9pV7c2N7Fny7i2laKRMgg4ZSCMgkfQmtVvGniltUGpt4l1s6ksXkC7N/L5ojyTs37s7cknGccmufooA0rrXdXu4mjutUv542uDeMslw7AzkAGUgn7+ABu64HWotX1XUdZvDd6vf3d/dlQpmupmlcgdBuYk4FUqKANSbxBrM2pwalNq+oSajAoSK6e5cyxqBgBXzkAZOMGpNS8T6/qi3S6nrmqXi3QjWcXF3JIJghJQPkndtLMRnpk461kDk1avbQ2ZhDSwS+bEkoMEocKGGdrY6MO4PSgDYg8X60kesebqmpTXOqKiXE7X025yp6vhsSfLlfmzjPGKz5Nc1eWe+nk1S/ea/UpeSG4ctcKSOJDnLjIBwcjgVnegNHvgD29adxWsdTZ+JNfSxsoY/Gd7bw2uTbwfa7kCDKlDtCghflZhx2JHc1Fa6tqlppE2lWvi6WHS5gRJZx3FykLg9cxhdpz7iub/AZ6Y9KUBiC2QccVHK+50KrBK3Iv/Jv8zSFtAEIGqWW3p9yY/8AtP2phsYDuH9rWZGcn5Zvz+571nnj3xxS7TnBA47HvRyvv+Qe2h/z7X/k3/yR6F4O0TTbvRpxci2vCZSPMRWG0bRwCQDWH4j0rRrAv9i1LdJ/z748z/x4dPxrnkuJ44TCkziJ8ExgnaT7io1fAxxj35rGNGSm5c2h6lfNMPUwsaCw8eZL4tfwtr97foICQ25QFwcjHIFIfu4I+lPUb8lui9gcYHtSR7gPlHXjnvXQeIJkDK5+X270vygdx74pcDpk56e39PrQfkAAYgn7w70AIq8AcFjjAxk/5/xo6ZCnrn+LpSADnH1HejJ6d+nFAEsLCM/e69cEVaurhZlCxKEA5JLZJ+tUkUEgMSR9M471atbV7qdU2nHXHAAHU/5/CgCBI93yYwM/8CP+f6VI0IjiPyEEd34P5V1cXhe5WD7Q2Iy/3VPLH6mmWHhe9vpmTGOfvPx+Q/r2oA5BeQVyABnj1/zxWjZadJKyZQs3G1F5I9z6D/IFdN/wiZa5WC2uIgzHDOTyB3J/w613C2GmaDYLHCY5bgrwFOST6tjqfbtmgDye90a4UDKhSvGMc/SsuSznSSSNoJQ8Y3MNp+Uep9BXocZktvE2nT38qwQ/aonIdtm0bwSWJ6ep/Gvb9a+I3hPVL/4lWtnLZw397omoQTXzzIIbtoh5dssDZ+dnR2yB18sYzQB8nXlpcWUipeW09u7oJFWVSpZGGVYZHIPXPeoMfj7Cvo+y1bQLSDxNpem3HhySW98M6d5f266XypZ02mWMuXAyOTsyDkDjgisOL/hC5fG/hvSreLwraaemlxXVxfS/vRNcm1YNDIzSeUp3nPzAYYDdn7pAPE4LS6uILiaC3llhgUNNIkZZY1JwCxA+XJ4yagznPTn2r6J8ZXHhHT9K8XRaBc6JatqPhqyMlvZ3kUiNdi7O9F2HaWCqpIUdOcYNfOwPA4GR7UANooooAKeUYRhyrbCSobHBIxkZ/EfnTK0Bq+pLpsunC+ujYyYD2xlJjODkHbnGQehoApAYPTJ9OuaTA74Hb6UDg5BwOOe9TwgSRsjsFb+GgCAcevvz2oA759+KcykH7v8AhTTk5yc89e5oAOP7pxn8cUDPTqew60pyeM5yeueKlixwAcD3OB/n/PsQCNcAA7TxzuoC4J6g9tw61bihf70LjZnlTx+lWbNJkz+78yM9gM4/IfX/AOtQBlhS3CklR2zikwRwce/tW8sUSRktFbvjnYTz+VVpLWKVWaB0h4OYy4/rQBlJnIIUHHPPenMhzkgH3OefzqeSLY37t2yDxkYx/hUT72bEp3Yx+HSgBdm2PAkXJ6jPH+f89qaS2c5zt5z0A+lKsWQChwRznmnL5edzlmPUAZP86AIwvPKE8YwD9KXaWz8hPOCATj65p8LKMgBl4znOfp0qewUzTrGpDKO5ycD/AD/kUASadYtd3CxxKME4LMSFH1PSu+0jwylttk87BwDlOT+BrlbhJTH5NrasExyyR/1/p/hWVbXV5pc5aCaWPHJG4rn1rKrGclaDsd+X1sLRqc2Kpua9bfh1+9HceI5EsrxYReLArIGCsGZu469O1ZUGtxWvmIb+ViwwdkPH6sP84rmtQ1W61C4Et1IskioEDFQOASf61TLA7R83B/z9O5ohCSilJ6jxmKoVK8p0aSUW9N1+Tt9x0qanaQEiGW8JyPnKKgx7cn/GtjStftInklQTtNgDJcbj7DjiuNYxqAiKu713dPx/w9etWRJBbBEgByMbm6Fj/Sr5e7Of6w18MUvlf87nT6k9tdFri9iUnGQjSnLcdMDHH/161b/4ca55Utw1rZWllbxW0wnExKyLc/6tlLH5j8pJ/u4OazvDdhBcxm9u2yScqg6tj+n/ANeu01n4k6pa+HdG0q1Fs39k3CT2xCFmJRiyeYc4Krk4GAMHnNCikTOtKas0vuS/JFGy+Cl0vijw/Y6zcJ/Zeqi6C3dk+SHit3lC4dR/dHOMY6GuMX4aeJH05b6G3hltW0+HUkaOTcHjlfy0VeOZCwI29QRXT6l8bdffU7K9j03RYprO6ubpESOZg8k8JikLbpScYYkYIwR6cVzVt8T/ABLaeBbPwtYXS2dlaXHnx3EG5LkjLnyy4OCgLscY6n04qjEXxn8MfEXg7SF1LVVtGgFwLSYQTeY0ExXcEcY9AeRkZGM5rh8e/wBMCu48c/EnVfGdkYtWstOWd5FlluoVlWSZlBAJUyFF687VWuHPpjnpxQA2lAycDrVvStOu9X1CGx02B7i7mOI406njJ/IAn8KNU0+60rULix1GB4LqBykiNg4P4cfiDginyu3N0J5o83LfUSeG3jtbSSK6WWWVW86IIwMJDEAEng5GDx+NVe1L9fTtRn3OaGNAfr04GBSg4PGMHseaCvyhux9f6VII9yFk+Vh1B/n/AC/OkMlRYpAFzhxnGP8AP/6qjmt2iG5l+QngjtTVwG4yP7u4cE/57/StSzYThoZUGfX0+tAGSww2Qv3s4X0pQOCw49R2z2H6dPar8lu8DGOVcg9n78diKrmFSTuV0P1z+v8ASgCezZXHz7gwGCw5/WpI7jyTgxNjsU7/AIdv0p1gskZItmDN0245HrirUtvDfIS4EVwOo6A/5/rQBn3/AJE4SSHcJD1BBwfeqIyACQCoxnIz6f5/Op7i3ntG2yI21T97GRSLcK2N0aBh1IGP0oADDI0attJXpg5wfbr/AJxTWicKRIojGMjI5pRcMFwyLjGeCQfzoDNIOH6fLzzkf5P+ewBbsdPW5lZHnWMnlSyEkn/P+eaZqGmyWkrCQhkPIYd+M1Ha39zbP+5lkXP8Kkj+Vb0Go2VzEwuIZDOR/wAtZGwT+dAGDp5T7QPODkZOV6ZPGcmu2S6s4ooVOn2yQhgW8rIc/U4qHQtL0qRzNezQADLKokK//r/Os7xJqEJulitnjdE/55kjA9Oef880Ad9Dqa3dm1vZQi3BXARflLcev515n4psZrO8driMqWPykLhT9D/9ettfE9tZ6P5dlaA3rdJ5dzFTntk9a3JfEdhcaLFJI9v59whAglOVD46N6Lnua561SdOSsrpnt5ZgMLjaU1Uqck46+TXp3v59djyxshiCSeec+tID79ew4qS5ikt55Ip12SKcMpGKj/8A15roPFknF2Y+N+T8wQ4OSB19hVy0YOwJHyjkDsP8+pqiexOR/T6U9ZTGSY1UDpkjP60CN2XWGt98cZ3dM9AP/r9KoXF69wTJIxK9doyB/nt/9fFZ8jliSSCTxSZI5BbA4BoAsSJ5aBn2l2Odv0qtnvwSPWnDH8eST0GcfnTgo2eZJ0JwAOPxoAjAOBjp3PpR14wOfepoYzNKd2Aq5LEDP8qZKyl8KMKOOO4+tAGj4WudNtNbtp9agu7iyjJLRWsvlu5xwN3YZ645+lQazJZzardS6XHcR2TuWhS4YO6qexPfHPNUR9aXHqMc4PHSi4BxjoPSlBAJDcjvzn8RSdB79qO/BPHQ+lAEsTYPPJIyOwP+fX2qZlAP7oYb1HH6fWqmTjg49hUsE5ibcAKALETpIoSQFGI+U4yCPU0qxPDMCNyN2IyV/D296kja3mcblCM3bGPxH+f/AK0xt5Lfa8EgdB/nH8qANJGMwMV3H5EpH8edrfT0+tUjagSGC4zG5+42cAj2Pf8Az2rStdWITY1uxjHG3hlI+h+lLCizg/ZxIEY8o2Dg+1AE3gvTnbXWklGUgQnJXqTwP5n8qo65pzWOqzRJ0DbkI67T0/LpW/pMeqadMPstvBJbzOvmEg7gO+AD6Vja7eandXPmzRRqVyiqFHTPfPP+TXOlP2zfSx7lSphHlUKav7RSb279Put80UXiuCiiZ2MPQhuT+Zq1FpFjcQja7lu6jIP9fy4qulzOmDKXtw3AAyFPPap472RHO6OOVD3Yg/5/Cug8Mp3tlZxJ86zRMOckZyPpnmqtrp0VwfkucDgAspx79K3FvHKSAxKj9Quflz9P89aqxzKdxkEW7sVYf4/pQBn3+km3OYriGT1UNyPwxVDyZcj5GAHoDjH1rutMkS4jEcxi+TkcoP6f561PfXFssIWOzlkKj70ZBH1+XGaAOd0xrm3tJN6x7McO6BiPfmsG+YvOzE7vfAA/Ku2hulnbyVhnjyO68+/vWBrNjLFMPJj3sere/wDIUAYJ7gEY68UH16D0qR4nTG8be/Xp71taXobah4cvL2EHz4JAFA/iUDLD68g/hUymoK7N8PhqmJk4UldpN/dqU7e6iuoEttRJwo2w3OMtH/sn1X9R29KqXlrLZzeXOADjcpByrA9CD3BqDvyMHtWnZzfuBbXyNJaZyrDl4T3Kn0z1U9frzSty6otTjWXLUdn0f6P9H09Nsz1xjjuaXBOTxxx09qs31m9myEuskL5aKVeUce3v6jtVXsOe/B9KpNNXRzzhKnLlkrMDgHAP4+tA9s59vSjtz/OgnOef0pkjkGSMdPU/r0qyluWbc5Kx9fmPOPekgt5B85O0epGT+AqwV2YMr4x83qT/AIfzoAguXKqFjXbH15A5/CqmOxxg9/SpZmDvkk9+Ae2aiGe2Dx6UAJ26j/ClGcDHHPB/+vRkf4896Dzkk5PU0AJ06E0o64HP4UuTnjg56elJ6Ad/WgBOw5FL68nFB6dhR0PoR3FAAD82R16nirNvNKkincSM8nk1W4x3/wDr0+NijcHHPPoaAOrgnjnQGNY5GGMlCCV98V1fhuGO7dY51WFmwFZ14/PpXl0UoEoJ+913A7SM/TrW7Y6vf2pUJKzRnnIIGD7/AKUAejar5mjSFHMsR9kLI49R2x9DVe/vra5V47y13BWKfIuN3b+lN8N+NnhWOG7YSRqMeXLGHjb8xla9Q0RvAGq6dFBrME9ld7NrzwzNtJ9cc/XAI/Cp+0dEdaEvVfk/8jzez0nSr6ILZ3EunyE8rPGZIm/qPypb34NeJb8G60aC01GEjk2bjP5dj+Aru9Z+F9zHJ9p8FamupWZPyPHP86+zDPr7VgzaF8R9PbMOn3cqrxuVdx/LB96o5zzPW/AfiDSnP2/TNRgZeqmM8flUEXh7UHjBEWSvJ81SDjHqa9Kn+IHxK0orHdxalHCnVHidlIB9COPyq4Pi9rUtkY57dg/97yyp/nQB5a2noHEQtJmn6EDOD+lW4PDd87BpClqg/hdip/LjmtrWPiLqbKfKUxSN92RQM/TOaoWPii6lYvMJPMIyZShYk9epJoAu2Ui6XJtNvHIQMCXG7PvjFYXjRluo90jSeYOAPuqKtX9xLduzmSRieqltv8jTtA8L6vqcsnkWgeEAgl0CqPxY0AectH8+AePUck16B4K1bTrLSYrSS4xdOzyeWEYnvjnGOgo1fwbdRXOy7SADOSInDHH4D3qC18PW9ld28xDI6OrDcpySDnGP8/Ssq1JVY8rPTynMJ5fiFVglro79m1ftqclqLWtxq00mnI0dq7ZCuMY9uM9+lOuCVjCggk8E9un+f8811U/h+2glk2jcQSP8n8P/ANdYl7pc6zEJAzJ3JH+f8/ppHZWOGu5OpJyVndnefBzwfpHiXwd41udYnCrpwszAZ7yO0gVpXkUszuCFPyjHIyeO9bOg/DnQL7VdDEtrCumah/bYEkd687EWo+Ri6AKyg4IZB8w7V5TZ61qmn6Nq2i2Vx5em6t5P26ERq3m+U5eP5iCRhiT8pGfSr2ieNvFOlJpMOlXnlppIuFs1NtE4iE/+uB3Kd27j72cdsUJJakyqSklFvbY6VPhGs0AvoPEtkuiNpR1Zb+a3lUeWsoidTGoZgQ3pnPFWLD4TTT6MLqz1q0a8msp9StoWt5AJrWJyN5c4CMwVmCkZx1Knpkr42126mvJNa1lZI7myGnywRQRKn2cMGESIqhUXIz8gBp8HxD8Ryaevhjw+Z5LSZWtIbSGASSMrtkxK20vhj1UHBz0pkHb6/wDDjQ9GOpQ6RfDU3h8NNrDtd71aM4ixIpUAHO87VOcAfNzivO/HfhC08KRG0vNegk8QpHDLcaetu/yCRA4Al+6WAZSRjvwTiq2o/ETxdKr2d9qIUpYyaRIHtIlcW7Fd0TNs3H/VryTuGDgjJzPPq/jfxNpOlaNeGWeyvlEdpLcW0URuEhJGBcsql1QjGC5AIx1oA4bJ9eaOwHTPUmjtzn/PSgnv1z3NAB2yB3/Kjp7jpmj6/pQM54zn2oA9h+Bvh7RdV8J+NtS1mw0i6n0x9PEEmqzyQ28SySuspZkZTyo49wPodW1+GPhDxHrNxc6Ff6odG1HXG0fSzaR+atviJXMkpf5imWwBwdoyTXlulabrb+CNe1LT714dESe3t762S4ZfPZixi3IOH2lSRnoeRWn4M0HxxNrMGgaCdX0qbWELGMyS2sU0Sglmc8bkAz69ffkA6rTvhZpE3gK61ltQvL3UrWG4ubm3tGijEMUTld4STBlQgZ3qcDOMEjnpfEHwm8LT+O/EUOnSalp2k6LY21zJbggs5kSPmORyx2jcWYnODwOMV5l4n0zxv4a8NQ2t9f6g3ha4lligWG7drORo3G/92SNvzH+JRk5xnBrLh1zxh9qsruDVNe+0W9uUtJkuJt6QDqIznIQY5xxxQB2vir4d+GfDvhrV9YfXdSuootSfTrD7PaLiYm0jnjMm5l2jMmGIBzjgc10ut/CjSZPGevC/nuzbprVposEOkWkaeW80IbznTosY6YHU9xXkGqTeKtS0+ObVZNcu7C9uPOSS5Mskc85ULvBbhn2qFzycDHatjRIviJe+I0TTZvEaazrTGHzmuJYXu9oIKtIxAbAGOTxQBpeM/AejeEvCdve3uq31xqlzeX1nBFbwI1u7Ws6xl2cuCqkEkYDde3fz63uWh+7lSOODjFaV3aa+8MOnX6al9lsnkVIZlcxWzEgyFR0XPyliOvBNJc+GNVTWL7TbK1l1KayOJWsonlUD1+6Dj6gUATWd5auV+1oEY8eZ7f7w/rXY2SJcyh478KpVcg5XoADnHuK86WzvUyPs1yuIhcEeUcCP/noePu9OenvXXah4Z8RaB4ivdF/s2W/u7FIpJvsELXCIJI1kUkhcj5WHpyPalbW5am1Fw6Oz+6/+Z1/2WVYw+nXjRS5+YQzblP1x0pR4j8V6K4eGedgpzv8Avf1zXDDUL82vnx2s8cY3HzREwQYIB5xjgkDnuRRBrOvN9n8mK7ZJi3lFFLCQDlscEHA646frTIPdPCHxi114Vhu5lY8L+9PQY9xjHtW/ca5b32LnVP7GA4yy2oMnv8wB/WvE/DV7q+oNEY9LmvJWXzFMNszsy5+8MdRnvXoeiaTf+IdMgaAW8DS6gNN2yRqjrOUL4OBwMKaAPQNIj8FamvzLYSleS1y/J+gVST1qt4g0bwZcMkGlaNpDTScNIHZQf++wfyrxSK6vre9l8maP5TtbbjOc1Uu9fvUuC9xeOWHZ3Ix9AB9KAPbrjwZoWk2sc72Wn4YA7Vuc5/BRSWEug2geeC00614OX8x2f8AWrwa48VX5+7cTKT3c5H6jPpVC41+6Cl3llduzbsfoBQB9CQeJdJvZGhCMICOWcLuI/wBkAZ/U1y+uahoFpOWjsIHCn/VuGYufdien4GvMNE1mVpPMkkmEnrljj8uf8/meJNZintCipMxJ5kYgD6dzQB0t74naAKLSCzjyCybIELYPq5GeO3NcZq+qzXhdr28DY6xxAKPxP+f6VialqDPpVo0EzAZeEnG48EHH/j/6VzzStjhnweOT1qYbWOjFa1XLvZ/er/qes/Bzxb4U0xdSsfGgC2Syw6jassBkLTwvnyvlBOJFJBz8vAzXTeEviR4XPgsxakdOtNUuJb2TU7a6s5WjvRMzFCvlowO0EKFYrtK8Gvn3JJBJy3Y5xjmk69Ko5z6jv1tB8IbrUysVroH/AAjVvBbWE1kYf9LLpvdJSuJC/wA3KsW55AxzDffFTwdDrOh3uk3Nimn2upW1xFbrp8oubGEKUlQDZ5YXaTkKzZwCBnmvmHt2FKfQ5GDyKAPpjwX498Hadr2rXWteJ7a9F3qpknD6dKIJ7UxKFKxpDksPukSYHykgEnJzfC3xD8MfYPh1Bq+s20djod1dpfWM2nPITGxk8h1KxkFQrKCM5JOSD1r55x0ycfWjPH8vagD2zRfGXhO2+G0Wnz3EKhNHurS40c2JZ7q+diYrkTbdoC5U5LBl24ANWfF/j/w7qmheK9GgubN9Pk0uwGmRrp+w/a08vzSH2BgeHGWOCOATxXhXGevFJ26fSgBTxkcdfWjsATj+lBI7DjtR068j+YoA7/wH43sfDPhW+sZ7KW7u5NWsNRjjIXyXW3dmZHOcjOQOAe9elyfHPRk8T6dqML66bKO6urqW3a2iV0M1u6bVcSkuN7Iedg+XOCcV8820E11cRW1vDJNcSsI4o41LM7E4AAHJJJGKlv7G7028ktdRtZ7S6ixvhuIjG6ZAIypGRkYPI70Ad14h8dRa78LNE0G9vNabV9OubiVy7h7e7WVw252L7ty4IA2n7xORWhoXxMtNO+E114fltLl/EUcVxY2F4u3yorO4aN5kY5zuyjY4P3z05z5YAMd8dzjpR06jHFAHvurfGnRtQsLTEGp2zGTTnuLBLaJ4V+zSRsTHKZNw4Q4XYvLctim2nxwtYtVa6u21y5CeLn1mFZXBMVi0cieQMucMA4+QfLx1rwQ9Tng9x680D0yOeelAHq+v/EyE+Fxoui6n4ibfrEt7czXDCM3Vu6Rr5cm2Rt2CpG05GMc+mzqfxU0HV7vxDE8niXSLa/1xdXgu9MEYuXAjCeTIN4AAI3KQzYJPBrw8c9s+w60Y46dvyoA9tufid4Vn0W4kNtro1ybwn/wjRDLE0GV27ZN24Nzt5449D20rH4weFovG2u669prUTXk2nywOkUch228CxujRmUICSG2v8xAPQc14B9Bjr19KOccEdKAPVviV8UI9e0GHTPD02q2Vs+pand3cLsI4547i4EsKsqsdxUZyCMAngnrVj4a/Fm18JeE3trqymutasr37VpUyqvlxrIEWdX5yMopxgHJY5xXkPTocDnmgY46D3oA94X4teFo/FN/Pa6dq1rpFtplvp2jlER3gCNubzIvMCNuYtgljjAOD0GtN8d/DjeIXvk07V1tz4ii1bASMN5C2piII3437znGcY5znivnEYyP8aMkcHPT1oA6V/FlyL+4mtxJ5TuzBWYZAJ+nXmornxLNcOG8lg3bEnf8AKufPI65470n4CgDUk1m4dQSM9vmORV6x0jV9Y8P6zrdrDG2naP5H2t/M2mPzn2R4BOTkg9PxrnTxn1Fei/DfxT4c0vwZ4z8O+Kf7XWHXvsRSbToY5GTyJGkOQ7qOSVHfv0oA5Sx/to6dJeWNnctY25/ezx25eOM/7TYIHXoa6/U/ht43n021upYftMlxYNqZs0lxLHbqud7KQF6EYUEtzjGa6jRfixoOl+C4NCtF1a3FjHe2kLC0ilF3BM7EGUGQCNyGAbAkHHHaksvjFaf23YPd3XiBLAeFBoU7xODLFdGMK1xGpkAPzAHJKscA9qAPI7C11DUVfS7Gwubq583zfKhiZ3UgEN8gGfTPpirdr4Q8QXOl6tqMOk3P2XSWRL1mG1oS+QAVJDHoc4BwOTgEVufDTxPo3hzxJql7rKalPHPbSRW88QDyJIXUh5Iy6rIMDlS2M4POK7nxL8XtH1n/AITmGOTX7S3122sRbyxLGHWaCPa4kUSABZOASCTgdD0pWsVKTla/Q8ksPDuoXLXglj+yfZraS5b7SjrvCKGKrhT8xBBGcDnkiqElheIZPNtLlfKRXl3Rt8inox9AcjGa9f1n4vWupeMPFF9JJrUmiX2gTaXYWcrAi3mkt44i2zeVVS6Ekrk4wcUviT4leFtS8P8AiBra11qPXNZ0iz0+VJFiNvG8BTlWDbiCE6kZz29GSeVr4b1x2iVdF1JmlZkQC1fLsoyQBjkgcmsrGCRj5hxX0PqXx5tbjX7u7tp/EKWkviGx1GOHcAVs4kAmhwJMAsR90fKe5FeF+KL+LVvEurahaoyW93eTTRK+AyqzlgCASAcH6UAZn16elGeM/gaBwc9u+KB2xnI547UAHGOv6Uep49T0oHXgd+M0cY70AGeODj8a2tWgiTQdKkRFWXDrIR3yQwz+DCtGP4d+NlYE+CvETgfwtpdxg/ktXm8E+N5IGjm8DeIWQEMijTZwFIUL/dyeAO9RJO6sY1YycotdP+G/Ux/h3x4/8MnnjVLXJxkf61a3/j4P+Lta8BjP7jp/17x0/wANeDvF2meItLvp/AfiQQ211FNIYdMufM2q4J2ZxhsA4ORz3FaPjnwv4k1rxPdXOmeAfFUejt5Yggl0yZJYgsaqwB2sBlgT36561V32Lcpdv6/rzPK+Me9GOuOnvXbyfD7xUP8AV+AfFOBx89lM3P4Rjj/OaiPgDxnn/kQ9ePv/AGZdf4UX8gUm+j/D/M5SwRZL+2jb7rSqDkdiRVzxJCkGt3SQ7BGWDgAAAAqG/rXRw+BfG0MqyJ4D1sOOQTpdycH8qfc+BvGdy3mz+BfEck+1VLHTrgBsDAJG30A71OvNczan7RTtpaxwyqWIVRljwAByTQRgkMCDXap4H8eRIVt/BniKDPUxaVOGPGPvFSR9B1zSnwH4zlJe58DeI3kI+Zk06dN3ufk5NVd9jTml2OJOAecdexo5B9x612rfD/xaFOzwF4lz0G6wnP6BAf1pp+H/AIv/AIPAXiMf72nXJ/koou+wcz7P8P8AMyPCNrHcX0/nBWUQso3dNzYQH/x6sWVDHI6EkEHafwNdxa+C/HFs26DwNr6EsrtjS7g52tuA5HTIFNm8B+LZZHkPgLxNudiSPsE+PX/nnUK6k2ZRU1UlJrR27dDiApfJAJxyeOBzj/CkHPA7+/eu1XwP48iIEPgzxFFHn5o00y42vxj5sqc8ZH4n1pw8AeKWBZ/AHikSHtHZThB9AYyf1q7vsa80l0OIJ7kdeee9AHHTj1x2rt/+Ff8AinI2eAvFQ56tZznH5RVH/wAK/wDF+7jwF4i2eh0653fntx+lF32BSf8AK/w/zMcWcI8Jfagq/aDc8ueoXGBj8c/5xWID9OK74+DfG7xC3n8DeJPsqoE8uLTp1OQc5yUPqf09KqnwD4xGDF4E8RAjp5mm3D+/TaBj6g1MeZXuZUueN+Zbs4vHHfHrR64xXWzfD7x1M5kl8H+JWc4GTpc/TGP7vYYFM/4Vz435x4N8S+3/ABK5/wD4mrOheZyvbj+XAoznJ6nuTXVH4ceN/wDoTfEh9/7Ln/8AiKP+Fc+N+P8AijvEv/grn4/8doA5U8gk557+poH4V1P/AArnxv8A9Cb4k/8ABXP/APE0p+HPjjr/AMIb4kP/AHC5/wD4mgDlKUDP0747V1X/AArnxvn/AJE3xLjv/wASyfn/AMco/wCFceN+/g3xJ+Glz/8AxNAHKDjkHB9aO2OK6v8A4Vz43PXwb4lP/cMn/wDiKUfDrxwSP+KO8S5zkY0ucYP/AHxQBygAyM0dMEHBrqh8OPG5/wCZN8SD0/4lc/8A8TR/wrnxv/0JviX/AMFc/wD8TQB1P/DQfxP/AOhm/wDJC1/+N0f8NB/E/wD6Gb/yQtf/AI3XlVdL4a8H3uv6bdX8F3p1paW0ixySXs/lKC3TkjFRUqRprmm7IuFOVR8sVdnYf8NB/E//AKGb/wAkLX/43R/w0H8T/wDoZv8AyQtf/jdcheeD9Q07VhY6o8Vtvga4inG6WOZQM/KUBzn9O+Kxf7Lv/sf2v7DdfZMZ87yW2Y/3sYpRrQkrxY5Upx0aPSf+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxuvNU069eyN4lnctaDOZxExQf8Cxir2u+G9U0SS1S/tnU3MSSxlQSDv6Ln+9x060/aQT5b6i9nK17aHef8NB/E/8A6Gb/AMkLX/43R/w0H8T/APoZv/JC1/8AjdcJpPhvUL/X7HSZYZLK5u32xm5jZB9emcVVOkXzXF3FbWs9z9ldkkeGNnVcEjJwOBx3o9rC9rh7OVr2PRf+Gg/if/0M3/kha/8Axuj/AIaD+J//AEM3/kha/wDxuvKqKsg9V/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG68qooA9V/4aD+J/8A0M3/AJIWv/xuj/hoP4n/APQzf+SFr/8AG68qooA9V/4aD+J//Qzf+SFr/wDG6P8AhoP4n/8AQzf+SFr/APG68tjRpJFRBlmIAHqTXV+F9ETzYri6UPyRg9FOOvoaAPQ774y/FKHTLOeHxFO87IWuEOn2eEO47duI8njGcgc08/F74q3EVs+meKvtTymNWR7CziId1iwACvzDdMFz7ZOM8Upo7ZYTHJ5bPjc5Lc7cjH+emOK4bxFJc22rQXtl5avb7CDFkAlAoUkZx/AvQDoKbdxJWPT/ABB8WviVpfhy21SLxnJLIb2XT7m2k0m0QwTRgFgGCsGHzdeK5f8A4aD+J/8A0M3/AJIWv/xuuH1bxLfapo1npcwhWztZHmVI0O5nb7zsxJJJ+vrWLz1I46/dpDPUv+Gg/if/ANDN/wCSFr/8bo/4aD+J/wD0M3/kha//ABuvLO3fGOeKXkdRz/u9xQB6l/w0H8T/APoZv/JC1/8AjdH/AA0H8T/+hm/8kLX/AON15b374H+z29aTGByDjHp+VAHqf/DQfxP/AOhm/wDJC1/+N0f8NB/E/wD6Gb/yQtf/AI3XlvPYc9fu/nRjHrj1x26UAepf8NB/E/8A6Gb/AMkLX/43R/w0H8T/APoZv/JC1/8AjdeWYOMYOe3HX/OaXqcjk9fu/nQB6l/w0H8T/wDoZv8AyQtf/jdH/DQfxP8A+hm/8kLX/wCN15b2746g4owTxg56Yx3oA9S/4aD+J/8A0M3/AJIWv/xuj/hoP4n/APQzf+SFr/8AG68t68jPPP3fzpOg5449PxFADa7/AMG3+iSeBNb0PWNXXTJru5iljc20kwwuCeFHt61wFFZVqKqx5W7ap6eWvW5rSqulLmSvuvvPXbTxloNpf6Vp9vdTNpul6ZdWy3k0TBp5ZQOijJC5Axnpn8as+GvFPh3StAtITq5Ky6Y8FxDcG5kkWYqflVR+6WPJ44z+teM0Vxyy2nJWu/6v5d2dMcwqRd7L+refkeuy+J9Gm+H62l7qiNdxaYLW3jsmuIn37cbJI/8AVsM5y+ecZHJGLT+NNNfXfC+r3WvzXFpBbxw3FkwlZoJ/KdTOVI2sQWHIyTnjNeMUUf2bS11et+3XfoH9oVNNFpbv0+Z6/ZeKdK03/hHbbUvEDazPa6q17JfmOVhBCU27MsNxyfmwAaseHPGekQ6Pbw299a2N5aX09wxuftKpOHcsr/uSAxAwu1weB9a8YoolltOSs2/w8/LzHHMKkXol+Pl5+Ro+IJ4rrXtSuLdo3hluZZEaNCilS5IIU8gY7HpWdRRXoRXKkjhk+Z3CiiimIKKVVLMFUEknAA7103h62tEtw11b/wCliTzI5zJlVULwuzGCScHJPY0AyxoHhxUEV1qEyxMGBETKcgep/wA8Gu3061tLSIyYlMhYr5KFlBBHUnA9R+Q+tQ33iCCfTwjxwh4WHlydCqjHBOPqMH1rmZNZlWaSSFyq9OG4JwB+H4elAHU6qI+YvLjlIXkluQvTr35A9TXKamIp386PYFGWBL4B+neqMl+C3mImXPWTcTgHuR9RVZ7tI7lcwsY8ltrDLD0/oKAMu5gaWV2tonMfU4G7GM559KqEYJ4x7E9K7GHxEY4pYYbe3WJ8BQBj156c8fyrm9Ujj+0l4FwhGWXuD3+goApEDPfFGDwMHJpOP8mjjH/16AFABPQ/T2oA47n1xRxnocZ9e1Jx3/nQAuOO/wBaQjjil49P1o4z0OPrQAEAeuOxx1oxzjBz0x70gx+NHGOP50ALxzwcUYGPfp7Ucc8HHbmk4/H60AGOOKXA4649fak4/wAmjjHP86AEr2jS/Duk6r8HvDc50Gzt9T1LX49Hl1JBMZFhO0+YAX2biTtzjGDwAea8XrqrfV/Gx8NKLfUPEh8P2zLtEc8/2WIowZcYOxSrAEehANAHrnh/4T+DW8TWKNdavf2lv4ml8O31vcosQlkWOR1ZGjbITMeDzk9cDpWP4b+FfhrVrG/1a+1XU9P0v+1W0y3V40EkBEatvlHOcluEGCQM57V5tJL4wiNu8kmvob26/tGEsZh59xgnz1/vSYJ+cZPPWtjw+vxIvdbvTo914kTVbm1N9cuLuWGWeBV++zMwLjA45OegzQBvyfDrwvp174PsdY1vVEvNeCEtFbJ5MIaV4txZmDdVHG3pnJrTs/graQa8ukazqk8eoWekzatqNvCFyqibZGiE5xlcOzEHAI45rye+OvX0lpHf/wBp3Lwxstus3mOURWJYID0AO4nHAOavpP4yudTXX0l8Qy6ixjC6kGmaUlvlTEvXnG0c84wKAPQ5fhl4SshrOoXeuatcaLZz2UcJtIE81xcBshixAyrKRuGQcdOeNTWfhX4Z0zw/LYs2pTauni3+xBqEa8eWVjYBl3bQoV87sZ3cfdrx7WNd8RyXN5b6zqmrtcSSKbqO7uJCzSR527wxyWXJxnkUR+KvEfmXITX9VDXkyTXB+2yDzpFIKu53csCAQx6YFAbno954F0S20/4h2GjX01xNok9rZyT6jZxpiU3phJjcMxVcYy3BPPAFWp/hLo8nifV/DtjJ4kOoaVDOZLia0UQXUkcLOojA5G4rwDkleRXmLtr8i6ipvriVdRYPehb0OLpg28NJhjvO75snPPPWrx1fxwBZEan4iIscm1K3Mx+z8YOzB+TjjjHFTzx7m/1Wv/I/uZ6Bp3w+stE8I6vdajA097deE/7UVLqEBrSY3Kp8ueQdo69ea05Pgbphh0+Jr/UbPURqVnYX9vN5chj88dQVG0MOuNzcHkivIL/WvFVx5v2/U9bl82E28nnTytviLbihyeV3c46Z5pZPGXioxQRS+I9cKW5Qwo1/LiIp9wqN3G3PGOnammnsZShKPxKxL4z0jTdC8S3On6Rc3twlqxhkmuI41JlBIO0I7Ar0xznrwMU3R98MiPM6kochixIYZyfx+vNYjSS3EjNK7yO7Fyzn5mJ6sSeua6VIL2ySNp7aWNXCsCehHpx/n1obSdhxpzlFySulv5DNdybgfZZIpISSVJ+8B2B/z/hWYtrLEy8b0UcYYf0z3NXhHi6VLpZR5jZDRfw8+3X/APXTWtWjSMxTPJg4II24/wA59PzpkD57LfGJFfOCBsOOv4dKoXkM32p0K4XIyNuV6+vpWoLxp2VVTDRtg4Yc+p/Wq95ciGdstuQDhN3GPTH+elAGds27VTyi4/iHOc++P61UkBOdwXdnnoavXVwy71BGG+6oGT/npWcznGWyx6hjxz6/5/woAYRhiFI9B7+9ID3wPpSggKeMnGBxSdM8j06UAHbsRQeB2NGec8cc9KOncH8KAA89cfWjvnjPWpbW3lu7qG2t08yeZ1jjRRyzE4AH1NeqeO/g3e6JrXh7T/Dt+muS6tLLZ5WMRiK7ibbLEeTgL1yccA0AeTe3HvR6nAxnOK71fhV4gmv7O2sZtKvIL22nuoLyG7X7O6QHEo3tjBU9c469cc1Y1v4XzaX4R0rWW8Q6HNJfXj2fkxXUbIpVlUMsoYhx82WwAFHJJoA857duf0pfQZGM4zXX+Ovh/rPgy10681RrSa01Hf5E1uxKsUxuGGVSPvAjjB7VyHtkemcUAH1xR3xxnpR75H5UdOhB/CgBtezWHxS0S3+GVtoV5aahqGo2tsILdXjEMcZ8zecypIDJH/sNHz3avGaKAPqTw/8AGHQPEPxB0Jnu7rTrWTU/t8yajHDHBbMLeVCROZCT94KPlTjrmuP0v4vaRpl1oVnFN4juNOstNv7OfUZigvJHuSCCF8wgrGVBUF88k8V4XRQB7loXxP8ACdpZ6JLfxeIptU0mz1CwjkCRMk6XBkKyPl92/wCf5hz65PeFPjFFb+HF02xuNct/L8Kw6PGsbhES8WUs0wAfgFMLuA3dsYrxOigDsPi14mtPGPj7Utd06O4jtrpIAFuQBJuSCNGJwSOWUnr3rj6KKAClBIIIOCO9JVm7t1tnjC3EM5eJZMxMcISM7TkD5h0OOM9zTt1C+tiS21K8t4pI4rh1WTAJGCwwc/Keqn6EZ6dKeusakBtN/dEDopkYj+dUfwwaOx5O3/PapcU90axr1YfDJr5m5Y6vcP8ALcsjHqpeNTk59x7131x4k08qUSOS4Rh2j+U+xz/hXlAYkAbcg8Adq6DRdPnu23WsscbBful/84/zmsamHhUab6HpYLO8Xg4zjTd+a2+trX2v6mjPfE3qPpNv5Eathh5nyn2weBWrfxskkPk2rLKo+Z+NrD0wOOmK5+2c3fmRkru5XHHXvg//AF63bOW5tnZXV5BgAKwIKfjWyVlZHl1akqs3OW77JL8FoM1jQfJg+3wKy2zkHhlIZuhyuc/15rlr6GSQtJHIFXPIJG78q7jUVsjPFHp83mRiPdO8ygKp9PrTrvwfBPZLeLdB4jllO1fnP+7nJHuaZB5hLtIJyWIOB0H4+/8A9ekZmGCHJJ9M10F9oJtxC1wm0SnIfd1H07U7S9PtLdnN3AsqkkI0pIB+g4oA5kg46c0qkZ5A56e1a2r2j+cHAjjt25REPUeoA7e9Uo7KR2CMQjYzg9f88UAVcnOcn1z70fTI7fjXXR+EJjp0d1ORErDK5GS+O+PSue1G0WCQGFi6nj3BoAteEdem8MeJNP1u0tra5uLGYTxRXSs0ZcfdJCkE4PI5HIFdnD8a/GS2lul1dQXlxa6guo291cRZlhkClSoIIGxlZgQQep5FebKNxAVSeegqzp9mbuRtzeXBGN0sp6Iv9T6DvSbSV2XCEqklGK1Z3DfFHWleB7LTNKsrC2srrT4bO3gkWCEXIPmsMuW3nGeWIGBxgVQ0P4h6po+h6VpkFnp0y6Vf/wBo2VzPCzSwPuQkDDBSp2DOQT6EVzGoXizqkNujRWsXEaE9T3ZvVjx/KqZxkcHH9KE21qOpGMZWi7+Z2vjz4i6n400+zsr6w06zhtbia5UWiy5Z5cb9xkdiRxx/hgDih7A4Pb2ox0GDuNJ16A0zMUdOh/CjqMZ7/gKODnAOP6Uh9DjjigBKKK928Y/Cq0vf2hrvwvpdtNo/h99hikSNnX5bRZXSMsfmYlX4zxz6YoA8Jor6G8K+CPBWia3rF9K8+sWlr4en1JILiFJfs8scio4OdqSEBlK8Y5OcECuG+MWg+HtJ07whd6DZ3ltPqmkQ31zuH7l2dnyR8x2tlfujCgAY70AeZUV69L8KdP8A+EQ0/wARR6xItjqkVjFYvIqgNeTSvHNEx9IvLZie4xXRXXwS8OjxRY6LBr9+s4vJ7O8V4VZ8JbSzLKgGAoJiI2sScEEGgD5/or3vwn8OPBd5LpWol9Zv9I1bQ9Qu4YJlVJo57Zihb5GAPIJVckZxnOazfD3gXQLXUvAsi3+pm/8AENx+5t57ON4UiFw0TCX5+cp1XaQTkE4oA8YAwfp19qB0HSvVdU8BaRp/hyPVb9tZu7rUrjUEtY9LtUaK2+zuV/eg+pGcLjC813Xib4U+G77xx4xvbu5Ok6JYalb2EdtYIiCHfCrmRsg/Lk8ADJJPIoA+cQjbNwB2/SlPygg7ST35zitHXrFNH1vUdPjn89bO6lgWYKVWUIxAbaemcdD06Vm5yBxxQAmD3B9SaeDIrcbs57fpjFMPQUEEcZGPUd6AJEldHDxs24c59Oa6fTfFTQxeXcxQyEdCVB/U/h3rlMHHf3OaXtkH8AKAPRdN8UNBZv8AZYbHzpDkmRATn2zUdrq7rfM5LNzllUkA5/HHevPgSOjYPrW7pWumy2rJGsgUjBZFbp9eKAPRLRQloxaC5dZj8pKKQoPYE8nrVCe0tTceQYpZrhznYgGF9evFZN/4obW5C81ysQK7VjACgfgP8O1YN9fiJESK5cyL/GpI/XvQB3vibRrXTLeFbiaMyuoLIG3eT7ZHX3rgVv0hv0NqkTbWGzLcH3J71ly3srjDyNJ9WP8An/P41AgZ8heB3yOn40AdrqfiIzwKjyLIQuX9PoB6DH+e/Kyu1xM0zICp5weAo+lSaZp/264SNWZYsjcWPX6CtnxHFBYCO2jZAiqBtUZYt7n/AD/SgBvgGw+16957L+7tQXz/ALR4UfzP4Ve+IL6eFSK0nRbrzN0sUQGGOPvMR3Hv6mubTWbqC0ktrRvs8cjZfy+GPHAJ9Pp71mEn2rn9i5VfaN7HtrM6VLL/AKlThdy1k338vlb8dA7ccevPWg8c4GM5xmvQfgFYWeqfGDw3ZanaW15ZyzSCSCeJZI3Aic8qQQeQDXqkml+Bb74cazdeFbS1luZdU0+7a6MCGWx+0zgG1RivAjVcccHd3roPEPmrHUcfnR/L619Ka/4M0G+0jVbf+xLy8vI/Gz6bc6nE6LJDCxjw77YsBCG2heBvOc87axNA+HnhjUvHHiuwsdI1O707w/cfZJ0e8LzyP9odA8ccMJJXCjOcBepPagDwbp169u9HXIHP4dq9s+KXhjT/AAr8NtV0ywVnSy8ZzW0c8oUymMWkbBSwA6Z/rXiZ+hAPTNADa6DUfGninU0gXUvEut3iwSieIXF/LII5ACA65bhgCeRzya5+igDbvfFniK/nlmvtf1a5mmga1kea8kdnhJBMbEnlCQCVPHFU7rWNSu9NtdPu9RvJ7C1JNvbSTs0UOeuxCcLn2FUKKALkuqahLpcOmy310+nQuZIrVpmMUbnqypnAJ9QK6Q+N9XuVtFuNe8QwNaZ+ztHqMsiw5Uodis2VypYHDdCR0NcjGjyyLHGrPIxCqqjJJPQAUpUqSrDaw65ByPak1c0p1HDon6r+mvkdTbXuo21vpcmh+KL37TYmVYIlne3NorHJ8olxjcSxYLjn1zVC91XxDDe2VxfX+qpdWbF7aWSeTfESxctGxPyksS2R3561iH36dcA1atr+7tEKwTyIh6oTlT/wE8UveWxpzUZfEnH01X3P/MuWniPXbS0vLWz1nVIba9JNzFFdSKk5b729QcNnnOetTW3izxHa6rc6jbeINYh1G54nuUvpFmkwMDe+ctj3NVPt8Ep/0uwjZv78J8pvywV/8dpxt7GYnyL1omIxtuYyB7YZc/mQKOa26D2Cl/Dkn+D/AB0+5sozzSXNxJPcyvJNKxeSRzkuTkkk9zmo1wfvE/UV2V94HnTTIprWTzLsJmWLgAn/AGf5e/6VyEsbRuVKsjKSCpGCp9DU06sKnws1xmXYjAtKvG19v679xhBAGfwPrQCe3JOMDFJ1PX3pVx3BA9Qe9aHEJnn1FOO3qCQfzNG09SR6UH7wCDK8dOtAGulxpRtkR7NzL0Z1c5resNZ0yzhjii0m1lLcFpV3MPfJ/rXGBwARj645/n/KlhlZDlcA+ucdv8/5xQB1Wq2tsyNLJPbRKeU8tBwfQ1jQ6JeXs4jsIWmX/npjCn3JPT6VQWR2LMD8397jr/StvTPEepWKCOGdTEBwrruH8gaifNb3Nzpwiw7qL6y2o/3Ur/j/AMEl1bwhd2FpbyqftDs2JEiUnaO3Pfv6VQg0y9jDmSONRj+OVEH45I9K37/xJFqVh5GoW67kfdmMcZxgYBPXn3rKhsbG6nCiZIwSPlI5Y+/pUUva8vv7nZmDy9Vv9lTcbLrbXrumV4bO6jBZbqyQ+q3CsfzXNRy2qNIRJqloW7/LIzfomPau3svC2lGARveia6YZ2g7VXjpnv9apXngWWTizLSMwJVVGBj/D3rSz7nF7Sktofe3+ljjzbWCAZ1Ekj/nnAT+pxT4bWwlkSOCW/nkc4VVt1Ut/48a6S38EzCUSXU6x26Hkgnn2H61rWejPc3DWemxCCL/lqVG6RvY/zxwPao1fws6UoU9asEvLW/3N6fP5JnKnS4UntbbTReT6rPIIYI4ZASHPAHC8sSQMA9+o6UWXhPxPPNHbWulX/mTXMlusYjKhpogWkTnjKAEn0xXRapZLp2pwR27eRPbkOHB+ZGBGD9c12HjH4qafdeNNG1Ofw9DNpdnBcebZh1P+lT5MlwN6su7JUgMpHy/TFxVlucleqqsrxiorsjg4vAPiOK28SSamLjTbrS7aG9kt7gMGuFeUIpU9Dyc59jWO/hfxRb3NyraTqi3AuVsZh5T7jO4yIiMZLkc46nrXd+Lfi5ba3p+p2sWkXUS3eh22jo81yjsPKuGl8xtqKDkNjAA5H4VPffHC6kvvCN9baVEt1pMy3eoF5SRqNwIUg8xuPlPlpgdcFs1RieceKNA1/wAOzxW/iOyvbR58yxifOJO24HoSOh79uKw+PfHr/Ku5+JfjW28WQaVbWNrf2lrYmZ0iuZYXVDKVJVFihjAHy5yck59ueG6njJPSgBtFFFABRTlIDAkBgD0PQ1o6jqMN3awRJplnaTRDb51vvBdeeGBYgnnr19c0AU7eSS1nSaGR4po2EkciEqwIOQQeoOcYNMlkklkeSZmeRyXZ3JLMTzkk9aQE9h1PA61IdjIDH8r5xjPJ/wA/40ARdOw9Tz1o6cYwehzR9cc0oUEfKefTHWgBFGSAOfYjr7UoJ4wCRnn0Jo4+775zmjBIB5I6fjigDpn8bas2SGgXtgR/rzWTqeo3WqSLLdvGz42hwgXPscD+dUQ0eDuXrngHp6UiKrd8epI4rONKEHeKsdtfMcViI8lao5Ls3oNByCDwO1GMgkDPqcdKk24X5WVhxkDigqW4RMMBzg5P+f8APFaHEIrDkMdoPt1HXtRndgZUDPJx+tMGPXj6U8bgu9QeP4uuP8/1oAGCgElWI6Z3cZpoI3dgMg4bmnFjlSMjHGT7f5FNJYgDk+goAcXJ4CqccAf/AFqlErRoDuIb2+vb/PrUGMdccdiOtGSRgk+nXj2oAf5zrg85x1I6iiJypyd2WIwR+tS29rLdybLZGkcg5wOMdySen1q4RZWJLOUvLnPRSfKU49er/wAvc1LlbTqbU6Eprmeke7/rX5FzTmuGjM3mC2tVPzTu3BP9T7CtweMLyGBrbTzOYv4pZDhn/D09ufw78dNeTXcoe5dW2jaikAKo9Ao6U17iZRtEpA784HPt1pcrfxF+2jS/grXu9/l2/F+Z1UHiG5uG23E5BJx82TtFddZeLY9M082mjeVDJMcSzkZdye/T9BXknEcY+YhuvGAR/nNWdPnVWLsx2gZK9Mn0z+tWczd9Wdb4kRUSCTzn3uMyOw+dye2O3HauXuS2AJBjdwqk8n3OOlacEv2tW2Nvck5bHOewGev1qzFpA8l7qfBOcZY9M/zoA5a7hWNhsbcvG7byFPp/k1XzxW7rMbxW6xBQi9TnA/Tt9Kz47pIbKa3extZWkIYTSb98fBACkMBjnPQ5PqKAKXTtz2Io5IwB+H9f0o7noQKBjHOfegBtFFOGAPX1oAtX9jc6dfT2V5E8F1Cdrxt94H0/KqzAYG3uO/600YxVmOMXAJDAODk57035CV7alfr1z7mnxHd8vH06ZpZ4nhcCQc9Qc5zUeOCDxjrx3pDJXjAIMYYAnp3H+f6VHtIGSPof8/jVqMmXBOC3Q+oB/ClaIkcqQ69jxj25/wD1UAVVUMPl6gZ56f5/z9ZkO1CMEFf4h79z+lMeMBM4KnHAIxn6evemxSMh+XJA7YoAmQBhvZRtxyeOBTZgikEgsh49G/wpBhnUAGIt0bOBSywzW4G9SEPIPVTQBEMk8kdic9/zqyVOCJIgB1yp6/T86q7gMEDkd+lPVyMDeSAcYzwaAHSsW+TJCg8Kc/4VDjkYOT04FPAMjcHPHfAx3ppwG+Y5PU98/rQA5icEIW2jqDz70hBUHj2yTj9Pzo3E/KMEdhiun8I6JBLKL/VHSKzjOVEpCiRh9ew/z3qKk1TjzM6sHhKmMrKjT69eiXdnOzW0sLokscqzSBWRCh+YHoffNXBYwWaBtUcq/X7NH/rT/vdlH159q7DxlrOny2P/ABL72L7chCq8a5bafvANjj14PavPfmcnqx/P3rOlOVWN2rHbmGFoZfWdOnJVOz0svWz1f3ejuXLvUZJoTDFGtva/88o84J7Fj1Y/XNU2PP3QMHkGkIxnpxx9aOnTvWySWx5dSpKo7ydxSc5OdxPc0meQQcY5HtW34MhjuPElrFNGHjdZA6kcEGNqXxVocmi3pCgvaSHMT4/8dPv/ADqPaJT9m9zqWAqywn1yOsVLlflonf0dzDJyec4+tBPOScj3o9TnOevNT20PmEEldo461ocR0vhqCMWbz3RJQNhUXHzcDmtKTU3uJAscapGvChe30z1PvXKXOpOIRBEwEYHboe/41X+3THoxAPAAFAG/qrrKNpfd1PHOPc/5965q4Xa2TwfQnJx71cFwyjbGMu33mPJz/k/56VIlqqqJrg7ST/n8qAMrqMc4HP0o5J9WJz65q/NCuUjVcOTkg9fTJqrcQiI/K25TyD0P1+lAHW/DWeS3k1doNd0vSJWtTGpv4RIJ8n7gyCAMA5JBHTj05G4Y+fISY928nMYAXOewHb0qMe/Q98Uduf5VTk2knsiVCKbklqwzjkHvwe9ORyjAoxGD1HX603t+pFHOMZPpj+lSUXFmFwixygZ7YqN7fyj+9BCA43DvUGe/Gfr0qzDcZUozZXsG6fSgBBEY23xHcvYjv7VZt5mkYeaqFM4JH+c/l/8ArWK2jmXEG4Buqk8Z/wA+tNS2aKUhvMQnqzA4/GgC1e2yxxAwsQpOSrL/ACI//XWeUCkecny8DKdv8+mK6Wxgj8rcZEY45Un730/z61Zm0WC7g8y3d1cD7hIOOOlAGFqekTWOnWN5G3mWtwgJOPuN29O2P1rKyNuyOTK/3ckZ+lep339mjw79jvJ4xFHCqHb8xQgYBwOeorzAKY2+aPKZ4wDg/wCBrnw9V1E+ZbHtZ1l9PBTg6Uk1JLS97Pr97/XsViCrYznGRnkfhzSmJwgJAHYZ4rSjsYZSpUPH9cnNXtjWuAlwjr/ErKMj6ZroPFMIwTBd3lSYP+zx2/SoM8EcgenvXdxW7tEGW5tjCRnGQG/I4qpLHZEnEYlkxxgsp/lQBzMCTllEXIOemPxH+f8AGtR9PupjvuvKkdh25I9jV6OGxgw0vmxMTyq4P8x/nFW4pUhVTaq8ijkfd6/nQBkz+H2RNwLgEcsV4FZd/YNaDczAgnjj9K7OTXdQg2kwDyR22gcfh/n+l2eOPWbYS/YWaVR1VWOP5igDzUK2M42++ccU3IGcHjp9a3tU0WWKR2Cck8gdh9axZInjfHOR3GeKALehagNK1SC98sS+Vu+TdtzlSOuD61teKfEFzqlhabFjitZskqOWEinkFvoVPb71cuM54Ukjgcd62NPtJLjTbq1Iyynz48AnkcNj6qc/8BFZTpx5lUa1R6WExtdUZ4OErRld289PnqlaxkKmRu2kqPXgfn9ac0rFdvygAdvQ1Pdb0/dkdOvbFVAO3GfrWp5oHJIBwT0p0fL8cevTGP8AOKkiSPyi0hx6DPWmswLnYBt9NuTigC5ajY25vmxyMcZP1/rV2KCa4YO2NyjC9lUev+f/ANdaxsp5FZ5D5addzcD1/wAj/wCvU9zcEI0cLMyk9B1b6+3NAFe4lSJ2WAk5HL/3j9PT6e1RaTaLqmqQ29xe21kszHdc3TERoACctgE+w4pJ9sUeHwXPVc5x9TVI85PfuOlABjGexHUGk4o7Glydxye/JzmgA64Axj34pOvpS+x4+o/Wjj6UAGcYIyPQ+9KDgdOPf9aToSDx9aOOvTPYdqAJYZ2ikDo2OP8AIrUg1JmYJcqWjPGRk/XI9fascHGdwyc8qeBTlKqfmBHrQB1cNjEVWRVV1HKsG6Z961hbXqxebBb+bGPvOh3AD3x+NchYam9q6nGUY4KseP8A636V2eg69Jp0yXNuGiI54YspHHBHf8fWgC3ZR6bd2rwyPJBcyDG1juXj5sg/hV600G0uohGL2DfzhZl2huOzrx3710NtqvhvxJI73enxWWoMpAmtGHlswHBZCOD64I61es/h3fi3S58M3D3KMoYRcPnPYj9OalaSZ0S96jF9m18t1+pw7+B7mzuC1zY3ptyP9baMGx7nHH4cVla5oKWyZtr+R0H8FxDjHtnpXc3l94k0Nw9/od3psgGPMiZ4w34Hj8qx5vHl4kpeeJLlc87vmP45BqjnPOpbeeKQb1BQnGQjDIq9HatlVEuzJx83HX612r+O9MuWB/sO3RgBko39MVqr8ULBIxHF4W0udsZzJGWP5D/P86AOE/sW8ERlkaN4xg7iQx/WqOLxpyFLFAcbtuP5fjXUaj4+Mjs6aRp9qeu1IMAc+jZqO5+I099aRW8lpHtAAAiCJj8QM+9AFKztiGWS5kZ0B/uj6V1LaukenrDbRsWA48zIx09/6Vy6a9ZxESz2rSH/AG3J/wA/59KedV+1uRp2mXLyN1VVJUe+aALSpLdSM1+bZFzwqRlyPzOKp6hoS3jAxJMlvn7zKFB9gMY/nV7TtLeSVZdUdbEDkrsJx74JA9K0tStJr2Nl00XVzEg5mkxHCv4+31oAwIdD0rTUVp4klmPIDyHI99oxisjVdX+y3sS2UCJGpG5QSS/qv45x/wDXqTVLUWzOr3SM4zkIuQD7H9K56aCaUs+wFcdTwCPX/P8A+pNXVmVCThJSjuiDUrb7PfTIGLIG3RuedykZU49wQfzqqNoBG3JHXB4rTuEe8063mVVM0DG2fPPHJQ/luH/ARWekRdhGBnBwdo5/+tSi9NTXERUZ3js9V8+ny2+QibpXG1SxHAIGPp0rd0PS5C5kkXJ7IV7/ANKm017Ozt2Yw+bJ1Yb+B9T/AEFRaj4imf8AdQeXFHjACDAqjAk1R5fM8qV02qTkA8Ke+ax7q7RTi1Jx/fI5J+nYVWnuHlUBzx7GoSPXGc4J7UAHJA4OM8elBxyB07cc0HB69SfSjucADNAHW/Cnwmnjvx/pfh2a8azW983M6x+YV2RPJ0JGc7cde9dNrvwjuI5NKm0TUGOn3umyanK+rxCzksYo32MZl3PgEkbcZJzwOM1yfw11/V/C3jKw1vw9YrfalZrKyQSQvKu1o2ViVQg4Csx6jHWl0HxzrOlape3txKurG+tGsruHUy8yTwnB2MdwbggEEEEEdetAG3ZfCHxPcX+q27fYYINOSF5rqS4zC6TDdEUKglgwGc4wMc4qxP8ACPUm0HwzeaXqenajf63cz2sdjDMmd0bhdyPuw45JY4G0YznNWYfij4s8P682t3ejWkNzeRQ/ZPPgnt0ihiXaiw7JF3R4xkMWB75rMg+LPiKJNNYRae1/p+oT6ja3xgIljknffMgAYJsc9RtzjgEUATz/AAa8URXSxI2mSQvZTXy3QuxHC0cUiJJl327SpkTOcDBzmom+GeoXFtoa6eYHlvIr+We8e8ja0EVrKUeVXUcRgL1JO7gjg4ovvitqt2L8RaVo9qL2wuNOlESznKTtGzsN8rYIMS4A+UZPy1T0f4l61penaJY28GnvZ6Va3dl5MsbMt1DcsXlSb5uRk8bdp6daALC/CfxCZr0ebpCWlrbW94b2W/SK3kgnYrHKsjEDaSD1wcjGM8VwUiFJGjBViDjKHIP0Peu31f4m6zqul6tpslvp0NjqFpa2CwQxuq2kFvJ5kaRZY4+bOS24nJ5rjZ7S5t4IJp7eaKG4UtE7oVWVQcEqSMEAjHFAEIJ7cZ46/wA6vafqc1uwXiRDjKMOo781Q+oH0qeSzuYra3uZ7edLafcIZWQhJNv3tp6HGRnHTNAHe6W+l3KoXNxZyHo6ncuf0NdPBe6/pk63egao20YwY2OeOvHpXkllqEtqgVSHiyeH/wA/yrVttfnSZSgSMjgMGyBzSa1uaRnaDg+tn91/82e56d8ZPFENsYNUgg1GHbgxzR57dMEfhT7T4i+H70n+0/AmjSDs6xqCeMdMY/L/ABrya08SSxy+ZKscw6soyD+Rrftdb07V1kWPSJ5HjjMkgj3ZjjHVjwcAZzk9PypmZ6/pp+G2tr8/gu0gmb5eN+M/UEY/Krcfws8MXEnmHT47KA/89LkyD/x0+teQWE0Gm6lHHMl5ZuNrqkpKHBwRz1wev410Wv68fLz59yw67hcK4z/3yDQB38fwp8BXZBS385lODi4aPPPX5j0701/h38LkkNm9nPbXIO1mS4LgH/eyQR1/T3x5Hp2oQ4ZpbiWIckeZj/PNY+oa7dwamzWl1IU3fKY2wP1z/nNAHr958P8AwnDOI7OG3mHQSPdkke+P8/pWzo3gDQ7NWk+23MBYZwpIQe24Ecc+teCJ4lmF2JnFwZF53K3X8h71tDxxdTxqtzeTRRjG0Z5/lgUAel63p2jWt2yJ+8YcZhhVifqzAn9aw9bvdFjjC3sM0oTtJcfd/wCA88/lXCXmvpKGSKSSbsWeU4/T/P8AWi2mX93oOsatYRK1jpXlfapRJgp5rFExuOTzxxQBo6prWirvFjpqux4AKhQR+Wa47WJ7a4lLzIoY/wACt8o+vesqS31S4tri/t7S9ksYj+9uFjZo4z6MwGB1711E/wAMPFo021uhZrM9zYNqf2OKXbLFbABi7LgDoRhQSx4+XNAHK2Eq3FxPYxsFjulKLngB+q8e5GPxrHDYBG48dQB71asLLUL+/W302yubi8TkQ28TPIMHngAnj9K17jwvrmpw63q9ro90lnpzxi+3IENu8meNh+YjIPQcDBOKm1pG8pKVJJ7p/g9fwd/vOcMr7cBjsHbp19qbnPfJPrWvY+HdQujeeZH9jNtbSXLfaY3TcEUMVX5T8xBBGcDkcjiqD2F3H5vmWlwoiVXkzG3yKcYY+gORjNUYFZevAz7etJ29RWsnhvW3aJF0bUi0rFIwLWQ7yBlgOOSB1ArKI2kZB+hoAO3ajHOBz9O9HTjoemDR2GScZoA9B+Bl9Z6b47NxqN1Ba2/9n3qeZPKsa7jbuAMk9SSAPeu5C+AofhdaS2FnoN5eLpaSzG5u447pL9TlgVZhK6EjbtUbSp6jrXgpHXIx3xQcH0xQB9SeMvG+l6zqvxW061u/DM6y21kmnPcXIEN2qOGkw5fazKCSApHKjg4NeUfBS08I6vPqmleMprCxTNveW9/cvsAEUqmWEEkZMkZYAeq8eleZDnoDjuO9HbkDp60AfQvgqT4c6loE93NpuhLPc3119ss7y7itpILdv9QIWkYEBVPVMsWGDmqFvL4HTQYtNex8NM0ngpr97xpR9o/tNd+2LdvwHOBmMDcc88YFeEjAGcZ+vf2o6d+aAPpHxlrHhTVNX1XXL2DwlqMSeHIZdPi+0/NJcL5AMciLIHDL8wC8HaD15rD0iTwZfR+GJr46El++iX8kVrPcEWkV+Z2MMcwLHYm0nAYgH5c+teFEfTjjjvQerdPfp+lAHv2l6H4V1WHTjrN34GstUtfEVrLqSW16qQSWBiiDIhyVb5t+4IcAk8gVZZ/Cd9J4J01tW0GOwsb7X28m4kjlhVWkHkKwLBVDAZRnO3gHnofnjjPI+vajPTk8dKAPonxg3w/0u21zVNOsPC97fLo+nTw2P2tZYmuzdSJMFELrkiMKWVMDHJGDz558IIfDmta7quleLJdNsIL+1b7Nf3DiJbaZXVuGJ+UFN689eBXnI6HA7fWjpz047UAfRN8fhtPdeGrjSZtGsF1zU0mmSZhIumQRRBGjkTcNokl5+YjjnOM41tUv/CGnfa7rTLrQ7G9u/Cur29zHaXsDK0wIWFT5bbN7A8BevvjNfL4/lS45PfHXFAHr/wAWfFOnTeN1ltLiC9gFhZr5tvKJF3CBAwypIyCCCPrXNXXiqFo8RXA+nlMK4Xr7856Uce3I9+KAO/tvF9osIR2RWHcRGsW+1xHmd4ZkwxJ4jbn65rmjjnp6/wD1qCRnIAFAGvJqNvMczedu/wCmfH9arG6RJSVWTyxkBXOf51R5Oep9eO1A6HA7c0Aa51pw3+rHAwAGIArt/APjXQbTwf4w8P8AipdXjt9aFkIpdNijkaPyZGc58x1HPygY9/QV5iDjGD7+4ox9PzoA9x0b4saDpnguHQbUatbixivLSBhaRSi8gmdiPMBkAjfawDYEg447U2z+Mdp/bdlJdXXiBLAeFBoU7xODLHdGMK1xGpkAJyAcllY4z2rxAZyABz2GOtHUfSgDu/hr4o0bw54l1S91kajPFPbSRW08IDvHIWUh5Ii6rJ93lS2M884ruPE3xe0fWh45hifxBaW+u21iLeWJUDrNBHtcSKJAAsnAJBJwPunpXhh6dvejqfU9ck0Ae0618XrfUfGPim+eXWpNGvtAm0vT7SRgRbTSW0cZbZv2qpdCSVySCDjPFHiP4leFtU0DxAbW01uPW9Z0iz0+VXSI28bwFMlSG3EEJ1x+HPHioGeBz6UvBz60AfQ2pfHm0uNfvLuCfxDHZy+IbHUo4i4G2ziQCWHAkwCxH3R8p7kV4Z4ovodU8TavqFqrx293dy3EaOAGCu5YAgEjOD61lnHtz6dqUdRtHOeO9AAM9Ovf6Ud+DjPBpO1Ke+eTnk9aAEGMVe1ez+wXSRZ3ZjRyD6lRkfnmobRoVnRrgt5akH5FBJGfqK0tZvLXU7hLkyMjlSrIEyc7mIPUDGCO9Q21JdjGc5Koklprf9DGPTntx9KB1HrnvVpGs4gWKy3DD7qsBGuffBJI+hH1qTZaXTZV47BsZKvvZD/ukBj+B/M1Vy3O3R2/r5/gUABivV/jtpdhpn/CKjTbC0s/P05Xl8iFI97ccsQBk8nk15o0FqpP+liTtiOJjn3GcV6V8btU07VX8M/Z761nWHTljY2cqzlTxw4BG08dOaLgpp/8MzzzQdPXUrySFtwxCzjBx8wHH61mgZ9Px71r6LfWul3P2hfPlbKjlAuBuBP8XtVJ4rVP+XppAeyRHP6kVKb5nfYzjOXtJX20t+pVHIA7due9HUH8SBnpV1J7SNdi2xdWGHkdvm+qAcL+OenXmmCC2YZ+1quezRNkflxVXNOfun/XoVeCQT+OOKBwD/hVsw2/T7bkt1IjYj6n/JppitQRi4kPuIuP1P8AjRcOdf0mS21kZ9MvLoDJhZPbg5z/AEqieg/wrc0+8soNOubTfLm4VgZCnCn5dowDns3rwfrWa0NsvzG83k9liJP64qYyd3czhUlzS5k99NGVeMdeSfxoznPv14q6txaMvkvb7U7TAkyA+p5wR7Y47d8qbO2BAOp2rfRJcfqg/wAmnzdy/aW3T+7/ACKPbnHX0oJ755x2GKufZrZTj7fGR32xvz+lNjjtPMG65cAEA/uuCPbn/D+lPmQ/aLz+5kut6f8A2deCHczAxq2498jt7ZyKodefX0rb1i6ttVlguGuUhaOMRmN1YtwzHsMdCO9Z2LWE7jvuGHQEbEP45yR7cfUVMG7a7mdGcuRKafN/XyKvODz255ox/k0EjOcD6UD88c81ZuHrjp15ox9fyoHfjjpn0pOOOtAC+wx0o4PAHXpzRnIPX1+lGevP50AHXkgc9/SjtjoO9HGc8euOfypCOKAFHXPQ569MUnb/AOtS87fb3FJxk4yAaAF7Y/8A15o7jgkflmj0zgCjGBzkUAC9G+n9aH6/gP5UUUDY2nxfeP8Aun+RoooEMp4/1Lf7w/rRRQAynp92T/d/qKKKAHN/rP8AgA/9BqKiigAp83+uf/eNFFABN/rn/wB40yiigCZf4P8Acb+tM/5a/wDAqKKTGgi+8f8AdP8AI0yiimImT78H4f8AoRpkP+uT/eFFFABF94/7p/kaRui/T+tFFAA/X8B/Km0UUAOf77fWm0UUAFPh/wBcn+8KKKAGU4fcP1H9aKKAG0UUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal long axis view from a 2-D echocardiogram shows a small, fibrotic vegetation on the left atrial surface of the anterior mitral valve leaflet, suggestive of healed endocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1427=[""].join("\n");
var outline_f1_25_1427=null;
var title_f1_25_1428="Bilateral BBB tutorial";
var content_f1_25_1428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Bilateral bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 109px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blocked or delayed conduction in both the left and right bundle branches leads to wide QRS complexes, which in this case have coexisting complexes with a left or right bundle branch block morphology. The first two beats have the appearance of a right bundle branch block, followed by four normal beats, and then beats with the appearance of a left bundle branch block.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1428=[""].join("\n");
var outline_f1_25_1428=null;
var title_f1_25_1429="Norepinephrine (noradrenaline): Pediatric drug information";
var content_f1_25_1429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Norepinephrine (noradrenaline): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"    see \"Norepinephrine (noradrenaline): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/53/10067?source=see_link\">",
"    see \"Norepinephrine (noradrenaline): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levophed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levophed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"      see \"Norepinephrine (noradrenaline): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Continuous I.V. infusion:",
"     <b>",
"      Note:",
"     </b>",
"     Dose stated in terms of",
"     <b>",
"      norepinephrine base",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 0.05-0.1 mcg/kg/minute, titrate to desired effect; maximum dose: 1-2 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 0.5-1 mcg/minute; titrate to desired response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Usual range: 8-30 mcg/minute as an infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ACLS dosage range: 0.5-30 mcg/minute",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F202385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [strength expressed as base]: 1 mg/mL (4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levophed&reg;: 1 mg/mL (4 mL) [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F202371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer into large vein to avoid potential extravasation.",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14473013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     16",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14473012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     8",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"     <b>",
"      or",
"     </b>",
"     16",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F202438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with alkaline solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, anidulafungin, argatroban, bivalirudin, caspofungin, cisatracurium, clonidine, dexmedetomidine, diltiazem, dobutamine, dopamine, doripenem, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, furosemide, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, inamrinone, labetalol, lorazepam, meropenem, micafungin, midazolam, milrinone, morphine, mycophenolate, nicardipine, nitroglycerin, nitroprusside, potassium chloride, propofol, ranitidine, remifentanil, telavancin, tigecycline, vasopressin, vecuronium, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Drotrecogin alfa, insulin (regular), thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Furosemide, nesiritide, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Readily oxidized, do not use if brown coloration; dilute with D",
"     <sub>",
"      5",
"     </sub>",
"     W,  D",
"     <sub>",
"      5",
"     </sub>",
"     W/NS, or NS (dilution in NS is not recommended by the manufacturer; however, stability in NS has been proven by others; Tremblay, 2008); not stable with alkaline solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of shock which persists after adequate fluid volume replacement; severe hypotension; cardiogenic shock",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Levophed&reg; may be confused with levofloxacin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F202437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, bradycardia, peripheral (digital) ischemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, headache (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Skin necrosis (with extravasation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, respiratory difficulty",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to norepinephrine, bisulfites (contains metabisulfite), or any component of the formulation; hypotension from hypovolemia except as an emergency measure to maintain coronary and cerebral perfusion until volume could be replaced; mesenteric or peripheral vascular thrombosis unless it is a lifesaving procedure; during anesthesia with cyclopropane or halothane anesthesia (risk of ventricular arrhythmias)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood/volume depletion should be corrected, if possible, before norepinephrine therapy; extravasation may cause severe tissue necrosis; do",
"     <b>",
"      not",
"     </b>",
"     give to patients with peripheral or mesenteric vascular thrombosis because ischemia may be increased and the area of infarct extended; use with caution during cyclopropane or halothane anesthesia and in patients with occlusive vascular disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent drug; must be diluted prior to use; monitor hemodynamic status; injection contains sodium metabisulfite which may cause allergic reactions in susceptible individuals. Extravasation may cause tissue necrosis (treat extravasation with phentolamine)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F202380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of Norepinephrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Norepinephrine may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F202382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13376222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Norepinephrine is an endogenous catecholamine and crosses the placenta (Minzter, 2010; Wang, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, urine output, peripheral perfusion",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors and alpha-adrenergic receptors causing increased contractility and heart rate as well as vasoconstriction, thereby increasing systemic blood pressure and coronary blood flow; clinically, alpha effects (vasoconstriction) are greater than beta effects (inotropic and chronotropic effects)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Very rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Limited duration following I.V. injection",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By catechol-o-methyltransferase (COMT) and monoamine oxidase (MAO)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (84% to 96% as inactive metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treat extravasations with local injections of phentolamine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/25/1429/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay M, Lessard MR, Tr&eacute;panier CA, et al, \"Stability of Norepinephrine Infusions Prepared in Dextrose and Normal Saline Solutions,\"",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2008, 55(3):163-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/25/1429/abstract-text/18310626/pubmed\" id=\"18310626\" target=\"_blank\">",
"        18310626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12650 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1429=[""].join("\n");
var outline_f1_25_1429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709175\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202404\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054472\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054466\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202385\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202371\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054476\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473013\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14473012\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202438\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054469\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054475\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174558\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202437\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054480\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054465\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054464\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299773\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202380\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202382\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376222\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054471\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054463\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054478\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054479\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054481\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=related_link\">",
"      Norepinephrine (noradrenaline): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/53/10067?source=related_link\">",
"      Norepinephrine (noradrenaline): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_25_1430="Aztreonam: Pediatric drug information";
var content_f1_25_1430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aztreonam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"    see \"Aztreonam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/58/23460?source=see_link\">",
"    see \"Aztreonam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azactam&reg;;",
"     </li>",
"     <li>",
"      Cayston&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14942062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cayston&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &lt;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;2000 g: 60 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 90 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &ge;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;1200 g: 60 mg/kg/day divided every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200-2000 g: 90 mg/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 120 mg/kg/day divided every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"      see \"Aztreonam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children: 90-120 mg/kg/day divided every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cystic fibrosis: 50 mg/kg/dose every 6-8 hours (ie, up to 200 mg/kg/day); maximum dose: 8 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Urinary tract infection: 500 mg to 1 g every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderately severe systemic infections: 1 g I.V. or I.M. or 2 g I.V. every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe systemic or life-threatening infections (especially if caused by",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ): I.V.: 2 g every 6-8 hours; maximum dose: 8 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral inhalation: Children &ge;7 years and adults: Cystic fibrosis: 75 mg 3 times daily (do not administer doses &lt;4 hours apart); administer in repeated cycles of 28 days on drug, followed by 28 days off drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Reduce dose by 50%; give at the usual interval",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Reduce dose by 75%; give at the usual interval",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation (nebulized): Dosage adjustment not required for mild, moderate, or severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azactam&reg;: 1 g (50 mL); 2 g (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azactam&reg;: 1 g, 2 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for reconstitution, for oral inhalation [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cayston&reg;: 75 mg [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection (powder for reconstitution)",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cayston&reg; (aztreonam inhalation solution) is only available through a select group of specialty pharmacies and cannot be obtained through a retail pharmacy. Because Cayston&reg; may only be used with the Altera&reg; Nebulizer System, it can only be obtained from the following specialty pharmacies: Cystic Fibrosis Services, Inc; IV Solutions; Foundation Care; and Pharmaceutical Specialties, Inc. This network of specialty pharmacies ensures proper access to both the drug and device. To obtain the medication and proper nebulizer, contact the Cayston Access Program at 1-877-7CAYSTON (1-877-722-9786) or at www.cayston.com.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer by IVP over 3-5 minutes at a maximum concentration of 66 mg/mL or by intermittent infusion over 20-60 minutes at a final concentration not to exceed 20 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Deep I.M. injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Administer only using an Altera&reg; nebulizer system; dose can be nebulized over 2-3 minutes. Do not mix with other inhaled nebulizer medications. Administer a bronchodilator before administration of aztreonam (short-acting 15 minutes to 4 hours before; long-acting: 30 minutes to 12 hours before). Administer doses &ge;4 hours apart.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F138631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solution for infusion: Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, mannitol 5%, mannitol 10%, LR, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, caspofungin, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, cisplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daptomycin, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doxorubicin HCl, doxorubicin liposome, doxycycline, droperidol, enalaprilat, etoposide, etoposide phosphate, famotidine, fenoldopam, filgrastim, floxuridine, fluconazole, fludarabine, fluorouracil, foscarnet, furosemide, gallium nitrate, gemcitabine, gentamicin, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, idarubicin, ifosfamide, imipenem/cilastatin, insulin (regular), leucovorin calcium, linezolid, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, methylprednisolone sodium succinate, metoclopramide, minocycline, morphine, nalbuphine, nicardipine, ondansetron, pemetrexed, piperacillin, piperacillin/tazobactam, potassium chloride, promethazine, propofol, quinupristin/dalfopristin, ranitidine, remifentanil, sargramostim, sodium bicarbonate, sulfamethoxazole/trimethoprim, teniposide, theophylline, thiotepa, ticarcillin/clavulanate potassium, tigecycline, tobramycin, vinblastine, vincristine, vinorelbine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, amphotericin B, amphotericin B cholesteryl sulfate complex, amsacrine, anakinra, azithromycin, chlorpromazine, daunorubicin HCl, ganciclovir, lorazepam, metronidazole, mitomycin, mitoxantrone, prochlorperazine edisylate, streptozocin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone, haloperidol, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Clindamycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation: Store intact vials and diluent ampules at 2&ordm;C to 8&ordm;C (36&ordm;F to 46&ordm;F). May be stored at 25&ordm;C (77&ordm;F) for up to 28 days; protect from light. Reconstituted solution must be used immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Reconstituted solution is stable 48 hours at room temperature and 7 days when refrigerated; incompatible when mixed with nafcillin or metronidazole. Store aztreonam infusion solution in GALAXY plastic container at or below -20&ordm;C (-4&ordm;F). The thawed solution is stable for 14 days at 2&ordm;C to 8&ordm;C (36&ordm;F to 46&ordm;F) or 48 hours at 25&ordm;C (77&ordm;F); do not refreeze thawed antibiotics.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Treatment of patients with documented multidrug resistant aerobic gram-negative infection in which beta-lactam therapy is contraindicated; used for UTI, lower respiratory tract infections, intra-abdominal infections, and gynecological infections caused by susceptible",
"     <i>",
"      Enterobacteriaceae",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      K. pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     ,",
"     <i>",
"      S. marcescens",
"     </i>",
"     ,",
"     <i>",
"      Citrobacter",
"     </i>",
"     species,",
"     <i>",
"      H. influenzae",
"     </i>",
"     , and",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     (FDA approved in ages &ge;9 months and adults); treatment of susceptible skin and skin-structure infections and septicemia (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation (nebulized): Improve respiratory symptoms in cystic fibrosis patients with",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     in the lungs (FDA approved in ages &ge;7 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aztreonam may be confused with azidothymidine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Inhalation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever (more common in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, cough, nasal congestion, pharyngeal pain, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Arthralgia, facial edema, hypersensitivity reaction, joint swelling, throat tightness",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever (more common in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (more common in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia (more common in children), neutropenia (more common in children), thrombocytosis (more common in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT/AST increased (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (erythema, induration; more common in children), pain at injection site (more common in children), phlebitis/thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased (children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, anemia, angioedema, aphthous ulcer,",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea, confusion, erythema multiforme, exfoliative dermatitis, hepatitis, insomnia, leukopenia, pancytopenia, pseudomembranous colitis, seizure, thrombocytopenia, toxic epidermal necrolysis, vaginitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aztreonam or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce injectable dose in patients with renal impairment; no dosing adjustment is necessary in patients receiving the inhalation formulation.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check for hypersensitivity to other beta-lactams (hypersensitivity reactions to aztreonam have occurred rarely in patients with a history of penicillin or cephalosporin hypersensitivity); prolonged use may result in superinfection.",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea has been reported with the use of aztreonam. Bronchospasm may occur following nebulization; administer a bronchodilator prior to treatment. Safety and efficacy have not been established for nebulized inhalation patients colonized with",
"     <i>",
"      Burkholderia cepacia",
"     </i>",
"     , for use in children &lt;7 years, or in patients with FEV1 &lt;25% or &gt;75% predicted. To reduce the development of resistant bacteria and maintain efficacy, reserve use of inhalation solution for CF patients with known",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F138563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies; therefore, the manufacturer classifies aztreonam as pregnancy category B. Aztreonam crosses the placenta and enters cord blood during middle and late pregnancy. Distribution to the fetus is minimal in early pregnancy. The amount of aztreonam available systemically following inhalation is significantly less in comparison to doses given by injection.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Periodic renal and hepatic function tests; monitor for stool frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation: FEV",
"     <sub>",
"      1",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to penicillin-binding protein 3 which produces filamentation of the bacterium inhibiting bacterial cell wall synthesis and causing cell wall destruction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Well absorbed; Oral inhalation: Poorly absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Injection: Widely distributed into body tissues, cerebrospinal fluid, bronchial secretions, peritoneal fluid, bile, bone, and breast milk; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 0.26-0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.2-0.29 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 56%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;7 days, &le;2.5 kg: 5.5-9.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;7 days, &gt;2.5 kg: 2.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1 week to 1 month: 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2 months to 12 years: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children with cystic fibrosis: 1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.3-2.2 hours (half-life prolonged in renal failure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 60 minutes after an I.M. dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Injection: 60% to 70% excreted unchanged in the urine by active tubular secretion and glomerular filtration; 12% excreted in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation: Urine (10% of the total dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemodialysis: 27% to 58% in 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peritoneal dialysis: 10% with a 6-hour dwell time",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10256625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/58/23460?source=see_link\">",
"      see \"Aztreonam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report persistent diarrhea to physician.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bosso JA and Black PG, &ldquo;The Use of Aztreonam in Pediatric Patients: A Review,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1991, 11(1):20-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/25/1430/abstract-text/1902290/pubmed\" id=\"1902290\" target=\"_blank\">",
"        1902290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le J, Ashley ED, Neuhauser MM, et al, \"Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(6):562-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/25/1430/abstract-text/20500046/pubmed\" id=\"20500046\" target=\"_blank\">",
"        20500046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Retsch-Bogart GZ, Quittner AL, Gibson RL, et al, \"Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2009, 135(5):1223-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/25/1430/abstract-text/19420195/pubmed\" id=\"19420195\" target=\"_blank\">",
"        19420195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stutman HR, Chartrand SA, Tolentino T, et al, &ldquo;Aztreonam Therapy for Serious Gram-Negative Infections in Children,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1986, 140(11):1147-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/25/1430/abstract-text/ 3766490 /pubmed\" id=\" 3766490 \" target=\"_blank\">",
"        3766490",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12949 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1430=[""].join("\n");
var outline_f1_25_1430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138579\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14942062\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045445\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442027\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045438\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138553\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138537\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233086\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045448\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138631\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045442\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045447\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138633\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138630\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045451\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045437\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045436\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298806\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138546\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138549\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138563\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045444\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045435\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045450\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10256625\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12949\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12949|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=related_link\">",
"      Aztreonam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/58/23460?source=related_link\">",
"      Aztreonam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_25_1431="Toxic shock syndrome due to Clostridium sordellii";
var content_f1_25_1431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxic shock syndrome due to Clostridium sordellii",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1431/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1431/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1431/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1431/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1431/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/25/1431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clostridium sordellii is a cause of toxic shock syndrome associated with gynecologic procedures, childbirth, and abortion (including spontaneous, surgical, and medical abortion) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. C. sordellii is part of the normal flora of the vagina and may gain entry to the uterus via the cervix during spontaneous or induced abortion, childbirth, or menstruation.",
"   </p>",
"   <p>",
"    The epidemiology, microbiology, pathogenesis, clinical manifestations, diagnosis and management of C. sordellii toxic shock (CSTS) syndrome will be reviewed here. Other issues related to clostridial myonecrosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. sordellii can be found in soil, sewage, and the gastrointestinal tracts of humans and animals [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/7\">",
"     7",
"    </a>",
"    ]. C sordellii has been identified in the gastrointestinal tracts of 0.5 percent of humans [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthy women can harbor clostridial species in the vagina. C. perfringens is the most common clostridial species (4 to 18 percent of healthy women); C. sordellii is less common (0.5 to 10 percent of healthy women) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Clostridial vaginal colonization following abortion has been observed in up to 29 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of CSTS is unknown; one review of death certificates suggested that CSTS was the cause of 1 in 200 deaths among young women of childbearing age [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for CSTS include abortion, childbirth, other gynecologic procedures, and intravenous drug use.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abortion &mdash; Medically induced and spontaneous abortions are risk factors for CSTS [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"       8",
"      </a>",
"      ]. The sentinel description included four deaths from CSTS within one week of medically induced abortions using intravaginal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"       mifepristone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/3,4,11,12\">",
"       3,4,11,12",
"      </a>",
"      ]. Additional cases have been reported subsequently [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8,13,14\">",
"       8,13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=see_link\">",
"       \"Mifepristone for the medical termination of pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=see_link\">",
"       \"Misoprostol as a single agent for medical termination of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is a synthetic prostaglandin that stimulates heavy vaginal secretions when administered by the intravaginal route and can impair female reproductive tract innate immunity. It has also been postulated that the intravaginal insertion of misoprostol may lead to ascending infection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     Mifepristone",
"    </a>",
"    inhibits the action of progesterone and can block glucocorticoid receptors, which may favor growth of C. sordellii [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Childbirth &mdash; One review described eight fatal cases of CSTS within one week of childbirth in previously healthy women following normal childbirth [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"       8",
"      </a>",
"      ]. The source of C. sordellii is likely the vagina, where this organism may be a part of the normal flora and may gain entry to the uterus through the cervix during childbirth.",
"     </li>",
"     <li>",
"      Intravenous drug use &mdash; There have been outbreaks of necrotizing soft tissue infections associated with subcutaneous or intramuscular infection of black-tar heroin (\"skin or muscle popping\") [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. In one review including 10 cases of C. sordellii infection occurring in intravenous drug users, 50 percent were fatal [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"       8",
"      </a>",
"      ]. Possible sources of C. sordellii include soil contamination of the drug or the paraphernalia in the setting of local ischemia with resultant anaerobic conditions.",
"     </li>",
"     <li>",
"      Other gynecologic cases &mdash; CSTS has been reported following procedures on the cervix including laser therapy and conisation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/6\">",
"       6",
"      </a>",
"      ]. A fatal case of spontaneous C. sordellii endometritis has been reported, as has a fatal case following episiotomy infection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/18-21\">",
"       18-21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Clostridium consists of anaerobic gram-positive spore forming bacilli most commonly found in soil and in the gastrointestinal tracts of animals and humans. Well known species include C. perfringens, C. septicum, and C. tetani.",
"   </p>",
"   <p>",
"    C. sordelli is an anaerobic gram-positive rod with subterminal spores and peritrichous flagella [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/22\">",
"     22",
"    </a>",
"    ]. This organism grows on blood agar with a small zone of beta-hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. It was initially named Bacillus oedematis sporogenes, reflecting the marked edema observed in clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. It has similarities with C. bifermentans, but urease production differentiates these species. Many strains of C. sordellii appear nonpathogenic, but virulent toxin producing strains cause fatal infections.",
"   </p>",
"   <p>",
"    Clostridium sordellii antitoxin is used for identification of Clostridium difficile: the C. sordellii antitoxin neutralizes the cytopathic effect (CPE) and all pathologic effects caused by C. difficile toxins A and B. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. sordellii causes a spectrum of clinical disease, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Localized skin infection",
"     </li>",
"     <li>",
"      Bacteremia without features of toxic shock; infection can be localized to a single organ system with manifestations such as pneumonia, empyema, endocarditis, or septic arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/7,22-27\">",
"       7,22-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Toxic shock syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Toxic shock syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clostridium sordellii toxic shock syndrome (CSTS) is characterized by rapid onset of severe illness with shock [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2\">",
"     2",
"    </a>",
"    ]. The illness frequently occurs in previously healthy individuals. Clinically presentation generally consists of systemic manifestations including edema, effusions, profound leukocytosis and hemoconcentration, followed by shock and multiorgan failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early symptoms are often nonspecific and may include nausea, vomiting, lethargy, influenza like symptoms, and abdominal tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/19,29\">",
"     19,29",
"    </a>",
"    ]. Progression from early symptoms to severe disease occurs within hours, and mortality is high [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. The systemic nature of the presentation with the paucity of localizing symptoms may make early diagnosis difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/28\">",
"     28",
"    </a>",
"    ]. Distinctive clinical features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid development of generalized and massive tissue edema [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8,18\">",
"       8,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pleural, pericardial and peritoneal effusions are common [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2,8\">",
"       2,8",
"      </a>",
"      ]. These occur secondary to capillary leak from toxin mediated changes in the vascular endothelium together with hypoalbuminemia [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Profound leukocytosis (leukemoid reaction) consisting of white blood cell (WBC) count &gt;50,000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      which can increase to 200,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      within 48 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2-4,8,30\">",
"       2-4,8,30",
"      </a>",
"      ]. In general an increased percentage of mature and immature neutrophils and increased absolute numbers of lymphocytes and monocytes are observed. The presence of leukemoid reaction is highly predictive of mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"       8",
"      </a>",
"      ]. In one study, patients who died had average WBC count of &gt;75,000",
"      <span class=\"nowrap\">",
"       cells/mm3;",
"      </span>",
"      survivors had average WBC count of 18,000",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"       8",
"      </a>",
"      ]. This is another property shared with C. difficile.",
"     </li>",
"     <li>",
"      Hemoconcentration &mdash; Hemoconcentration is common; hemoglobin levels up to 24.6",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      and hematocrit levels up to 80 percent have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2,4,5,15,29,30\">",
"       2,4,5,15,29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence of fever &mdash; The majority of patients who have died of CSTS remain afebrile throughout the clinical course [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2,4,8\">",
"       2,4,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Refractory hypotension and tachycardia &mdash; Many patients present with hypotension unresponsive to usual supportive measures [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2,8\">",
"       2,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In postpartum women the uterus can be large but there is usually no evidence of retained fetal or placental tissue. Gas in tissues usually indicates the presence of other organisms such as Clostridium perfringens or Bacteroides species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The virulence of C. sordellii is due to production of exotoxins which may lead to CSTS even with minimal signs of local infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2\">",
"     2",
"    </a>",
"    ]. Diffuse capillary leak, massive edema, and hemoconcentration are probably due to one or more exotoxins.",
"   </p>",
"   <p>",
"    The most studied toxins are large molecular weight cytotoxins designated lethal toxin (LT) and hemorrhagic toxin (HT). Administration of these toxins to animals results in rapidly spreading edema and necrosis and shock [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/5\">",
"     5",
"    </a>",
"    ]. Both have some antigenic and pathophysiological similarities with Clostridium difficile toxins A and B [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/31\">",
"     31",
"    </a>",
"    ]. The LT inhibits glucocorticoid receptor function and can act to prevent glucocorticoid suppression of TNF-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another toxin, C. sordellii neuraminidase (NanS), modifies vascular cell adhesion molecules and stimulates promyelocytic proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/33\">",
"     33",
"    </a>",
"    ]. NanS appears to modulate the leukemoid reaction by preventing margination and movement of leukocytes through the vascular endothelium, such that these cells remain in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sordellilysin (SDL) is a cholesterol dependent cytolysin which serve as a cytotoxin in strains without LT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a case report of C. sordellii infection in a child whose recovery was linked to the development of toxin neutralizing antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. sordellii infection should be suspected in young women with rapid clinical deterioration in the postpartum period or in the setting of recent abortion or gynecological procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/18\">",
"     18",
"    </a>",
"    ]. C. sordellii sepsis should also be suspected in patients who took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1753?source=see_link\">",
"     mifepristone",
"    </a>",
"    (Mifeprex) within 24 hours of presenting with nausea, vomiting, or diarrhea without fever [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/11\">",
"     11",
"    </a>",
"    ].The diagnosis should also be considered in the setting of intravenous drug use, especially with the use of black tar heroin.",
"   </p>",
"   <p>",
"    The differential diagnosis includes infected retained products of conception, postpartum hemorrhage and uterine perforation. Other causes of toxic shock should be considered, including Clostridium perfringens, Streptococcus pyogenes, and Staphylococcus aureus. CSTS may be distinguished from these other causes by the absence of rash and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2\">",
"     2",
"    </a>",
"    ]. (See related topics).",
"   </p>",
"   <p>",
"    Blood cultures should be obtained (both aerobic and anaerobic); in one series blood cultures were positive in 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. Gram stain and cultures of specimens from suspected sites of infection (including vaginal specimens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    wound aspirates) should also be obtained. A complete blood count should be obtained to detect hemoconcentration, leukocytosis, or a leukemoid reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. sordellii is usually not the only pathogen identified from the clinical specimens, so Gram staining may demonstrate mixed gram-negative and gram-positive bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. Frequent pathogens isolated in the setting of C. sordellii infection include peptostreptococcus, S. milleri, C. perfringens, E. coli, and a variety of other coliforms and anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2,5,8,19,36\">",
"     2,5,8,19,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical intervention may be necessary to obtain optimal specimens. Endometrial biopsy was the diagnostic procedure in one report; Gram stain revealed numerous large gram-positive bacilli suggestive of clostridia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/5\">",
"     5",
"    </a>",
"    ]. Resected necrotic tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraoperative frozen section biopsies may confirm necrotizing subcutaneous infection, Gram stain may suggest the causative organism, and culture may be diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of C. sordellii toxic shock syndrome consists of antibiotic therapy, surgical debridement (including removal of infected organs including hysterectomy when warranted), and aggressive resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the identification of the specific causative organism, broad spectrum parenteral antimicrobial therapy that covers beta lactamase producing anaerobes should be initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/11\">",
"     11",
"    </a>",
"    ]. Options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    (4.5 g, intravenously every 8 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"     ticarcillin-clavulanate",
"    </a>",
"    (3.1 g, intravenously every 8 hours) PLUS",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (900 mg intravenously every 8 hours).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    may be added when methicillin-resistant Staphylococcus aureus is a possible pathogen (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 24 hours in two equally divided doses).",
"   </p>",
"   <p>",
"    Antibiotic therapy for CSTS should consist of the combination of penicillin (3 to 4 million units every 4 hours IV) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (600 to 900 mg every 8 hours IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. For patients with penicillin allergy, clindamycin can be used alone. No human trials have compared the efficacy of antibiotics for treatment of C. sordellii toxic shock syndrome; this approach is extrapolated from the treatment of traumatic gas gangrene due to C. perfringens and is based on animal models. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antitoxin effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    may be of benefit in addition to the antibiotic properties, although C. sordellii may be less susceptible to clindamycin than other organisms causing toxic shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for removal of necrotic tissue and to obtain tissue for diagnostic testing is important. Case series suggest that aggressive debridement including hysterectomy is warranted to decrease the risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive hypoxia and hemodynamic instability requires aggressive resuscitation with intensive care, ventilation, and vasopressive support [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antitoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible that specific antitoxin may be a beneficial future therapy for C. sordellii infections; in a mouse model C. sordellii antitoxin prevented mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. There is a case report of C. sordellii infection in a child whose recovery was linked to the development of antibodies that neutralized the preformed toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSTS is frequently fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. In a review of 45 cases of C. sordellii infections mortality was 69 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"     8",
"    </a>",
"    ]. Mortality was 100 percent in cases associated with medical induced and spontaneous abortions and childbirth; mortality was 50 percent in cases associated with intravenous drug use. The time from onset of symptoms to death was 2 to 6 days.",
"   </p>",
"   <p>",
"    Autopsy findings include massive pleural effusions and ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/2,5,19\">",
"     2,5,19",
"    </a>",
"    ]. Necrotizing endomyometritis may be found in fatal cases following medical and spontaneous abortions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/15\">",
"     15",
"    </a>",
"    ]. Histological examination may demonstrate acute inflammatory changes, localized thrombosis of blood vessels and massive coagulation necrosis of the uterine wall [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunohistochemical and molecular studies have been performed on hysterectomy and other post mortem tissues. Polymerase Chain Reaction (PCR) assays on extracted DNA, 16sRNA methodology, and sequencing of amplified products can be used confirmed the presence of clostridial species, C. sordellii, and specific toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clostridium sordellii is a cause of toxic shock syndrome (CSTS) associated with gynecologic procedures, childbirth, and abortion (including spontaneous, surgical, and medical abortion). Gastrointestinal and vaginal colonization of C sordellii can occur in healthy individuals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of CSTS include edema, effusions, profound leukocytosis and hemoconcentration, followed by shock and multiorgan failure. Fever is typically absent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The virulence of C. sordellii is due to production of exotoxins which may lead to CSTS even with minimal signs of local infection. Diffuse capillary leak, massive edema, and hemoconcentration are probably due to one or more exotoxins. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood cultures should be obtained (both aerobic and anaerobic), along with Gram stain and cultures of specimens from suspected sites of infection (including vaginal specimens",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wound aspirates). C. sordellii is usually not the only pathogen identified from the clinical specimens, so Gram staining may demonstrate mixed gram-negative and gram-positive bacilli. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of C. sordellii toxic shock syndrome consists of antibiotic therapy, surgical debridement (including removal of infected organs including hysterectomy when warranted), and aggressive resuscitation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1431/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the identification of the specific causative organism, broad spectrum parenteral antimicrobial therapy that covers beta lactamase producing anaerobes should be initiated. For therapy of CSTS we suggest treatment with penicillin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dosing is as follows: penicillin (3 to 4 million units every 4 hours IV) and clindamycin (600 to 900 mg every 8 hours IV). For patients with penicillin allergy, clindamycin can be used alone. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Smith LDS. Clostridium sordelli. In: The pathogenic anaerobic bacteria, 2, Charles C Thomas Publishing, Springfield 1975. p.291.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/2\">",
"      McGregor JA, Soper DE, Lovell G, Todd JK. Maternal deaths associated with Clostridium sordellii infection. Am J Obstet Gynecol 1989; 161:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol--United States and Canada, 2001-2005. MMWR Morb Mortal Wkly Rep 2005; 54:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/4\">",
"      Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005; 353:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/5\">",
"      Sinave C, Le Templier G, Blouin D, et al. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin Infect Dis 2002; 35:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/6\">",
"      Ho CS, Bhatnagar J, Cohen AL, et al. Undiagnosed cases of fatal Clostridium-associated toxic shock in Californian women of childbearing age. Am J Obstet Gynecol 2009; 201:459.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/7\">",
"      Foroulis CN, Gerogianni I, Kouritas VK, et al. Direct detection of Clostridium sordellii in pleural fluid of a patient with pneumonic empyema by a broad-range 16S rRNA PCR. Scand J Infect Dis 2007; 39:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/8\">",
"      Aldape MJ, Bryant AE, Stevens DL. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin Infect Dis 2006; 43:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/9\">",
"      Goplerud CP, Ohm MJ, Galask RP. Aerobic and anaerobic flora of the cervix during pregnancy and the puerperium. Am J Obstet Gynecol 1976; 126:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/10\">",
"      Bartlett JG, Onderdonk AB, Drude E, et al. Quantitative bacteriology of the vaginal flora. J Infect Dis 1977; 136:271.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Advisory file://www.fda.gov/drugs/drugsafety/publichealthadvisories/ucm051298.html (Accessed on April 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/12\">",
"      Greene MF. Fatal infections associated with mifepristone-induced abortion. N Engl J Med 2005; 353:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/13\">",
"      Soper DE. Abortion and clostridial toxic shock syndrome. Obstet Gynecol 2007; 110:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/14\">",
"      Fjerstad M, Trussell J, Sivin I, et al. Rates of serious infection after changes in regimens for medical abortion. N Engl J Med 2009; 361:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/15\">",
"      Cohen AL, Bhatnagar J, Reagan S, et al. Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet Gynecol 2007; 110:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/16\">",
"      Bangsberg DR, Rosen JI, Arag&oacute;n T, et al. Clostridial myonecrosis cluster among injection drug users: a molecular epidemiology investigation. Arch Intern Med 2002; 162:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/17\">",
"      Brett MM, Hood J, Brazier JS, et al. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect 2005; 133:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/18\">",
"      Sosolik RC, Savage BA, Vaccarello L. Clostridium sordellii toxic shock syndrome: a case report and review of the literature. Infect Dis Obstet Gynecol 1996; 4:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/19\">",
"      Wiebe E, Guilbert E, Jacot F, et al. A fatal case of Clostridium sordellii septic shock syndrome associated with medical abortion. Obstet Gynecol 2004; 104:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/20\">",
"      Hogan SF, Ireland K. Fatal acute spontaneous endometritis resulting from Clostridium sordelli. Am J Clin Pathol 1989; 91:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/21\">",
"      Soper DE. Clostridial myonecrosis arising from an episiotomy. Obstet Gynecol 1986; 68:26S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/22\">",
"      Spera RV Jr, Kaplan MH, Allen SL. Clostridium sordellii bacteremia: case report and review. Clin Infect Dis 1992; 15:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/23\">",
"      Buchman AL, Ponsillo M, Nagami PH. Empyema caused by Clostridium sordellii, a rare form of pleuropulmonary disease. J Infect 1991; 22:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/24\">",
"      File TM Jr, Fass RJ, Perkins RL. Pneumonia and empyema caused by Clostridium sordellii. Am J Med Sci 1977; 274:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/25\">",
"      Barnes P, Leedom JM. Infective endocarditis due to Clostridium sordellii. Am J Med 1987; 83:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/26\">",
"      Spindler AJ, Musa H. Clostridium sordelli septic arthritis. J Rheumatol 1987; 14:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/27\">",
"      Matten J, Buechner V, Schwarz R. A rare case of Clostridium sordellii bacteremia in an immunocompromised patient. Infection 2009; 37:368.",
"     </a>",
"    </li>",
"    <li>",
"     Lorber B. Gas gangrene and other Clostridium-associated diseases. In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2005. p.2828.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/29\">",
"      Bitti A, Mastrantonio P, Spigaglia P, et al. A fatal postpartum Clostridium sordellii associated toxic shock syndrome. J Clin Pathol 1997; 50:259.",
"     </a>",
"    </li>",
"    <li>",
"     Stevens DL. Clostridial infections. In: Stevens DL, Mandell GL, Atlas of Infectious Diseases (Ed), Churchill Livingstone, Philadelphia 1995. p.13.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/31\">",
"      Martinez RD, Wilkins TD. Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun 1988; 56:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/32\">",
"      Tait AS, Dalton M, Geny B, et al. The large clostridial toxins from Clostridium sordellii and C. difficile repress glucocorticoid receptor activity. Infect Immun 2007; 75:3935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/33\">",
"      Aldape MJ, Bryant AE, Ma Y, Stevens DL. The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation. J Infect Dis 2007; 195:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/34\">",
"      Voth DE, Martinez OV, Ballard JD. Variations in lethal toxin and cholesterol-dependent cytolysin production correspond to differences in cytotoxicity among strains of Clostridium sordellii. FEMS Microbiol Lett 2006; 259:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/35\">",
"      Grimwood K, Evans GA, Govender ST, Woods DE. Clostridium sordellii infection and toxin neutralization. Pediatr Infect Dis J 1990; 9:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/36\">",
"      R&oslash;rbye C, Petersen IS, Nilas L. Postpartum Clostridium sordellii infection associated with fatal toxic shock syndrome. Acta Obstet Gynecol Scand 2000; 79:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1431/abstract/37\">",
"      Staneck JL, Washington JA 2nd. Antimicrobial susceptibilities of anaerobic bacteria: recent clinical isolates. Antimicrob Agents Chemother 1974; 6:311.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5539 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5CA193EFE4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1431=[""].join("\n");
var outline_f1_25_1431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antitoxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33386?source=related_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28330?source=related_link\">",
"      Misoprostol as a single agent for medical termination of pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_25_1432="EEG Breach rhythm";
var content_f1_25_1432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Breach rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breach rhythm noted at the C3 electrode in a 61-year-old man with history of head trauma and a left frontoemporal craniotomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mushtaq, R, Van Cott, AC, Benign EEG variants. Am J Electroneurodiagnostic Technol 2005; 45:88. Copyright &copy;2005 American Society of Electroneurodiagnostic Technologists.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1432=[""].join("\n");
var outline_f1_25_1432=null;
var title_f1_25_1433="Tension-type headache in adults: Preventive treatment";
var content_f1_25_1433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tension-type headache in adults: Preventive treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1433/contributors\">",
"     Frederick R Taylor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1433/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1433/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/25/1433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headache (TTH) is the most common headache in the population. Yearly prevalence rates for episodic TTH are approximately 80 percent in men and women. Due to its high prevalence in the population, TTH causes a high degree of disability. Despite its frequency, few placebo-controlled preventive therapeutic trials have been conducted in TTH. Different methods for efficacy measurement characterize these trials, making it difficult to compare results among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available, proven, and speculative preventive therapies of TTH in adults are reviewed here. Acute treatment of TTH in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=see_link\">",
"     \"Tension-type headache in adults: Acute treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other aspects of TTH are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"     \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS AND APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preventive therapy of TTH ranges from drugs to nonpharmacologic therapies such as behavioral and cognitive interventions. The goals of preventive therapy in TTH are reasonably extrapolated from those devised for migraine headache [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/2\">",
"     2",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduce attack frequency, severity, and duration",
"     </li>",
"     <li>",
"      Improve responsiveness to treatment of acute attacks",
"     </li>",
"     <li>",
"      Improve function and reduce disability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylactic headache treatment is indicated if the headaches are frequent, long lasting, or account for a significant amount of total disability [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/2\">",
"     2",
"    </a>",
"    ]. With respect to TTH, both the frequent episodic subtype (1 to 14 headache days a month) and chronic subtype (&ge;15 headache days a month) warrant prevention as they may be associated with significant disability, especially when accompanied by migraine, comorbid depression, or anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, preventive treatment is appropriate for most patients with chronic TTH, and is probably appropriate for many patients with frequent episodic TTH. In contrast, patients with infrequent episodic TTH (headache &lt;1 day per month) do not require preventive treatment.",
"   </p>",
"   <p>",
"    Preventive therapy may be also indicated when acute therapy fails or is inappropriate because of inadequate response, adverse events, overuse, or contraindications.",
"   </p>",
"   <p>",
"    To achieve benefit, prophylactic headache therapy requires a sustained commitment on the part of the patient and clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/3\">",
"     3",
"    </a>",
"    ]. It is important to address patient expectations and consider patient preferences when deciding between different preventive therapies. In addition, the patient should be informed of the rationale for a particular treatment, the expected benefits of therapy, the duration of treatment that will likely be needed to achieve improvement, and the possible and likely side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tricyclic antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    is the mainstay of pharmacologic preventive treatment for TTH. Other antidepressant medications may also be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines published in 2010 by the European Federation of Neurological Societies (EFNS) for the treatment of TTH conclude that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    has a clinically relevant prophylactic effect in patients with chronic TTH and should be the drug of first choice [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    for TTH prophylaxis has been demonstrated in several small trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. As an example, one trial randomly assigned 34 patients with chronic TTH to treatment with amitriptyline (75 mg daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    (20 mg daily), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared with placebo, amitriptyline treatment was associated with a statistically significant reduction of area under the headache curve (the sum of the daily recordings of headache duration times headache intensity) at 32 weeks of 30 percent, while citalopram had no significant benefit.",
"   </p>",
"   <p>",
"    Additional evidence that tricyclics are beneficial for TTH comes from a meta-analysis published in 2005, which found that tricyclics significantly reduced headache duration by 1.26 hours per day (95% CI 0.06-2.45) and marginally reduced headache indexes (standardized mean difference 0.42, 95% CI 0.00-0.85) compared with selective serotonin reuptake inhibitors (SSRIs) in patients with chronic TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/10\">",
"     10",
"    </a>",
"    ]. Compared with placebo, SSRIs did not show any benefit in patients with chronic TTH.",
"   </p>",
"   <p>",
"    Tricyclic antidepressants are reuptake inhibitors of serotonin and noradrenaline, and these neurotransmitter interactions are the presumed mechanism of action for this class of drugs. Negative data regarding SSRIs suggest that other potential mechanisms, including inhibition of norepinephrine reuptake and antagonism of N-methyl-D-aspartate (NMDA) receptors, may be more likely to mediate the analgesic effect of tricyclics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    also reduces pericranial muscle tenderness, leading to peripheral antinociception and inhibition of central sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Patients should be informed that amitriptyline is an antidepressant agent but has an independent action on pain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"     1",
"    </a>",
"    ]. The beneficial effect for TTH is not related to the presence of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    for patients with frequent episodic TTH or chronic TTH. Exceptions include patients with obesity, bipolar disease, or cardiac conduction defects. This recommendation is best suited for patients who have a preference for pharmacologic treatment rather than behavioral or other nonpharmacologic therapies.",
"   </p>",
"   <p>",
"    The utility of combined tricyclic and behavioral therapy for the treatment of chronic TTH is reviewed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Combined behavioral and tricyclic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dosing and duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following principles to guide preventive drug therapy for TTH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Start the drug at the lowest dose, and increase the dose gradually until either therapeutic benefit is achieved, the maximum dose of the drug is reached, or side effects become intolerable.",
"     </li>",
"     <li>",
"      Give the prophylactic medication an adequate trial in terms of duration and dosage. Benefit is often first noted only after four to six weeks of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. In addition, benefit may continue to accrue for three months.",
"     </li>",
"     <li>",
"      Avoid overuse of analgesic medications. Ongoing analgesic overuse must be eliminated, or preventive therapy will likely be ineffective.",
"     </li>",
"     <li>",
"      Measure the effectiveness of therapy by use of a patient headache diary to track daily headache frequency and intensity.",
"     </li>",
"     <li>",
"      Once effective, maintain drug therapy for at least three to six months. Thereafter, a slow taper off the medication can be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With these principles in mind, we start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    at 10 to 12.5 mg nightly and increase the dose in 10 to 12.5 mg steps every two to three weeks as tolerated and as needed for sleep, until there is improvement in headache or until a maximum dose of 100 to 125 mg nightly is reached.",
"   </p>",
"   <p>",
"    It is common for practitioners to initiate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    at 25 mg each night and increase the dose in 25 mg increments each week, but in the author's clinical experience, such a regimen is complicated by increased side effects and reduced adherence compared with the one outlined above.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     Nortriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     protriptyline",
"    </a>",
"    can be considered as alternative tricyclics if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    is poorly tolerated. The effects of these tricyclic medications on sleep, anxiety disorders, and body weight can guide the choice among them.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      is the most sedating,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      is mild to moderately sedating, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"       protriptyline",
"      </a>",
"      is nonsedating and may be somewhat stimulating in some. Thus, protriptyline should be used cautiously for patients who have anxiety and panic disorders.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      can cause weight gain, while",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"       protriptyline",
"      </a>",
"      may cause weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     Nortriptyline",
"    </a>",
"    is manufactured in capsules only and therefore is initiated and titrated in 10 or 25mg increments (the same doses as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ), but it can usually be increased on a weekly basis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     Protriptyline",
"    </a>",
"    is usually started at 5 mg each morning and increased in 5 mg increments every week with a target dose of 20 mg each morning.",
"   </p>",
"   <p>",
"    Tricyclic medications are associated with an increased risk of cardiac conduction abnormalities and arrhythmias. Before initiating treatment with any of the cyclic antidepressants, patients should be screened for cardiac conduction system disease, which precludes the use of these medications. We and others suggest that patients age 40 years and older have a baseline ECG for this purpose. Patients younger than age 40 can be screened by history for evidence of cardiac disease. They do not require an ECG if the history is negative. Patients who have a normal ECG before starting a tricyclic antidepressant do not need additional ECG monitoring while on the antidepressant, unless symptoms arise suggestive of cardiac toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link&amp;anchor=H28#H28\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\", section on 'Cardiac evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data from small randomized controlled trials suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    (a noradrenergic and specific serotonergic antidepressant) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (a serotonin-norepinephrine reuptake inhibitor) may be effective for the treatment of chronic TTH in patients without depression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an eight-week trial involving 24 patients with chronic TTH, including subjects not responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      (15 to 30 mg daily) treatment was associated with a 34 percent lower area under the headache curve (the sum of the daily recordings of headache duration times headache intensity), the primary outcome measure, than placebo, and the difference was statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/15\">",
"       15",
"      </a>",
"      ]. In addition, mirtazapine treatment was associated with statistically significant reductions in headache intensity, duration, and frequency.",
"      <br/>",
"      <br/>",
"      More patients treated with mirtazapine had sedation, dizziness, and weight gain than did patients receiving placebo, but the difference was not statistically significant. However, weight gain is a known side effect of mirtazapine, and the short duration of the trial may explain why the relationship did not achieve statistical significance.",
"     </li>",
"     <li>",
"      In a 12-week trial involving 60 patients with TTH and more than five headaches a month at entry, treatment with extended-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      (150 mg daily) was associated with a statistically significant reduction in days with headache, the primary outcome measure, compared with placebo (45 percent reduction versus 16 percent increase) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/16\">",
"       16",
"      </a>",
"      ]. However, there were no statistically significant differences between treatment groups on any of the secondary outcome measures. Adverse events, mainly gastrointestinal symptoms, were more frequent in the venlafaxine group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results appear promising, but are preliminary. We believe the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    for TTH prevention requires further confirmation in larger trials before either can be recommended as a routine treatment. The 2010 European guidelines consider mirtazapine and venlafaxine to be drugs of second choice for the prophylactic treatment of chronic TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available evidence suggests that selective serotonin reuptake inhibitors are",
"    <strong>",
"     not",
"    </strong>",
"    effective for the treatment of TTH in patients without depression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/12\">",
"     12",
"    </a>",
"    ]. This conclusion is supported by a meta-analysis published in 2005, which found that SSRIs did not show any benefit compared with placebo in patients with chronic TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    may be beneficial for patients with chronic TTH.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct evidence of benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      in TTH prevention is lacking, but one randomized trial evaluated this drug in 95 patients with chronic daily headache, including 25 patients with TTH and 58 with a combination of TTH and migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/17\">",
"       17",
"      </a>",
"      ]. Treatment with gabapentin (2400 mg daily) was associated with a statistically significant improvement in headache-free days compared with placebo. The strength of this finding is limited by methodologic problems with the study, including failure to use an intention-to-treat analysis.",
"     </li>",
"     <li>",
"      An open label study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      (initially 25 mg daily, then increased to 100 mg daily) in 51 patients with TTH reported a significant decline in headache frequency after three months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evidence from randomized clinical trials is needed to clarify whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    have a role in TTH prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tizanidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited and conflicting data regarding the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"     tizanidine",
"    </a>",
"    , a muscle relaxant and antispasticity agent, for the prophylaxis of TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. An early clinical trial of 37 women with chronic TTH found that tizanidine (6 to 18 mg daily) was more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/19\">",
"     19",
"    </a>",
"    ]. However, a larger trial of 185 patients with chronic TTH showed that tizanidine (6 or 12 mg modified release daily) was without benefit compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Botulinum toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence from several randomized placebo-controlled clinical trials that botulinum toxin injection is",
"    <strong>",
"     not",
"    </strong>",
"    effective for chronic TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. As an example, one of these trials enrolled 112 patients with chronic TTH and found that injection of botulinum neurotoxin A (500 U) in a fixed set of predetermined pericranial muscles was without benefit compared with placebo injection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, an evidence-based review published in 2008 by the American Academy of Neurology (AAN) concluded that botulinum toxin is probably ineffective for patients with chronic TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, use of botulinum toxin therapy for the preventive treatment of TTH cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BEHAVIORAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of behavioral treatments is to prevent headaches by identifying and defusing headache triggers, which are particularly important in TTH, and by using self-regulation to modulate involuntary and subconscious physiologic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/27\">",
"     27",
"    </a>",
"    ]. European guidelines for the treatment of TTH published in 2010 state that non-drug management should be considered for all patients with TTH even though the scientific evidence is sparse and contradictory [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"     1",
"    </a>",
"    ]. The guidelines note that a therapeutic effect may be attained simply by taking the problem seriously, particularly if the patient is worried that the headache is caused by a serious problem such as a brain tumor.",
"   </p>",
"   <p>",
"    Behavioral treatments for headache include the following methods [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cognitive-behavioral therapy",
"     </li>",
"     <li>",
"      Relaxation",
"     </li>",
"     <li>",
"      Biofeedback",
"     </li>",
"     <li>",
"      Combinations of the above (eg, stress management therapy often consists of a combination of behavioral methods, with an emphasis on cognitive-behavioral therapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Behavioral treatments may be particularly well suited for patients with the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those who prefer nonpharmacologic treatment",
"     </li>",
"     <li>",
"      Those who have an insufficient response to, or poor tolerance of, pharmacologic treatments",
"     </li>",
"     <li>",
"      Women who are pregnant, planning to become pregnant, or nursing",
"     </li>",
"     <li>",
"      Those with a history of excessive use of analgesics or acute medications",
"     </li>",
"     <li>",
"      Those who have significant stress or deficient stress-coping skills",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identifying the triggering or exacerbating factors for headache may be important for success in headache therapy. Epidemiologic studies suggest that stress and mental tension are the most frequent identified triggers for TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/30\">",
"     30",
"    </a>",
"    ]. Coping with headache triggers is probably a more valuable strategy than advice to avoid the triggers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/31\">",
"     31",
"    </a>",
"    ]. Since there is an important behavioral component to nearly all of the known headache triggers, behavioral therapies are a potentially useful means of coping with",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alleviating these triggers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H482163804\">",
"    <span class=\"h2\">",
"     Biofeedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofeedback methods are based upon the notion that an individual can learn to control involuntary and subconscious physiologic processes when information about these processes is fed back in the form of a visual or auditory signal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/27\">",
"     27",
"    </a>",
"    ]. Electromyography (EMG) feedback is the predominant method used in TTH treatment.",
"   </p>",
"   <p>",
"    Pericranial muscle tenderness is often associated with TTH, but many patients are either not aware of the relationship, or overly fixate on its importance. Biofeedback may be helpful in either circumstance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy combines principles of cognitive therapy, which teaches patients to identify, evaluate, and better respond to their dysfunctional thoughts and beliefs, and behavior therapy, which helps patients develop new and adaptive ways of behaving.",
"   </p>",
"   <p>",
"    As applied to headache, cognitive-behavioral therapy attempts to modify a maladaptive response (eg, headache) to stressful events by altering the usual interpretations, thoughts, and assumptions associated with such events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/27\">",
"     27",
"    </a>",
"    ]. Identifying headache triggers (whether physical, psychologic, or behavioral) and developing effective coping strategies are important aspects of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Relaxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation techniques are based upon the premise that an unwanted outcome, such as headache, can be diminished or avoided by altering physiologic responses and decreasing sympathetic arousal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/27\">",
"     27",
"    </a>",
"    ]. Various forms of relaxation include progressive muscle relaxation, autogenic training (ie, learning self-statements that suggest warmth and heaviness), meditative or passive relaxation, and self-hypnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of behavioral interventions for TTH is difficult to assess, as many of the studies are limited by methodological problems, particularly small sample sizes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/27\">",
"     27",
"    </a>",
"    ]. Furthermore, study results are conflicting. Several meta-analytic reviews have evaluated behavioral therapies for TTH, including one from 2001 that was not published in a peer-reviewed journal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 meta-analysis of biofeedback for TTH included 53 studies and concluded that biofeedback was more effective than headache monitoring, placebo, and relaxation therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/33\">",
"       33",
"      </a>",
"      ]. In addition, the effect was long lasting and enhanced by combination with relaxation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1,33\">",
"       1,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2009 review of randomized trials evaluating behavioral treatments for chronic TTH included 44 trials with 2618 patients, but only five studies were considered to have low risk of bias [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/34\">",
"       34",
"      </a>",
"      ]. Most trials lacked adequate statistical power, and rates of recovery or improvement frequently failed to reach clinical relevance. In 11 studies, biofeedback was compared with wait list conditions; and in eight studies, relaxation treatment was compared with wait list conditions, both showing inconsistent results.",
"     </li>",
"     <li>",
"      In the 2001 meta-analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/32\">",
"       32",
"      </a>",
"      ], the clinical magnitude of the benefit of behavioral therapy for TTH compared favorably with that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      , which was associated with an average 33 percent reduction in headache in the three randomized controlled trials included as a comparator [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, we suggest treatment using biofeedback combined with relaxation therapy rather than other behavioral therapy options for patients with frequent episodic TTH or chronic TTH. This recommendation is similar to the conclusions of the 2010 European guidelines for the treatment of TTH, which observed that there is no convincing evidence to support an effect of cognitive-behavioral therapy and relaxation training alone for TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, it is possible that cognitive-behavioral therapy may be beneficial for patients with TTH who have underlying behavioral problems or stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Combined behavioral and tricyclic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are limited, behavioral therapy and tricyclic therapy appear to have equivalent modest effectiveness for the treatment of chronic TTH, while tricyclic therapy achieves benefit more rapidly. In addition, a combination of the two therapies may be superior to either alone.",
"   </p>",
"   <p>",
"    Supporting evidence comes from a clinical trial that randomly assigned 203 patients with chronic TTH to one of four treatment arms: tricyclic antidepressant treatment, placebo, stress management plus placebo, or stress management plus tricyclic antidepressant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients assigned to tricyclics received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    (12.5 mg to 100 mg nightly as tolerated);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    (25 mg to 75 mg nightly as tolerated) was substituted if amitriptyline was poorly tolerated or ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/9\">",
"     9",
"    </a>",
"    ]. Stress management therapy consisted of the following elements: three one-hour teaching sessions and two telephone contacts with a psychologist or counselor; instruction manuals and audio tapes to guide home-based stress management skills; deep muscle relaxation training; and cognitive coping or problem-solving techniques to manage and prevent headache-related stress.",
"   </p>",
"   <p>",
"    The following outcomes were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with placebo, all three active treatments (tricyclic antidepressant, stress management plus placebo, or stress management plus tricyclics) were associated with similar, statistically significant improvements in the headache index (a measure of overall headache activity) at six months, the primary outcome measure.",
"     </li>",
"     <li>",
"      The magnitude of benefit was modest for all active treatments; each reduced the number of days a month with a headache of moderate or greater severity by half (from approximately 14 to 7 days).",
"     </li>",
"     <li>",
"      Tricyclic treatment was associated with a more rapid improvement in headache index scores than stress management alone.",
"     </li>",
"     <li>",
"      Tricyclic treatment was also associated with significantly more adverse events, mainly dry mouth and drowsiness, than placebo treatment.",
"     </li>",
"     <li>",
"      The proportion of patients who achieved a clinically significant (ie, &ge;50 percent) reduction in headache index scores was higher in the combined stress management plus tricyclics treatment group than in the tricyclic only group (64 versus 38 percent), and the difference was statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, and despite limited evidence supporting benefit, we suggest treatment with combined tricyclic antidepressant therapy plus stress management therapy for patients with frequent episodic TTH or chronic TTH, rather than treatment with tricyclics alone or behavioral therapy alone. This recommendation is best suited for patients who are willing to undergo both pharmacologic and nonpharmacologic treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Self-management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are few data, many experts believe that a behavioral self-management program is important to minimize disease progression in the preventive treatment of TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/29\">",
"     29",
"    </a>",
"    ]. A potential advantage of these methods is that they encourage greater responsibility on the part of the patient to engage in health promotion, while maintaining essential collaboration between patient and practitioner [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Self-management involves developing knowledge of headache triggers with attention to reducing these triggers. For headache in general, this process includes attention to sleep problems, lack of exercise, medication and caffeine overuse, stress related to life events, and any other obvious factors. For TTH in particular, the emphasis of self-management is focused on developing stress awareness and control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral treatments can be applied in a clinic-based format with sessions involving one-to-one contact between the patient and a psychologist or counselor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/29\">",
"     29",
"    </a>",
"    ]. Alternative formats for delivery of behavioral self-management techniques include small group therapy and home-based (minimal-contact) treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some individuals can gain expertise through self-learning via commercially available videos or internet-based programs, current evidence supports professional application. Referral to a community-based pain psychologist is advised if the practitioner does not have access to readily available behavioral therapy resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER NONPHARMACOLOGIC THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Acupuncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence regarding acupuncture for TTH suggests that any benefit is likely to be modest.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 meta-analysis of pooled data from five randomized controlled trials concluded that acupuncture has limited efficacy for the reduction of headache frequency compared with sham treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2009 meta-analysis with data from five randomized trials with sham controls (largely overlapping with the trials included in the 2008 meta-analysis) concluded that acupuncture led to a small but statistically significant benefit for the primary outcome, the proportion of patients who achieved a &ge;50 percent reduction of headache frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one of the larger individual trials that used 42 trained physician acupuncturists [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/37\">",
"       37",
"      </a>",
"      ] and enrolled 270 patients with chronic TTH, acupuncture treatment was associated with a statistically significant benefit of fewer days with headache compared with no treatment (ie, wait-list controls), but acupuncture was not beneficial compared with minimal (sham) acupuncture [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/38\">",
"       38",
"      </a>",
"      ]. This result suggests that treatment with any acupuncture technique may have measurable therapeutic effects [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although of limited benefit for the prevention of TTH, acupuncture is safe and may be used for patients who do not tolerate or desire more effective treatments such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Physical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of physical therapy for TTH is unproven. In addition, there are no true randomized double-blind placebo-controlled trials evaluating the effectiveness of physical therapy for TTH prevention.",
"   </p>",
"   <p>",
"    Various physical therapy methods, alone or in combination, have been used to treat TTH, including specific exercises, therapeutic heat or cold, massage, postural correction, therapeutic touch, traction, trigger point therapy, spinal manipulation, and electrical therapies such as transcutaneous electrical nerve stimulation (TENS), electromagnetic therapy, ultrasound, and laser [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis published in 2004 identified eight trials that evaluated different types of physical therapies for TTH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/39\">",
"     39",
"    </a>",
"    ]. The following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spinal manipulation therapy had fewer side effects but was less effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      for reducing pain intensity after six weeks of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/40\">",
"       40",
"      </a>",
"      ]. However, spinal manipulation but not amitriptyline had sustained benefit four weeks after both therapies were stopped. Spinal manipulation added to massage therapy was not beneficial compared with massage alone [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was limited evidence that cranial electrotherapy was superior to placebo for reducing pain intensity after 6 to 10 weeks of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/42\">",
"       42",
"      </a>",
"      ]. The treated group had longer duration headaches at baseline, which may have affected the outcome.",
"     </li>",
"     <li>",
"      Other potential treatment options for TTH had only preliminary evidence suggesting possible benefit; these were a combination of TENS and electrical neurotransmitter modulation compared with relaxation training, and a combination of auto-massage, TENS, and stretching compared with acupuncture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a later trial with blinded outcome assessment, 81 patients with TTH were randomly assigned to a program of craniocervical endurance exercises combined with standard physical therapy (massage, oscillation techniques, postural correction) or to physical therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/43\">",
"     43",
"    </a>",
"    ]. At the end of the six-week treatment, combined craniocervical training plus physical therapy was associated with a nonsignificant reduction in headache frequency compared with physical therapy alone (0.94 fewer headaches per week), but the benefit was sustained, and the reduction in headache frequency was statistically significant at six months (1.95 fewer headaches per week, 95% CI 1,14-2.76). Furthermore, headache intensity and duration at six months were significantly reduced with combined treatment.",
"   </p>",
"   <p>",
"    Given the lack of definitive evidence of benefit for physical therapy, its role in the preventive treatment of TTH remains unclear. However, these treatments are associated with a low risk of serious side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1433/abstract/39\">",
"     39",
"    </a>",
"    ]. We suggest treatment with physical therapy that includes craniocervical exercises for patients with frequent episodic TTH and chronic TTH who do not tolerate or desire more effective treatments such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and behavioral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"       \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylactic headache treatment is indicated if headaches are frequent, long lasting, or associated with a significant amount of disability. Preventive treatment is appropriate for most patients with chronic tension-type headache (TTH), and for many patients with frequent episodic TTH. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications and approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tricyclic antidepressants, particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      , are the mainstay of preventive pharmacologic treatment for TTH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Tricyclic antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other agents have been studied for TTH prophylaxis, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/35/12855?source=see_link\">",
"       tizanidine",
"      </a>",
"      . However, the benefit of these drugs for TTH prevention is not established, and more clinical trial data are required. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Other antidepressants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Anticonvulsants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Tizanidine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavioral treatments for headache include biofeedback, relaxation, and cognitive-behavioral therapy (ie, stress management). The goal of these treatments is to prevent headaches by identifying and defusing behavioral headache triggers, and by using self-regulation to modulate involuntary and subconscious physiologic processes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Behavioral therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EMG biofeedback, alone or combined with relaxation therapy, appears to have modest effectiveness for TTH prevention. There is no convincing evidence to support an effect of cognitive-behavioral therapy or relaxation training alone for TTH. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent episodic TTH or chronic TTH we suggest treatment with combined tricyclic antidepressant therapy plus stress management therapy rather than treatment with tricyclics alone or behavioral therapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Combined behavioral and tricyclic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent episodic TTH or chronic TTH who have a preference for pharmacologic treatment rather than behavioral therapy, we suggest tricyclic therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Guidelines for drug dosing and duration of therapy are given above. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Tricyclic antidepressants'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Dosing and duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent episodic TTH or chronic TTH who wish to avoid pharmacologic therapy, we suggest EMG biofeedback combined with relaxation therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Behavioral therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with frequent episodic TTH and chronic TTH who do not tolerate or desire more effective treatments such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      and biofeedback, we suggest treatment with acupuncture (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or physical therapy that includes craniocervical exercises (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Other nonpharmacologic therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/1\">",
"      Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/2\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/3\">",
"      Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/4\">",
"      LANCE JW, CURRAN DA. TREATMENT OF CHRONIC TENSION HEADACHE. Lancet 1964; 1:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/5\">",
"      Diamond S, Baltes BJ. Chronic tension headache--treated with amitriptyline--a double-blind study. Headache 1971; 11:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/6\">",
"      Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/7\">",
"      Bendtsen L, Jensen R. Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 2000; 20:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/8\">",
"      Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain 2004; 108:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/9\">",
"      Holroyd KA, O'Donnell FJ, Stensland M, et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination: a randomized controlled trial. JAMA 2001; 285:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/10\">",
"      Moja PL, Cusi C, Sterzi RR, Canepari C. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; :CD002919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/11\">",
"      Bendtsen L. Central sensitization in tension-type headache--possible pathophysiological mechanisms. Cephalalgia 2000; 20:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/12\">",
"      Lenaerts ME. Pharmacoprophylaxis of tension-type headache. Curr Pain Headache Rep 2005; 9:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/13\">",
"      G&ouml;bel H, Hamouz V, Hansen C, et al. Chronic tension-type headache: amitriptyline reduces clinical headache-duration and experimental pain sensitivity but does not alter pericranial muscle activity readings. Pain 1994; 59:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/14\">",
"      Cohen GL. Protriptyline, chronic tension-type headaches, and weight loss in women. Headache 1997; 37:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/15\">",
"      Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/16\">",
"      Zissis NP, Harmoussi S, Vlaikidis N, et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007; 27:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/17\">",
"      Spira PJ, Beran RG, Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 2003; 61:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/18\">",
"      Lampl C, Marecek S, May A, Bendtsen L. A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache. Cephalalgia 2006; 26:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/19\">",
"      Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. Headache 1992; 32:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/20\">",
"      Murros K, Kataja M, Hedman C, et al. Modified-release formulation of tizanidine in chronic tension-type headache. Headache 2000; 40:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/21\">",
"      Saper JR, Lake AE 3rd, Cantrell DT, et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002; 42:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/22\">",
"      Warner JS. Tizanidine is not a cure for chronic daily headache. Headache 2003; 43:296; author reply 296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/23\">",
"      Schulte-Mattler WJ, Krack P, BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004; 109:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/24\">",
"      Padberg M, de Bruijn SF, de Haan RJ, Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004; 24:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/25\">",
"      Silberstein SD, G&ouml;bel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/26\">",
"      Naumann M, So Y, Argoff CE, et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/27\">",
"      Rains JC, Penzien DB, McCrory DC, Gray RN. Behavioral headache treatment: history, review of the empirical literature, and methodological critique. Headache 2005; 45 Suppl 2:S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/28\">",
"      Penzien DB, Rains JC, Andrasik F. Behavioral management of recurrent headache: three decades of experience and empiricism. Appl Psychophysiol Biofeedback 2002; 27:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/29\">",
"      Penzien DB, Rains JC, Lipchik GL, Creer TL. Behavioral interventions for tension-type headache: overview of current therapies and recommendation for a self-management model for chronic headache. Curr Pain Headache Rep 2004; 8:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/30\">",
"      Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/31\">",
"      Martin PR, MacLeod C. Behavioral management of headache triggers: Avoidance of triggers is an inadequate strategy. Clin Psychol Rev 2009; 29:483.",
"     </a>",
"    </li>",
"    <li>",
"     McCrory, DC, Penzien, DB, Hasselblad, V, Gray, RN. Evidence Report: Behavioral and physical treatments for tension-type and cervicogenic headache, Foundation for Chiropractic Education and Research, (Product Number 2085), Des Moines, Iowa 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/33\">",
"      Nestoriuc Y, Rief W, Martin A. Meta-analysis of biofeedback for tension-type headache: efficacy, specificity, and treatment moderators. J Consult Clin Psychol 2008; 76:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/34\">",
"      Verhagen AP, Damen L, Berger MY, et al. Behavioral treatments of chronic tension-type headache in adults: are they beneficial? CNS Neurosci Ther 2009; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/35\">",
"      Davis MA, Kononowech RW, Rolin SA, Spierings EL. Acupuncture for tension-type headache: a meta-analysis of randomized, controlled trials. J Pain 2008; 9:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/36\">",
"      Linde K, Allais G, Brinkhaus B, et al. Acupuncture for tension-type headache. Cochrane Database Syst Rev 2009; :CD007587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/37\">",
"      Melchart D, Streng A, Hoppe A, et al. The acupuncture randomised trial (ART) for tension-type headache--details of the treatment. Acupunct Med 2005; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/38\">",
"      Melchart D, Streng A, Hoppe A, et al. Acupuncture in patients with tension-type headache: randomised controlled trial. BMJ 2005; 331:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/39\">",
"      Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst Rev 2004; :CD001878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/40\">",
"      Boline PD, Kassak K, Bronfort G, et al. Spinal manipulation vs. amitriptyline for the treatment of chronic tension-type headaches: a randomized clinical trial. J Manipulative Physiol Ther 1995; 18:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/41\">",
"      Bove G, Nilsson N. Spinal manipulation in the treatment of episodic tension-type headache: a randomized controlled trial. JAMA 1998; 280:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/42\">",
"      Solomon S, Elkind A, Freitag F, et al. Safety and effectiveness of cranial electrotherapy in the treatment of tension headache. Headache 1989; 29:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1433/abstract/43\">",
"      van Ettekoven H, Lucas C. Efficacy of physiotherapy including a craniocervical training programme for tension-type headache; a randomized clinical trial. Cephalalgia 2006; 26:983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3360 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1433=[""].join("\n");
var outline_f1_25_1433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS AND APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dosing and duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tizanidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Botulinum toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BEHAVIORAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H482163804\">",
"      Biofeedback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Relaxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Combined behavioral and tricyclic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Self-management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Implementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER NONPHARMACOLOGIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Physical therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=related_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=related_link\">",
"      Tension-type headache in adults: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_25_1434="Normal puberty";
var content_f1_25_1434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal puberty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Frank M Biro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/25/1434/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/25/1434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents experience several types of maturation, including cognitive (the development of formal operational thought), psychosocial (the stages of adolescence), and biological. The complex series of biological transitions are known as puberty, and these changes may impact psychosocial factors.",
"   </p>",
"   <p>",
"    The most visible changes during puberty are growth in stature and development of secondary sexual characteristics. Equally profound are changes in body composition; the achievement of fertility; and changes in most body systems, such as the neuroendocrine axis, bone size, and mineralization; and the cardiovascular system. As an example, normal cardiovascular changes, including greater aerobic power reserve, electrocardiographic changes, and blood pressure changes, occur during puberty.",
"   </p>",
"   <p>",
"    Recent observations have begun to account for the cognitive characteristics observed in adolescents, in which they make very different decisions when under the influence of strong emotions (\"hot\" cognition) as compared to decisions made under conditions of low emotional arousal (\"cool\" cognition) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/1\">",
"     1",
"    </a>",
"    ]. The dorsolateral prefrontal cortex, an area of the brain involved in impulse control, matures later than the remainder of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/2\">",
"     2",
"    </a>",
"    ]. In times of stress, the brain of the adolescent may be less able to modulate the affective component when responding to that stressor.",
"   </p>",
"   <p>",
"    The normal sequence of pubertal events and perils of puberty are reviewed here. Precocious and delayed puberty are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=see_link\">",
"     \"Diagnosis and treatment of delayed puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adrenarche is the activation of the adrenal cortex for the production of adrenal androgens, and typically occurs before the onset of puberty. This process is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23302?source=see_link\">",
"       \"Normal adrenarche\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21481?source=see_link\">",
"       \"Premature adrenarche\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gonadarche is the activation of the gonads by the pituitary hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH)",
"     </li>",
"     <li>",
"      Pubarche is the appearance of pubic hair",
"     </li>",
"     <li>",
"      Thelarche is the appearance of breast tissue",
"     </li>",
"     <li>",
"      Menarche is the age of onset of the first menstrual period",
"     </li>",
"     <li>",
"      Spermarche is the age at first ejaculation (heralded by nocturnal sperm emissions and appearance of sperm in the urine) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PUBERTAL CHANGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sexual maturity rating (Tanner stages)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conceptually, pubertal maturation can be described in terms of timing of onset, sequence, and tempo (",
"    <a class=\"graphic graphic_figure graphicRef52047 graphicRef72046 \" href=\"UTD.htm?26/57/27543\">",
"     figure 1A-B",
"    </a>",
"    ). Puberty consists of a series of predictable events, and the sequence of changes in secondary sexual characteristics has been categorized by several groups.",
"   </p>",
"   <p>",
"    The staging system utilized most frequently is that published by Marshall and Tanner [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], and the sequence of changes is described by sexual maturity ratings (SMR), also known as \"Tanner stages\". These consist of systematized descriptions of the development of secondary sexual characteristics, consisting of breast changes in females, pubic hair changes in both males and females, and genital changes in males. SMR for pubic hair, breast, and genitalia consists of five categories, with stage one representing prepuberty and stage five representing adult development (",
"    <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"     table 1",
"    </a>",
"    ). The stages are illustrated by the figure in boys (",
"    <a class=\"graphic graphic_picture graphicRef80005 \" href=\"UTD.htm?32/26/33187\">",
"     picture 1",
"    </a>",
"    ) and in girls (",
"    <a class=\"graphic graphic_picture graphicRef72038 graphicRef79782 \" href=\"UTD.htm?39/9/40088\">",
"     picture 2A-B",
"    </a>",
"    ). In girls, estrogen stimulation of the vaginal mucosa causes a physiologic leukorrhea, which is a thin white non foul-smelling vaginal discharge that typically begins 6 to 12 months before menarche. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=see_link&amp;anchor=H10#H10\">",
"     \"The pediatric physical examination: The perineum\", section on 'Preadolescent and adolescent females'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    As is discussed below, the timing of pubertal maturation has an important influence on self-esteem, behavior, growth, and weight. As an example, early maturation is associated with slightly shorter adult stature [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and with greater adult ponderosity and adiposity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Details of the physiological changes expected during puberty are discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Physiology of pubertal maturation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peak height velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 17 to 18 percent of adult height accrues during puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/9\">",
"     9",
"    </a>",
"    ]. The increase in height affects both axial (trunk) and appendicular (limbs) components [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/10\">",
"     10",
"    </a>",
"    ]. The limbs accelerate before the trunk, with the distal portions of the limbs accelerating before the proximal portions; thus, the adolescent in early puberty is \"all hands and feet.\" In later puberty, however, the growth spurt is primarily truncal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/10\">",
"     10",
"    </a>",
"    ]. The timing of the growth spurt (peak height velocity) varies by gender, occurring approximately two years earlier during puberty in girls than in boys (",
"    <a class=\"graphic graphic_figure graphicRef52047 graphicRef72046 \" href=\"UTD.htm?26/57/27543\">",
"     figure 1A-B",
"    </a>",
"    ). In girls, peak height velocity occurs, on average, 0.5 years prior to menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disparity in mean adult height of men and women results from the timing and peak of the growth spurt in boys and girls. On average, boys are 2 cm taller at the age girls begin their peak height velocity and continue to accrue 3 to 4 cm per year for an additional one to two years, until they enter puberty. Boys experience a greater peak height velocity than do girls (10.3 versus 9.0",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef66909 graphicRef74573 \" href=\"UTD.htm?32/1/32792\">",
"     figure 2A-B",
"    </a>",
"    ). When calculated over a 12-month span rather than a shorter period of peak growth, these values fall to 9.5 and 8.3 cm, respectively. When evaluating growth, the clinician should look at whole-year changes because of seasonal variability; greater growth typically occurs in spring, although the time of year may vary when a given individual has a seasonal peak.",
"   </p>",
"   <p>",
"    Growth charts are generated by either longitudinal (such as the series of charts published by the Harvard Six-Cities study) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/12\">",
"     12",
"    </a>",
"    ] or cross-sectional data (such as the",
"    <a class=\"external\" href=\"file://www.cdc.gov/growthcharts/\">",
"     Centers for Disease Control growth charts",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/13\">",
"     13",
"    </a>",
"    ]. The charts published by Tanner and Davies, although utilized as longitudinal data, were generated from cross-sectional data. Cross-sectional charts do not follow the growth of any given individual. Longitudinal charts can determine individual patterns and allow the distinction to be made between early, average, and late maturers. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relation between pubertal events and bone growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following studies describe important associations between pubertal events, peak height velocity, and bone mineralization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of total body calcium, approximately one-half is laid down during puberty in females, and one-half to two-thirds in males [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]; by the end of puberty, males have nearly 50 percent more total body calcium than do females.",
"     </li>",
"     <li>",
"      In a longitudinal study of girls, peak bone mineral content velocity took place at the age of menarche and 9 to 12 months after peak height velocity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/16\">",
"       16",
"      </a>",
"      ]. Similar findings were noted in another longitudinal study in which menarche always occurred after peak height velocity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another longitudinal study, bone width increased before mineral content, which in turn increased before bone density [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/14\">",
"       14",
"      </a>",
"      ]. The changes occurred earlier in girls than in boys, with most of the changes in girls occurring in the 12 months before and after menarche. The increase in bone density during puberty is greater in African-American females than in Caucasian females [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disparities in the timing of bone growth and mineralization may place the growing adolescent at increased risk for fracture. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Musculoskeletal injuries'",
"    </a>",
"    below.) Furthermore, the risk for subsequent osteoporosis of the femur and vertebrae may be related to both specific \"insults\" and the timing of factors impacting bone deposition during puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/10\">",
"     10",
"    </a>",
"    ]. Given these data, the window of opportunity to maximize peak bone mass may be limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extremely early onset of puberty (precocious puberty) and earlier peak height velocity is been associated with reduced adult height, due to early epiphyseal closure. Whether pubertal onset that is early but within the normal range is associated with reduced adult stature is less clear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In girls, several studies that have investigated the impact of pubertal timing on adult stature, with conflicting conclusions. One study reconciles some of these differences: when relative pubertal timing was determined by age at menarche, those with an earlier age of menarche had a greater peak height velocity but shorter adult stature. When relative pubertal timing was determined by age of onset of breast tissue, there was no impact of relative pubertal timing on height velocity or adult stature [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link&amp;anchor=H8#H8\">",
"       \"Comorbidities and complications of obesity in children and adolescents\", section on 'Growth and puberty'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      In boys, those who mature relatively early but within the normal range have a modest reduction in adult height, which is attributable to shorter leg length; sitting height is not reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/20\">",
"       20",
"      </a>",
"      ]. In the same study, underweight in boys during childhood was associated with longer leg length and no change in adult height. It is probably not appropriate to extrapolate these results to girls, because obesity is sometimes associated with earlier onset of puberty in girls, and obesity may have the opposite effect in boys.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Weight changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight changes occur in the context of issues regarding gender, stage of pubertal maturation, and timing of pubertal maturation. Standards have been constructed for weight curves, similar to those by Tanner and Davies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/21\">",
"     21",
"    </a>",
"    ]. Weight changes, particularly during pubertal maturation, reflect gender-specific alterations in body composition, especially in lean body mass and the proportion of body fat.",
"   </p>",
"   <p>",
"    In early puberty, change in body fat (as measured by skinfold thickness) decreases especially in boys, but there is an increase in body fat after peak height velocity, especially in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/22\">",
"     22",
"    </a>",
"    ]. Adolescent girls have a greater proportion of body fat, with adipose tissue distributed along the upper arms, thighs, and upper back. These differences between the genders increase throughout puberty. In adolescents younger than 16 years of age, the annual increase in body mass index (BMI) is driven primarily by changes in fat-free mass. However, after 16 years of age, the increase in BMI in girls is largely because of increases in fat mass [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity tracks from adolescence to adulthood, and earlier onset of obesity is associated with increased cardiovascular morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Body mass index, a measure of ponderosity, allows the clinician to evaluate obesity. Published tables permit comparison of adolescents across age and ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physiology of pubertal maturation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some variability occurs in a given individual's timing, sequence, or tempo of pubertal maturation. However, most adolescents follow a predictable path through pubertal maturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Girls",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest secondary sexual characteristic in most girls is",
"    <span class=\"nowrap\">",
"     breast/areolar",
"    </span>",
"    development (thelarche) (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 2A",
"    </a>",
"    ), although a substantial minority have pubic hair as the initial manifestation (pubarche) (",
"    <a class=\"graphic graphic_picture graphicRef79782 \" href=\"UTD.htm?29/33/30227\">",
"     picture 2B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/28\">",
"     28",
"    </a>",
"    ]. Menarche occurs, on average, 2.6 years after the onset of puberty (",
"    <a class=\"graphic graphic_figure graphicRef52047 \" href=\"UTD.htm?28/38/29283\">",
"     figure 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/4,11,17\">",
"     4,11,17",
"    </a>",
"    ]. The specific initial manifestation may affect body morphology and composition both at the onset of puberty and throughout pubertal maturation into early adulthood. Girls with breast development as the initial manifestation of puberty, for example, have both an earlier age of menarche and greater body mass index throughout puberty and as adults [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/29\">",
"     29",
"    </a>",
"    ]. Maternal preeclampsia increased threefold the likelihood of pubarche as the initial manifestation of puberty; the likelihood was directly related to the severity of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age at onset of puberty and the age of menarche are influenced by several factors. Genetics accounts for the majority of the variability; other factors include overall health, social environment (such as family stress or the presence of an adult nonbiologically-related male), and possibly environmental exposures, such as endocrine disruptors (environmental contaminants that may affect endocrine processes) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/32\">",
"     32",
"    </a>",
"    ]. Studies have suggested an interaction between genetics and the environment. As an example, age of menarche decreased to a greater extent in black girls as compared to white girls from the 1970s to the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/33\">",
"     33",
"    </a>",
"    ]. The influence of environmental factors, including endocrine disruptors, on timing of pubertal maturation is a subject of active research [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Earlier onset of puberty'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Boys",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest stage of male maturation, which has a mean duration of six months, is an increase in testicular volume (",
"    <a class=\"graphic graphic_figure graphicRef60225 \" href=\"UTD.htm?43/46/44781\">",
"     figure 3",
"    </a>",
"    ). Almost all boys have an increase in testicular volume (&ge;3 mL) prior to the appearance of penile growth and pubic hair (",
"    <a class=\"graphic graphic_picture graphicRef80005 \" href=\"UTD.htm?32/26/33187\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/28,35\">",
"     28,35",
"    </a>",
"    ]. Thus, if one considers only pubic hair in the assessment of early male puberty, misclassification and unnecessary testing may result. The appearance of sperm in the urine and the onset of nocturnal sperm emissions occur shortly after the attainment of peak height velocity; many consider these events the male equivalent of menarche (",
"    <a class=\"graphic graphic_figure graphicRef72046 \" href=\"UTD.htm?43/1/44048\">",
"     figure 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Testicular volume is typically measured using the Prader orchidometer, a series of three-dimensional ellipsoids with a volume from 1 to 25 mL or more. Penile length is measured from the pubic ramus to the tip of the glans while compressing the suprapubic fat pad and applying gentle traction. Mean stretched penile stretch length (measured from the pubis symphysis to the tip of the non-erect penis excluding foreskin) is approximately 3.75 cm (&plusmn; 0.54 cm) at 1 year and gradually increases to 4.84 cm by late childhood, then increases sharply to about 9.5 cm (&plusmn; 1.12 cm) by late puberty (according to measurements from a predominantly white population) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/36\">",
"     36",
"    </a>",
"    ]. This measurement is rarely used for monitoring of pubertal progress.",
"   </p>",
"   <p>",
"    Clinical problems may arise when considering whether a given testicular volume is appropriate for a pubic hair stage (eg, when one is concerned about endogenous or exogenous androgens). The following figure allows the clinician to evaluate the relationship between testicular volume and pubic hair (",
"    <a class=\"graphic graphic_figure graphicRef60225 \" href=\"UTD.htm?43/46/44781\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Body fat, leptin, and onset of puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of puberty is controlled by many factors that remain incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/37\">",
"     37",
"    </a>",
"    ]. The overall earlier onset of puberty among the general population has been attributed to the increasing prevalence of obesity. It has been proposed that a critical body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/38\">",
"     38",
"    </a>",
"    ] or body composition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/39\">",
"     39",
"    </a>",
"    ] is the most salient issue in the development and maintenance of pubertal events [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. However, body weight alone probably is not a sufficient explanation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Earlier onset of puberty'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Leptin has been proposed as the hormone responsible for the initiation and progression of puberty. Leptin is produced largely in adipocytes; large fat cells produce more leptin than do small ones, and serum leptin concentrations are highly correlated with body fat content. The potential importance of leptin is illustrated by the observation that mice deficient in leptin fail to undergo pubertal development, whereas the administration of leptin to such animals results in pubertal onset [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/41\">",
"     41",
"    </a>",
"    ]. Furthermore, higher serum leptin concentrations in girls are associated with increased body fat and an earlier onset of puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/42\">",
"     42",
"    </a>",
"    ]. In this study, a 1",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    increase in serum leptin lowered the age at menarche by one month, and a gain in body fat of 1 kg lowered the timing of menarche by 13 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Leptin appears to be one of several factors that influence the maturation of the gonadotropin-releasing hormone (GnRH) pulse generator, probably as a signal of the availability of metabolic fuel [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/43\">",
"     43",
"    </a>",
"    ]. Serum leptin concentrations increase immediately before puberty in both genders but differ after the initiation of puberty.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In males, serum leptin falls after the onset of puberty, returning to baseline 30 to 40 months later [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In females, leptin values rise throughout puberty and may be influenced by many factors. In one study, leptin values in pubertal girls were correlated with the sum of skinfolds (abdominal subcutaneous more than abdominal visceral more than peripheral subcutaneous fat), as well as serum free testosterone and free estrogen; these three factors accounted for 74 percent of the variance in leptin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Genetic contributors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common genetic variants have been identified that appear to be associated with variation in age at menarche.",
"   </p>",
"   <p>",
"    In a meta-analysis of 32 genome-wide association studies that included more than 85,000 women, 32 common variants or single nucleotide polymorphisms (SNPs) associated with age at menarche were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the genes in the 6q21 region, LIN28B, has emerged as an important candidate for mediating variation in age at menarche. Genetic variation in this region was also associated with age at menarche in several different human populations and was analyzed in a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. A study employing direct genotyping of LIN28B confirmed that variations in a particular region of this gene were associated with earlier puberty in both boys and girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/49\">",
"     49",
"    </a>",
"    ]. LIN28B is a regulator of microRNA processing involved in developmental timing in C. elegans; a common variant in this gene was previously associated with reduced adult height.",
"   </p>",
"   <p>",
"    A few other genetic variants associated with adult height also were associated with age at menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. These observations suggest a genetic basis for previously observed associations between age at menarche and height; in some cases, this association might be mediated by earlier epiphyseal closure caused by earlier exposure to estrogens. Similarly, several genes that are associated with childhood obesity, including FTO (fat mass and obesity associated gene), SEC16B, TRA2B, TMEM18, and NEGR1 (neuronal growth regulator 1), were also associated with earlier age at menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of obesity\", section on 'Common obesity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the studies cited above also identified genetic variants associated with age at natural menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=see_link&amp;anchor=H179689173#H179689173\">",
"     \"Ovarian development and failure (menopause) in normal women\", section on 'Genetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The GPR54 gene on chromosome 19p13.3, which encodes a G-protein coupled receptor, appears to have an important role in the initiation of puberty via its effect on hypothalamic GnRH [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/51\">",
"     51",
"    </a>",
"    ]. Its ligand, kisspeptin, appears to modulate the negative feedback on GnRH secretion exerted by sex steroids. Loss-of-function mutations in GPR54 cause autosomal recessive idiopathic hypogonadotropic hypogonadism in humans and in a GPR54 knockout mouse model. Conversely, gain-of-function mutations in the GPR54 gene are associated with a form of central precocious puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/52\">",
"     52",
"    </a>",
"    ]. Thus, the GPR54-kisspeptin complex, appears to be an important gatekeeper for the onset of puberty and normal reproductive function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=see_link\">",
"     \"Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Earlier onset of puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secular changes regarding onset of puberty and menarche are illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study from the United States utilizing data from the National Health and Nutrition Examination Survey 1988 to 1994 (NHANES) III and NHANES 1999 to 2002 reported a decline of 2.3 months in the average age of menarche between the two surveys (12.53 to 12.34 years, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/53\">",
"       53",
"      </a>",
"      ]. In addition, there was an overall decline of 4.9 months since the 1960s through the 1999 to 2002 NHANES survey [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. Within three ethnic groups, the average age of menarche also decreased between the two study periods; however, the change for each group was smaller than the entire cohort. In non-Hispanic white girls, the age of menarche decreased from 12.57 to 12.52 years, non-Hispanic blacks 12.09 to 12.06 years, and for Mexican Americans 12.23 to 12.09. Changes in the population distribution of",
"      <span class=\"nowrap\">",
"       race/ethnicity",
"      </span>",
"      and anthropometric changes in body weight and height may, in part, explain the larger change seen in the overall group compared with changes within each ethnic group.",
"     </li>",
"     <li>",
"      A 1997 study from the Pediatric Research in Office Settings Network defined the timing of pubertal development in more than 17,000 healthy young girls in the United States and Puerto Rico [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/55\">",
"       55",
"      </a>",
"      ]. The earliest signs of puberty were at ages considerably younger than had been reported previously, and striking racial differences in timing were found. The mean ages for the onset of breast development and pubic hair growth were 8.9 and 8.8 years, respectively, in African-American girls, and 10.0 and 10.5 years, respectively, in white girls (",
"      <a class=\"graphic graphic_figure graphicRef72226 \" href=\"UTD.htm?19/24/19855\">",
"       figure 4",
"      </a>",
"      ). No Hispanic or Asian girls were studied.",
"     </li>",
"     <li>",
"      A 2001 study from the United States compared maturational timing between",
"      <span class=\"nowrap\">",
"       race/ethnic",
"      </span>",
"      groups [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/56\">",
"       56",
"      </a>",
"      ]. This study found that the rates of early maturation (menarche &le;11 years) varied substantially among groups (White 7.8 percent, Black 12.3 percent, Hispanic 13.6 percent, and Asian 5.2 percent). The frequency of late maturing (menarche &ge;14 years) ranged from 15.2 percent among White girls to 27 percent among Asian girls. This relationship appears to be primarily mediated by differences in rates of overweight; within each",
"      <span class=\"nowrap\">",
"       race/ethnic",
"      </span>",
"      group, early maturing girls were approximately twice as likely to be overweight as compared to those maturing at an average age. The data in this study did not establish whether the relationship between age of menarche and obesity varies among racial and ethnic groups. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When menarche occurs before the individual reaches the age of 12 years, it is associated with increases in weight and body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/40,57,58\">",
"     40,57,58",
"    </a>",
"    ]. In addition, girls who mature early are at an increased risk for obesity when compared with late maturers [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pubertal onset in boys also appears to be occurring earlier in the United States. In a study including more than 4000 healthy boys, the mean age for entering puberty (SMR for genital development stage 2) was 10.14 years for white boys, 10.04 years for Hispanic boys, and 9.14 years for African American boys [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/59\">",
"     59",
"    </a>",
"    ]. These thresholds are 1.5 to 2 years earlier than historical norms. Similar trends have been reported from several European and Scandinavian countries and China [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. The relationship between pubertal onset and obesity in boys is not clear. Some studies suggest that being overweight or obese is associated with later onset of puberty in boys, in contrast to findings in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/35,65-67\">",
"     35,65-67",
"    </a>",
"    ]. Conversely, other studies report that increased BMI and fat mass is associated with earlier puberty in boys, similar to findings in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/59,60,68,69\">",
"     59,60,68,69",
"    </a>",
"    ]. However, several studies are inconclusive or demonstrate no relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/40,70\">",
"     40,70",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The earlier onset of puberty has had important implications for the diagnosis of precocious puberty. It has been suggested that, at least in the United States, evaluation for precocious puberty be performed if breast or pubic hair development occurs before age seven in white girls and before age six in African-American girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/6\">",
"     6",
"    </a>",
"    ], and if signs of secondary sexual development occur before age nine in boys. However, following these recommendations for girls may lead to under-diagnosis of endocrine disorders; the appropriate threshold for evaluation remains controversial and probably varies among populations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PERILS OF PUBERTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some aspects of pubertal maturation may be normal but may be viewed by the patient, family, or provider as abnormal. These \"perils of puberty\" include anemia, gynecomastia, acne, psychological correlates of puberty, certain types of sports-related injuries, myopia, scoliosis, and dysfunctional uterine bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia and iron deficiency are common among adolescent girls as compared to adolescent boys or to school-aged children. The Third National Health and Nutrition Examination Survey (NHANES III) found a 9 percent incidence of iron deficiency and a 2 percent incidence of anemia among American girls between the ages of 12 and 15 years; the respective values were less than 2 percent for boys in this age group (",
"    <a class=\"graphic graphic_table graphicRef66255 \" href=\"UTD.htm?13/28/13772\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/72\">",
"     72",
"    </a>",
"    ]. This is because hemoglobin and serum ferritin concentrations change as a function of gender and pubertal stage. They both increase with advancing pubertal stage in males, but not in females [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Although girls tend to eat less high iron-containing foods (such as meat), no association has been found between total iron intake and serum ferritin. However, low intake of heme iron increased the risk of low iron stores in girls but not in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/74\">",
"     74",
"    </a>",
"    ]. The gender differences were thought to result from biological differences (perhaps androgens), in addition to menstrual bleeding and insufficient iron intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gynecomastia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pubertal gynecomastia (in contrast to neonatal or senescence gynecomastia) occurs in approximately one-half of teen-age boys at an average age of 13 years, and it persists for 6 to 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/75\">",
"     75",
"    </a>",
"    ]. Boys with persistent gynecomastia (ie, lasting two years or more) have a diameter of palpable tissue &ge;2 cm during the first year (odds ratio 8.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/76\">",
"     76",
"    </a>",
"    ]. Although the underlying diagnosis usually is \"idiopathic pubertal gynecomastia,\" a variety of other etiologies including drugs, hypogonadism, testicular tumors, and hyperthyroidism, must be considered. The underlying mechanisms presumably reflect an imbalance in the effective estrogenic-to-androgenic stimulation, through an increase in the production or action of estrogens or estrogen-like agents, a decrease in the production or action of androgens, or enhanced breast tissue sensitivity to these hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/76\">",
"     76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne, a disorder of the pilosebaceous unit, is characterized by follicular occlusion and inflammation caused by androgenic stimulation. If the opening of the comedone is widely dilated, oxidation of keratinous material leads to the development of a blackhead without inflammatory acne. With a small opening, a closed comedo (whitehead) forms and may lead to inflammatory acne if the comedo ruptures into the dermis. With maturation in both boys and girls, the number of acne lesions increases, with a greater number of comedones than inflammatory lesions at all stages [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/77\">",
"     77",
"    </a>",
"    ]. In girls, the severity of acne in later puberty is associated with higher serum levels of dehydroepiandrosterone sulfate and a greater number of acne lesions in early puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/78\">",
"     78",
"    </a>",
"    ]. Despite its high prevalence during puberty, moderate or severe acne in early puberty, usually with other signs of androgen excess, should alert the clinician to the possibility of an endocrinologic disorder, such as non-classical congenital adrenal hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Psychological changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pubertal maturation has an impact on psychological and social issues [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/79\">",
"     79",
"    </a>",
"    ]. Puberty does not affect cognitive development [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/80\">",
"     80",
"    </a>",
"    ], although the timing of pubertal maturation may affect psychosocial functioning.",
"   </p>",
"   <p>",
"    Prior to adolescence, no gender differences in depression occur; during adolescence, however, the prevalence of depression is twice as great in girls compared with boys [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/81\">",
"     81",
"    </a>",
"    ]. As puberty progresses, boys develop a more positive self-image and mood, but girls experience a diminished perceived physical appearance that is more pronounced in Caucasian as compared with African-American girls. Caucasian girls also exhibit diminished self-worth as they pass from early to mid-adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pubertal development may have an especially negative impact when a lack of synchrony between the timing of pubertal development and chronologic age exists. For example, the early-maturing girl may experience a greater decrease in self-esteem and body satisfaction when compared with on-time or late-maturing girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/83\">",
"     83",
"    </a>",
"    ]. In a large cross-sectional study, girls who were early maturing and boys who were late maturing were more likely to have psychopathology. Girls who matured early were more likely to have a lifetime history of disruptive behavior (attention-deficit, hyperactivity, oppositional, or conduct disorders) and suicide attempts, whereas boys who were late maturing were more likely to have internalizing behaviors and emotional reliance on others [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/84\">",
"     84",
"    </a>",
"    ]. Girls with early maturation are more likely to have older friends [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/85\">",
"     85",
"    </a>",
"    ] and to be more vulnerable to peer pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Musculoskeletal injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pubertal status may help predict the specific type of musculoskeletal injuries that adolescents may encounter during participation in sports [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/87\">",
"     87",
"    </a>",
"    ]. The greatest risk of damage to epiphyseal growth plates occurs during periods of peak height velocity, which also is the time of greatest change in bone mineral content [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/16\">",
"     16",
"    </a>",
"    ]. The asynchronous growth of body parts may result in a limited range of motion of some joints; when combined with the increase in muscle mass that occurs shortly after peak height velocity, the limited range of motion may lead to sprains or strains. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Peak height velocity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A common overuse injury in teens is Osgood-Schlatter disease, which is an inflammation of the tibial tubercle apophysis. Not surprisingly, the age of peak incidence of distal radius fractures matches the age of peak height velocity in both boys and girls [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Gynecologic consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several gynecologic consequences are associated with maturation of the hypothalamic-pituitary-ovarian axis. Rapid maturation of the reproductive axis apparently occurs once the pubertal girl attains menarche, with 65 percent reporting 10 or more periods per year one year after menarche [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/89\">",
"     89",
"    </a>",
"    ]. Progression to ovulatory cycles is longer with a later age of menarche; when menarche occurs after the age of 13, only one-half will ovulate regularly within 4.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dysfunctional uterine bleeding (DUB) refers to excessive, prolonged,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irregular endometrial bleeding. In adolescents, anovulation accounts for approximately 80 percent of cases of DUB. Unopposed estrogen stimulates the endometrium, leading to a sustained proliferative phase rather than maturation to a secretory endometrium. Estrogen levels ultimately cannot sustain the hyperplastic endometrial lining, leading to irregular, sometimes heavy, bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H3#H3\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Abnormal uterine bleeding (AUB) in adolescents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=see_link\">",
"     \"Management of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Myopia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest incidence of myopia occurs during puberty and is caused by growth in the axial diameter of the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Scoliosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated progression of the degree of scoliosis occurs during puberty because of growth in the axial skeleton. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33770?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sexually transmitted disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexually active adolescents represent the highest-risk age group for nearly all sexually transmitted diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/92\">",
"     92",
"    </a>",
"    ]. Both behavioral and biological factors are important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=see_link&amp;anchor=H7#H7\">",
"     \"Adolescent sexuality\", section on 'Adolescent development'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H2#H2\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Behavioral issues that increase risk for sexually transmitted diseases include younger age at onset of intercourse, the number of lifetime partners, and the perceived prevalence of sexually transmitted infections [",
"      <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Biological factors include age of menarche (which influences behavioral factors) and gynecologic maturation. In the first year or two after menarche, a persistence of both columnar epithelial cells on the exocervix (cervical ectopy) and the transformation zone of columnar to squamous epithelial cells on the exocervix occur. These factors may enhance infection with Chlamydia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/94\">",
"     94",
"    </a>",
"    ] and genital human papillomavirus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/25/1434/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=see_link\">",
"       \"Patient information: Normal sexual development (puberty) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=see_link\">",
"       \"Patient information: Early puberty (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=see_link\">",
"       \"Patient information: Late puberty (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22627003\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pubertal maturation consists of a series of predictable events including development of secondary sexual characteristics, skeletal growth, and changes in body composition. These can be described in terms of sequence, timing, and tempo.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual maturity ratings (Tanner stages) for pubic hair, breast, and genitalia consists of five categories, with stage one representing prepuberty and stage five representing adult development (",
"      <a class=\"graphic graphic_table graphicRef55329 \" href=\"UTD.htm?8/1/8220\">",
"       table 1",
"      </a>",
"      ). These stages are illustrated by the figure in boys (",
"      <a class=\"graphic graphic_picture graphicRef80005 \" href=\"UTD.htm?32/26/33187\">",
"       picture 1",
"      </a>",
"      ) and in girls (",
"      <a class=\"graphic graphic_picture graphicRef72038 graphicRef79782 \" href=\"UTD.htm?39/9/40088\">",
"       picture 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sexual maturity rating (Tanner stages)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The timing of the growth spurt (peak height velocity) occurs approximately two years earlier during puberty in girls than in boys (",
"      <a class=\"graphic graphic_figure graphicRef52047 graphicRef72046 \" href=\"UTD.htm?26/57/27543\">",
"       figure 1A-B",
"      </a>",
"      ). In girls, peak height velocity occurs about 0.5 years prior to menarche. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Peak height velocity'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The earliest secondary sexual characteristic in most girls is",
"      <span class=\"nowrap\">",
"       breast/areolar",
"      </span>",
"      development (thelarche) (",
"      <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"       picture 2A",
"      </a>",
"      ), although a substantial minority have pubic hair as the initial manifestation (",
"      <a class=\"graphic graphic_picture graphicRef79782 \" href=\"UTD.htm?29/33/30227\">",
"       picture 2B",
"      </a>",
"      ). Menarche occurs, on average, 2.6 years after the onset of puberty (",
"      <a class=\"graphic graphic_figure graphicRef52047 \" href=\"UTD.htm?28/38/29283\">",
"       figure 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Girls'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The earliest stage of male maturation is an increase in testicular volume, followed by penile growth and the appearance of pubic hair (",
"      <a class=\"graphic graphic_picture graphicRef80005 \" href=\"UTD.htm?32/26/33187\">",
"       picture 1",
"      </a>",
"      ). The appearance of sperm in the urine and the onset of nocturnal sperm emissions occur shortly after the attainment of peak height velocity; many consider these events the male equivalent of menarche (",
"      <a class=\"graphic graphic_figure graphicRef72046 \" href=\"UTD.htm?43/1/44048\">",
"       figure 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Boys'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The age at onset of puberty and the age of menarche are influenced by several factors. Genetics accounts for the majority of the variability; other factors include overall health, body weight, and possibly environmental exposures, such as endocrine disruptors. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Body fat, leptin, and onset of puberty'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Genetic contributors'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      In the United States and other developed countries, the average age of onset of puberty has declined during the past four decades. Between 5 and 12 percent of girls have menarche younger than 11 years of age; this rate varies by",
"      <span class=\"nowrap\">",
"       race/ethnic",
"      </span>",
"      group and weight status. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Earlier onset of puberty'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Typical thresholds for evaluation are signs of pubertal development before age eight years in girls and nine years in boys. Given the increasing frequency of earlier pubertal onset, some authorities suggest that these thresholds are too high. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Earlier onset of puberty'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Puberty is associated with a variety of physiologic changes which may come to medical attention, including acne and scoliosis, gynecomastia in boys, and anemia and dysfunctional uterine bleeding in girls. Psychological and emotional changes are common, with increased rates of depression and risk-taking behaviors. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Perils of puberty'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/1\">",
"      Dahl RE. Adolescent brain development: a period of vulnerabilities and opportunities. Keynote address. Ann N Y Acad Sci 2004; 1021:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/2\">",
"      Giedd JN. Structural magnetic resonance imaging of the adolescent brain. Ann N Y Acad Sci 2004; 1021:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/3\">",
"      Laron Z. Age at first ejaculation (spermarche)--the overlooked milestone in male development. Pediatr Endocrinol Rev 2010; 7:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/4\">",
"      Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/5\">",
"      Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970; 45:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/6\">",
"      Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics 1999; 104:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/7\">",
"      Biro FM, McMahon RP, Striegel-Moore R, et al. Impact of timing of pubertal maturation on growth in black and white female adolescents: The National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr 2001; 138:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/8\">",
"      Garn SM, LaVelle M, Rosenberg KR, Hawthorne VM. Maturational timing as a factor in female fatness and obesity. Am J Clin Nutr 1986; 43:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/9\">",
"      Abbassi V. Growth and normal puberty. Pediatrics 1998; 102:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/10\">",
"      Bass S, Delmas PD, Pearce G, et al. The differing tempo of growth in bone size, mass, and density in girls is region-specific. J Clin Invest 1999; 104:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/11\">",
"      Biro FM, Huang B, Crawford PB, et al. Pubertal correlates in black and white girls. J Pediatr 2006; 148:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/12\">",
"      Berkey CS, Dockery DW, Wang X, et al. Longitudinal height velocity standards for U.S. adolescents. Stat Med 1993; 12:403.",
"     </a>",
"    </li>",
"    <li>",
"     Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Advance data from vital and health statistics; no. 314. National Center for Health Statistics, Hyattsville, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/14\">",
"      Magarey AM, Boulton TJ, Chatterton BE, et al. Bone growth from 11 to 17 years: relationship to growth, gender and changes with pubertal status including timing of menarche. Acta Paediatr 1999; 88:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/15\">",
"      Lloyd T, Rollings N, Andon MB, et al. Determinants of bone density in young women. I. Relationships among pubertal development, total body bone mass, and total body bone density in premenarchal females. J Clin Endocrinol Metab 1992; 75:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/16\">",
"      McKay HA, Bailey DA, Mirwald RL, et al. Peak bone mineral accrual and age at menarche in adolescent girls: a 6-year longitudinal study. J Pediatr 1998; 133:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/17\">",
"      Taranger J, Engstr&ouml;m I, Lichtenstein H, Svennberg- Redegren I. VI. Somatic pubertal development. Acta Paediatr Scand Suppl 1976; :121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/18\">",
"      Gilsanz V, Roe TF, Mora S, et al. Changes in vertebral bone density in black girls and white girls during childhood and puberty. N Engl J Med 1991; 325:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/19\">",
"      Huang B, Biro FM, Dorn LD. Determination of relative timing of pubertal maturation through ordinal logistic modeling: evaluation of growth and timing parameters. J Adolesc Health 2009; 45:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/20\">",
"      Lorentzon M, Norjavaara E, Kindblom JM. Pubertal timing predicts leg length and childhood body mass index predicts sitting height in young adult men. J Pediatr 2011; 158:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/21\">",
"      Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/22\">",
"      Gasser T, Ziegler P, Kneip A, et al. The dynamics of growth of weight, circumferences and skinfolds in distance, velocity and acceleration. Ann Hum Biol 1993; 20:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/23\">",
"      Maynard LM, Wisemandle W, Roche AF, et al. Childhood body composition in relation to body mass index. Pediatrics 2001; 107:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/24\">",
"      Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med 2011; 364:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/25\">",
"      Whitaker RC, Wright JA, Pepe MS, et al. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997; 337:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/26\">",
"      Baker JL, Olsen LW, S&oslash;rensen TI. [Childhood body mass index and the risk of coronary heart disease in adulthood]. Ugeskr Laeger 2008; 170:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/27\">",
"      Rosner B, Prineas R, Loggie J, Daniels SR. Percentiles for body mass index in U.S. children 5 to 17 years of age. J Pediatr 1998; 132:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/28\">",
"      Susman EJ, Houts RM, Steinberg L, et al. Longitudinal development of secondary sexual characteristics in girls and boys between ages 91/2 and 151/2 years. Arch Pediatr Adolesc Med 2010; 164:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/29\">",
"      Biro FM, Lucky AW, Simbartl LA, et al. Pubertal maturation in girls and the relationship to anthropometric changes: pathways through puberty. J Pediatr 2003; 142:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/30\">",
"      Ogland B, Nilsen ST, Forman MR, Vatten LJ. Pubertal development in daughters of women with pre-eclampsia. Arch Dis Child 2011; 96:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/31\">",
"      Ib&aacute;&ntilde;ez L, de Zegher F. Puberty after prenatal growth restraint. Horm Res 2006; 65 Suppl 3:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/32\">",
"      Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/33\">",
"      Freedman DS, Khan LK, Serdula MK, et al. Relation of age at menarche to race, time period, and anthropometric dimensions: the Bogalusa Heart Study. Pediatrics 2002; 110:e43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/34\">",
"      Buck Louis GM, Gray LE Jr, Marcus M, et al. Environmental factors and puberty timing: expert panel research needs. Pediatrics 2008; 121 Suppl 3:S192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/35\">",
"      Biro FM, Lucky AW, Huster GA, Morrison JA. Pubertal staging in boys. J Pediatr 1995; 127:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/36\">",
"      Tomova A, Deepinder F, Robeva R, et al. Growth and development of male external genitalia: a cross-sectional study of 6200 males aged 0 to 19 years. Arch Pediatr Adolesc Med 2010; 164:1152.",
"     </a>",
"    </li>",
"    <li>",
"     Grumbach MM, Sizonenko PC, Aubert ML. Control of the onset of puberty, Williams &amp; Wilkins, Baltimore 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/38\">",
"      Frisch R, Revelle R. Variation in body weights and the age of the adolescent growth spurt among Latin American and Asian populations, in relation to calorie supplies. Hum Biol 1969; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/39\">",
"      Frisch RE, Revelle R, Cook S. Components of weight at menarche and the initiation of the adolescent growth spurt in girls: estimated total water, llean body weight and fat. Hum Biol 1973; 45:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/40\">",
"      Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 2009; 123:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/41\">",
"      Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature 1996; 382:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/42\">",
"      Matkovic V, Ilich JZ, Skugor M, et al. Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 1997; 82:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/43\">",
"      Roemmich JN, Rogol AD. Role of leptin during childhood growth and development. Endocrinol Metab Clin North Am 1999; 28:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/44\">",
"      Mantzoros CS, Flier JS, Rogol AD. A longitudinal assessment of hormonal and physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of puberty. J Clin Endocrinol Metab 1997; 82:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/45\">",
"      Roemmich JN, Clark PA, Berr SS, et al. Gender differences in leptin levels during puberty are related to the subcutaneous fat depot and sex steroids. Am J Physiol 1998; 275:E543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/46\">",
"      Elks CE, Perry JR, Sulem P, et al. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet 2010; 42:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/47\">",
"      Sulem P, Gudbjartsson DF, Rafnar T, et al. Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet 2009; 41:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/48\">",
"      Perry JR, Stolk L, Franceschini N, et al. Meta-analysis of genome-wide association data identifies two loci influencing age at menarche. Nat Genet 2009; 41:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/49\">",
"      Ong KK, Elks CE, Li S, et al. Genetic variation in LIN28B is associated with the timing of puberty. Nat Genet 2009; 41:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/50\">",
"      He C, Kraft P, Chen C, et al. Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet 2009; 41:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/51\">",
"      Seminara SB, Crowley WF Jr. Kisspeptin and GPR54: discovery of a novel pathway in reproduction. J Neuroendocrinol 2008; 20:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/52\">",
"      Teles MG, Bianco SD, Brito VN, et al. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med 2008; 358:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/53\">",
"      Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr 2005; 147:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/54\">",
"      Anderson SE, Dallal GE, Must A. Relative weight and race influence average age at menarche: results from two nationally representative surveys of US girls studied 25 years apart. Pediatrics 2003; 111:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/55\">",
"      Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics 1997; 99:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/56\">",
"      Adair LS, Gordon-Larsen P. Maturational timing and overweight prevalence in US adolescent girls. Am J Public Health 2001; 91:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/57\">",
"      Wellens R, Malina R, Roche A , et al. Body size and fatness in young adults in relation to age at menarche. Am J Hum Biol 1992; 4:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/58\">",
"      Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics 2001; 108:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/59\">",
"      Herman-Giddens ME, Steffes J, Harris D, et al. Secondary sexual characteristics in boys: data from the Pediatric Research in Office Settings Network. Pediatrics 2012; 130:e1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/60\">",
"      S&oslash;rensen K, Aksglaede L, Petersen JH, Juul A. Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. J Clin Endocrinol Metab 2010; 95:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/61\">",
"      Liu YX, Wikland KA, Karlberg J. New reference for the age at childhood onset of growth and secular trend in the timing of puberty in Swedish. Acta Paediatr 2000; 89:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/62\">",
"      Ma HM, Chen SK, Chen RM, et al. Pubertal development timing in urban Chinese boys. Int J Androl 2011; 34:e435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/63\">",
"      Goldstein JR. A secular trend toward earlier male sexual maturity: evidence from shifting ages of male young adult mortality. PLoS One 2011; 6:e14826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/64\">",
"      Monteilh C, Kieszak S, Flanders WD, et al. Timing of maturation and predictors of Tanner stage transitions in boys enrolled in a contemporary British cohort. Paediatr Perinat Epidemiol 2011; 25:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/65\">",
"      Lee JM, Kaciroti N, Appugliese D, et al. Body mass index and timing of pubertal initiation in boys. Arch Pediatr Adolesc Med 2010; 164:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/66\">",
"      Wang Y. Is obesity associated with early sexual maturation? A comparison of the association in American boys versus girls. Pediatrics 2002; 110:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/67\">",
"      Kleber M, Schwarz A, Reinehr T. Obesity in children and adolescents: relationship to growth, pubarche, menarche, and voice break. J Pediatr Endocrinol Metab 2011; 24:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/68\">",
"      Sandhu J, Ben-Shlomo Y, Cole TJ, et al. The impact of childhood body mass index on timing of puberty, adult stature and obesity: a follow-up study based on adolescent anthropometry recorded at Christ's Hospital (1936-1964). Int J Obes (Lond) 2006; 30:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/69\">",
"      Boyne MS, Thame M, Osmond C, et al. Growth, body composition, and the onset of puberty: longitudinal observations in Afro-Caribbean children. J Clin Endocrinol Metab 2010; 95:3194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/70\">",
"      Karpati AM, Rubin CH, Kieszak SM, et al. Stature and pubertal stage assessment in American boys: the 1988-1994 Third National Health and Nutrition Examination Survey. J Adolesc Health 2002; 30:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/71\">",
"      Midyett LK, Moore WV, Jacobson JD. Are pubertal changes in girls before age 8 benign? Pediatrics 2003; 111:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/72\">",
"      Looker AC, Dallman PR, Carroll MD, et al. Prevalence of iron deficiency in the United States. JAMA 1997; 277:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/73\">",
"      Daniel WA Jr. Hematocrit: maturity relationship in adolescence. Pediatrics 1973; 52:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/74\">",
"      Bergstr&ouml;m E, Hernell O, L&ouml;nnerdal B, Persson LA. Sex differences in iron stores of adolescents: what is normal? J Pediatr Gastroenterol Nutr 1995; 20:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/75\">",
"      Biro F, Lucky A, Huster G, et al. Difficulties in differentiating transient from persistent gynecomastia in adolescents. Pediatr Res 1990; 27:3A.",
"     </a>",
"    </li>",
"    <li>",
"     Biro F. Gynecomastia. In: Ambulatory Pediatric Care, Dershewitz R (Ed), Lippincott-Raven, Philadelphia 1999. p.516.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/77\">",
"      Lucky AW, Biro FM, Huster GA, et al. Acne vulgaris in early adolescent boys. Correlations with pubertal maturation and age. Arch Dermatol 1991; 127:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/78\">",
"      Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr 1997; 130:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/79\">",
"      Joinson C, Heron J, Lewis G, et al. Timing of menarche and depressive symptoms in adolescent girls from a UK cohort. Br J Psychiatry 2011; 198:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/80\">",
"      Orr DP, Brack CJ, Ingersoll G. Pubertal maturation and cognitive maturity in adolescents. J Adolesc Health Care 1988; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/81\">",
"      Angold A, Worthman CW. Puberty onset of gender differences in rates of depression: a developmental, epidemiologic and neuroendocrine perspective. J Affect Disord 1993; 29:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/82\">",
"      Brown KM, McMahon RP, Biro FM, et al. Changes in self-esteem in black and white girls between the ages of 9 and 14 years. The NHLBI Growth and Health Study. J Adolesc Health 1998; 23:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/83\">",
"      Striegel-Moore RH, McMahon RP, Biro FM, et al. Exploring the relationship between timing of menarche and eating disorder symptoms in Black and White adolescent girls. Int J Eat Disord 2001; 30:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/84\">",
"      Graber JA, Lewinsohn PM, Seeley JR, Brooks-Gunn J. Is psychopathology associated with the timing of pubertal development? J Am Acad Child Adolesc Psychiatry 1997; 36:1768.",
"     </a>",
"    </li>",
"    <li>",
"     Magnusson D, Stattin H, Allen V. Differential maturation among girls and its relation to social adjustment: A longitudinal perspective. In: Life-Span Development and Behavior, Featerman D, Lerner R (Eds), Academic Press, New York 1986. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/86\">",
"      Ge X, Conger RD, Elder GH Jr. Coming of age too early: pubertal influences on girls' vulnerability to psychological distress. Child Dev 1996; 67:3386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/87\">",
"      Backous DD, Farrow JA, Friedl KE. Assessment of pubertal maturity in boys, using height and grip strength. J Adolesc Health Care 1990; 11:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/88\">",
"      Bailey DA, Wedge JH, McCulloch RG, et al. Epidemiology of fractures of the distal end of the radius in children as associated with growth. J Bone Joint Surg Am 1989; 71:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/89\">",
"      Legro RS, Lin HM, Demers LM, Lloyd T. Rapid maturation of the reproductive axis during perimenarche independent of body composition. J Clin Endocrinol Metab 2000; 85:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/90\">",
"      Apter D, Vihko R. Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab 1983; 57:82.",
"     </a>",
"    </li>",
"    <li>",
"     Tanner J. Growth at Adolescence, Blackwell Scientific Publications, Oxford 1962.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/92\">",
"      Gevelber MA, Biro FM. Adolescents and sexually transmitted diseases. Pediatr Clin North Am 1999; 46:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/93\">",
"      Rosenthal SL, Biro FM, Succop PA, et al. Impact of demographics, sexual history, and psychological functioning on the acquisition of STDS in adolescents. Adolescence 1997; 32:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/94\">",
"      Harrison HR, Costin M, Meder JB, et al. Cervical Chlamydia trachomatis infection in university women: relationship to history, contraception, ectopy, and cervicitis. Am J Obstet Gynecol 1985; 153:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/95\">",
"      Moscicki AB, Winkler B, Irwin CE Jr, Schachter J. Differences in biologic maturation, sexual behavior, and sexually transmitted disease between adolescents with and without cervical intraepithelial neoplasia. J Pediatr 1989; 115:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/25/1434/abstract/96\">",
"      Shew ML, Fortenberry JD, Miles P, Amortegui AJ. Interval between menarche and first sexual intercourse, related to risk of human papillomavirus infection. J Pediatr 1994; 125:661.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5849 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1434=[""].join("\n");
var outline_f1_25_1434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22627003\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PUBERTAL CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sexual maturity rating (Tanner stages)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peak height velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relation between pubertal events and bone growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Weight changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physiology of pubertal maturation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Girls",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Boys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Body fat, leptin, and onset of puberty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Genetic contributors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Earlier onset of puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PERILS OF PUBERTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Psychological changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Gynecologic consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Myopia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Scoliosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sexually transmitted disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22627003\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5849\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5849|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/38/29283\" title=\"figure 1A\">",
"      Pubertal events girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/1/44048\" title=\"figure 1B\">",
"      Pubertal events boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4692\" title=\"figure 2A\">",
"      Height velocity in boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16387\" title=\"figure 2B\">",
"      Height velocity in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/46/44781\" title=\"figure 3\">",
"      Testicular volume and sexual maturity rating",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/24/19855\" title=\"figure 4\">",
"      Time of puberty onset",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5849|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/26/33187\" title=\"picture 1\">",
"      Sexual maturity rating of pubic hair in boys",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/43/10932\" title=\"picture 2A\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/33/30227\" title=\"picture 2B\">",
"      Sexual maturity rating of pubic hair in girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5849|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/1/8220\" title=\"table 1\">",
"      Sexual maturity rating of secondary sexual characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/28/13772\" title=\"table 2\">",
"      Rate iron deficiency anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9866?source=related_link\">",
"      Adolescent sexuality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33770?source=related_link\">",
"      Clinical features; evaluation; and diagnosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2170?source=related_link\">",
"      Congenital gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=related_link\">",
"      Definition and evaluation of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22424?source=related_link\">",
"      Diagnosis and treatment of delayed puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17529?source=related_link\">",
"      Management of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23302?source=related_link\">",
"      Normal adrenarche",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=related_link\">",
"      Ovarian development and failure (menopause) in normal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/58/31650?source=related_link\">",
"      Patient information: Early puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/31/13810?source=related_link\">",
"      Patient information: Late puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21481?source=related_link\">",
"      Premature adrenarche",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_25_1435="Indications bariatric surgery";
var content_f1_25_1435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for surgical management of severe obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Obesity Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        BMI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Exceptions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        &gt;35",
"       </td>",
"       <td>",
"        With comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;III",
"       </td>",
"       <td>",
"        &gt;40.0",
"       </td>",
"       <td>",
"        Regardless of comorbidities",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vivian Sanchez, MD, and Edward Mun, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1435=[""].join("\n");
var outline_f1_25_1435=null;
var title_f1_25_1436="Norton scale for predicting pressure sore risk";
var content_f1_25_1436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Norton scale for predicting pressure sore risk*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physical condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mental condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Activity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mobility",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incontinent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 = Good",
"       </td>",
"       <td>",
"        4 = Alert",
"       </td>",
"       <td>",
"        4 = Ambulant",
"       </td>",
"       <td>",
"        4 = Full",
"       </td>",
"       <td>",
"        4 = Not",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3 = Fair",
"       </td>",
"       <td>",
"        3 = Apathetic",
"       </td>",
"       <td>",
"        3 = Walk/help",
"       </td>",
"       <td>",
"        3 = Slightly limited",
"       </td>",
"       <td>",
"        3 = Occasional",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 = Poor",
"       </td>",
"       <td>",
"        2 = Confused",
"       </td>",
"       <td>",
"        2 = Chairbound",
"       </td>",
"       <td>",
"        2 = Very limited",
"       </td>",
"       <td>",
"        2 = Usually/urine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 = Very bad",
"       </td>",
"       <td>",
"        1 = Stupor",
"       </td>",
"       <td>",
"        1 = Bed",
"       </td>",
"       <td>",
"        1 = Immobile",
"       </td>",
"       <td>",
"        1 = Doubly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Score:",
"        </strong>",
"        __________",
"       </td>",
"       <td>",
"        <strong>",
"         Score:",
"        </strong>",
"        __________",
"       </td>",
"       <td>",
"        <strong>",
"         Score:",
"        </strong>",
"        __________",
"       </td>",
"       <td>",
"        <strong>",
"         Score:",
"        </strong>",
"        __________",
"       </td>",
"       <td>",
"        <strong>",
"         Score:",
"        </strong>",
"        __________",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Calculated as the sum of the scores in all five areas. A score less than 14 indicates a high risk of pressure ulcer development.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Norton D, Decubitus 1989; 2:24.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1436=[""].join("\n");
var outline_f1_25_1436=null;
var title_f1_25_1437="Child abuse neglect resources B";
var content_f1_25_1437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Child abuse and neglect resources (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Military Family Resource Center (MFRC)",
"       </td>",
"       <td rowspan=\"2\">",
"        The MFRC, funded by the Department of Defense, collects, reviews, processes, and disseminates information on the military family lifestyle and quality of life issues of military members and their families. Program areas include family advocacy (child and spouse abuse), family support, relocation services, child and youth programs, and activities which affect force readiness and quality of life.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1745 Jefferson Davis Hwy",
"        <br/>",
"        CS4, Suite 302, Room 309",
"        <br/>",
"        Arlington, VA 22202-3424",
"        <br/>",
"        (703) 602-4964",
"        <br/>",
"        <a href=\"file://www.militaryhomefront.dod.mil\" target=\"_blank\">",
"         www.militaryhomefront.dod.mil",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        National Children's Advocacy Center (NCAC)",
"       </td>",
"       <td rowspan=\"2\">",
"        The NCAC provides prevention, intervention, and treatment services to physically and sexually abused children and their families within a child-focused team approach. The NCAC also provides education and training to support the development of Children's Advocacy Centers across the country.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 Westside Sq., Suite 700",
"        <br/>",
"        Huntsville, AL 35801",
"        <br/>",
"        (256) 533-0531",
"        <br/>",
"        <a href=\"file://www.nationalcac.org/\" target=\"_blank\">",
"         www.nationalcac.org/",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        National Data Archive on Child Abuse and Neglect (NDACAN)",
"       </td>",
"       <td rowspan=\"2\">",
"        The mission of NDACAN is to facilitate the secondary analysis of research data relevant to the study of child abuse and neglect. By making data available to a larger number of researchers, NDACAN seeks to provide a relatively inexpensive and scientifically productive means for researchers to explore important issues in the child maltreatment field.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family Life Development Center",
"        <br/>",
"        Beebe Hall - FLDC",
"        <br/>",
"        Cornell University",
"        <br/>",
"        Ithaca, NY 14853-4401",
"        <br/>",
"        (607) 255-7799",
"        <br/>",
"        <a href=\"file://www.ndacan.cornell.edu\" target=\"_blank\">",
"         www.ndacan.cornell.edu",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        National Indian Child Welfare Association (NICWA)",
"       </td>",
"       <td rowspan=\"2\">",
"        The NICWA is the only Native American organization focused specifically on issues of child abuse and neglect and Tribal capacity to prevent and respond effectively to these problems. NICWA sponsors a national conference; provides publications and information packets and technical assistance; and maintains a library for information on child welfare and child abuse and neglect that is culturally relevant and useful to the American Indian population.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5100 SW Macadam Ave., Suite 300",
"        <br/>",
"        Portland, OR 97201",
"        <br/>",
"        (503) 222-4044",
"        <br/>",
"        <a href=\"file://www.nicwa.org\" target=\"_blank\">",
"         www.nicwa.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Prevent Child Abuse America",
"       </td>",
"       <td rowspan=\"2\">",
"        Prevent Child Abuse America promotes healthy parenting and community involvement as effective strategies for preventing all forms of child abuse. The organization's nationwide network of chapters and local affiliates work to implement direct service programs in hundreds of communities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 S. Michigan Ave., 17th Floor",
"        <br/>",
"        Chicago, IL 60604-2404",
"        <br/>",
"        (800) CHILDREN",
"        <br/>",
"        (312) 663-3520",
"        <br/>",
"        <a href=\"file://www.preventchildabuse.org\" target=\"_blank\">",
"         www.preventchildabuse.org",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Selected National Organizations Concerned with Child Maltreatment Resource Listing. National Clearinghouse on Child Abuse and Neglect Information (www.calib.com/nccanch/pubs/reslist/rl_dsp.cfm?subjID=10).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1437=[""].join("\n");
var outline_f1_25_1437=null;
var title_f1_25_1438="Weight loss and FBG in NIDDM";
var content_f1_25_1438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F78027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F78027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Initial fasting blood glucose concentration determines degree of weight loss required to achieve normoglycemia in type 2 diabetes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 217px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glycemic response to weight reduction according to initial fasting blood glucose (in mmol/L) in type 2 diabetes. Patients who had mildly elevated fasting blood glucose concentrations of 6 to 8 mmol/L (108 to 144 mg/dL) initially had to lose 10 kg (16 percent of initial body weight) to achieve a value below 6 mmol/L (&lt;108 mg/dL). Greater degrees of weight loss were required in patients with higher initial values, rising to 26 kg and 41 percent, respectively, in patients with an initial value above 14 mmol/L (&gt;252 mg/dL).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group.&nbsp;Metabolism 1990; 39:905.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1438=[""].join("\n");
var outline_f1_25_1438=null;
var title_f1_25_1439="Angiogram showing postpartum hemorrhage";
var content_f1_25_1439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right hypogastric angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 226px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADiAPgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzKikpaAClP0pBQehoCwE8+pra8JeH7jxLrMWn2uFB+aSQjKomcEk9utZNtC9xMkMQy8jBFHua+iPh94Vj8MaRzh725RTMSPu8Z2g/ln6VcIc25jWqcqsi/p+j22k6VHplgZPs0fzCQ9WJ7/WtC3x9nPnKdoG5R3zTrlcAjnnvUcV0ZGJZeV710pJK1jibbe5Pu8xQHGecinREB/kAV9uD78mm2zCQlyMhcj9KSSMK/Bw3XIosILe6UeYNuMHn3qCedJZ41dWHJIY9B2qGeKT7YBHyCMnP0rlNb1O7PiKxsHAhtmJ3uD3wcfrS07AdZLNAI5QrIFHEjMwC4+tUtJmW5imkjmhlVT83kuHGO3IrkvG9+2j232fTJ/OlmTZJGeeSB0PTrWP4dF/4avtPsmbM2oL86yHITp6cd6Vwsz0bUZ0dGtoWImdfmHoPf9as28KRWW932qFwBTNM0wxRSNM5a443Mf4vpUt+qxaeylS2TwDVCLlkwWFtv3SKbGx80yZOMYqHzRbRDdgcZxVaS4Edm891IIUQ5+uf/wBdAy9c3O2OQ9Sg3H+dVdNuXuozOq7S3OD71Rs9Yh1MiC2iYg9ZcEZH410VpbIiLhQBgcD6UIB1n5qsCxGO1XkduQeaaqLtAApw4biqSAl3GMAgYqQHeN3eoCWPXkVNFwgNOwxyMA2D1qwo6EVWBG7OKmBB6VLQFwn5QOPyqD7jlvzqRTlRmmTDjPapsMoiL7Lcsg+4/wAwJqxM2xQQadInnQ4H3hyKr8uoVuo6imgCJQeVoqWIYX0oqkSz4rpaSlrhPUCgDPbr0o//AF1Y0+1N7fQ264BkbH09aN9BSdlc9C+Dvh0XV8+sXceYbf8A498k/M/cn2HNexvctJlgxzjOCapeG9Oh0/Rba0gCiKJew6nv+pNVdZt5ty3FnIyzLxs9R2/kK64x5UedOfO7mpcynyFI5Zjio7U7B82CD1rL0K8N47xyEefGcMM9K1GXO3HTPOKdyC2vlpEdhAUcYpqsinD9T3qvcqGmTJxGOop0rRshKDGOlFwIWnaO4JyODjmsDZF4i1a8Ty1EEZ8pnYkYIxyMe4rbvNiRtKxwF5JrG0W385JpYnwjyM2R35NIZleINDjtbNYbRUI8wAu5yRgHoaz/ABdMSNO1NsLd2b7PK67h/kV0PilXitllhAzGd4zWPpeljWPEQ1SZ0EIAzGeQWpNAdpomt22rxebbOgdmwYz1FJ4jvltNNLsy5EiKB681h3/hu1M8lxbGSzvC2Ukj+6D3Ncn4ovtYtraCK/jae2imWQyrnJAIobaGejRSNKyG5jJJ5ANcv411ixjv7TS9QDmIt5j7eM8HA6/SqeleP9MeYG5MkIXkBiOwrzrxTqza/wCKHmi3NGzKic59BSchwi5anu3he4t76132MSw2qDEYxjODjJ/WukRHHv8ASsrwnp6WGgWMG3DBPm49STW7GwVema0jsSKnC81PEFxzVUv1z0qP7bGp27v1piNLaucAU7AAxWHNr0ELBTIFJ68jkVW0/wAU22oX32e13uwOOMHFHMM6RI9zcU6aCRRkZq9p8I2BpB89XXQEdOKylVszVU21cxYWYAbgatjDrjFOvYR5e5eDUNs+Mg8007q5DVnYY+I3HNQyJhzIg4NW54d5BqGV1jTaapMCpNcLGNxPFFZGqSZYr0GKKpMhs+Su9FHvR2PoK4T1ROtb/hu1liv7K824UvhAe/Uf41m6Pp8up6lb2cSkmZwhx6dz+Ar1/WPDkMFrHFaZBtox5ZzwD3/rWkIdTmxFS3unU2mprAixNhCx6Mf5VpSjzFVoW6HdnueK4Dw/f22sI0VzIVu7bH3zgnBxjiu4ifbAmxvn2jk8iujdHJaxnyWCWWofboGKPLkOo6GteI8KM5VhksKo6rM32aR0UM4wKlsA5jX5cKp5FIRZKgt1JFVZHaNiVTOKt5Dgsh+71oKuFPBpgZck3n21ykkfBU/L61LoGxtItAsJi2ggjPfOKmmgLEsTjdT7aJIEEafdGe/vmlYZm+KYbie1e0iVCzfICf51V8Jx/wBm+Zpd4B50CD5+zf8A163JYwQHYknPeqV5YNPC0loxF0GyM9+vFOwFy+ZfKI4AyME/rVELHIgidBIOmCOAK5d/FEmoMsMSA3DsQwx93p/9eqGt+Ll0zSykbj7e5ZRxnHFJtISTk7I5z4nT2QvVtrWONZUw7bO/t+lQ/CvRm1TxPA5QmCAFyccZxj+tc1FHeaxqPyK8txK3OB0Fe/fDXw+NE0tUABmfJcj3rGK5pXOmT9lHl6nbRR5LFvYAfhU8cQB5PHpTUBABanplsmum1tDnM3VJ1hQ8gCvNdb8RNbu62sbyNnHeu/1a1Z255GegrlX0pVkdlVevXrUyTER+FdNuNU1C2udZQpAmCNvfp1616loui2GmRyTWcCozZOQOa5Xw6xuYREDgIwyB36V6IiDyQoGBiom7FwVznhezx32xU+UnrXS27F4wT3FU2toywJGTVyAbQABxUTaa0NaN7lfUjtt3I6gVm2L7lU561qamN1q4rFsgyAD0q6esSaqtI0Zmwp54rntYnmA3RLnHWtuTcwzUC26tuWQcHpVpEHJPeLep6TKcEUVb1TSBFcl4BtY0U0Zs+UMcUg9+3NA60YGc1xHrPTU7T4aSQ2F/LqV9GRAqmNJFGcORjp9CK67UfFdosUkaS7hL8oLfKV59vpWN8P8AxZZabpqadfKYwH3MXOA2cc813FzZaTqlwk72kckKruWRACCNvr+Nbx0R51Vu+pxOl6Q08t/NZzKLmICXcOrLjPWu/wDDV4upabbyKQZFRUl9mAwf1BrzmzmsPDnjBnUMum3AYDzMDac/liumtri4s9fiu4Gt30y9bhlOeW565x61cSGrHW3UStZMwzvJ5qSyuyLYKq4IGSaoX8ab2l8h47lgMqBjdWgFLQBkXySY8Fs9aoRZtc7pAADG3JPvSzOQ5QEnniq0UhkAAZgicHPenDZJJlQ2B0IoAScTMQiuAKgBMUuGbJ6VefZ0PX1rM1G9tbXLXMyQxL829u9AFuWRkCghsE1na9qP9k2b3cjvHGpHI9arWevWepGRrORnEJCcDGffH4VxfxKmt/7V0lrli1sy7ph/L+tS3YaV9jK0vVY7zxK1xDutIpRuDerDJI/UVyGqXDXN/NMW35YjJ7Vd8S6suq6gxtoxDbAEJF2PPX61j84wMdKwlNNnZSpcr5me5eBPDthp2lW1xCY5rqYljJtGR2x+lelWUQjVcYHHavPvhkn/ABSmmho8kliGJ6DJ/wAK9Ith8o3eldMLJHG003cssmVHOabGCOBTgcDio7iaO2hluJ+I4kMjEnsAT/Sq8xpX2HzxB4yCOvFcFPC1pfyRb2MZbPP1rh/BHx+tvFXibTtGbw5c2c15KIg6XqyqD3JBRSB19fxrr/GK6hBcpLGP3ZPIXrUKalsOdNw3Om0GAW8uUP3iCa9BjwYlPtXm/hO+trshBKu4DkOwyDXaM95bWDfZ41ncDcvvU1FdFU3qafeh5VgQs5wK4eDxFr7OwuNIaI9BlGwferkS3t/Mst620Dny8cCpUGx8/LsdBLcef0+4arRR/PSRnoMVcjUH2rS3KiG+Z3YKnFV5Gw/vVx/ljOaq20ZlkLn7tJPqFh3kJIQXAP4UVbCjNFQ5A0fC+fSrOnWk19fQW9sm6V2wPT8arDpU1ndT2c4ntZNkoBGfbH0rFNHoSUmnYv8AiaCeC/EdyIt4QDEZ4xUmk+ItR01FijmJtwOUODxnPWo9M06/1y7cRBpnUZZmPAz7/jRq2gX+lkG7gwrNtWQHgn0p67oy93l5JvU0NS8SwX1tKktkrysNquxI2jPsazdP1u9sVWNH3RR8qjchT6g9a7jwn8P/ADbMXmuQhlcArGrkHB6dMVS8e+F7PTNPS40u2ZWMgUnczYXac5yT6CrtJq5kpUk+VGhoHjSfWr+ygvZI4miyNw43njj+dentboXRc5Cknr1r5kjd433oSpznI7V754M1m31fS7ef7TiVVCurZzuxVU530ZFamoO6OglyjAAYXv701W8qZSknysvTHQ1V1G/trMS+fcRhkXIHJyPWuci8T2pvPKjmMq4yDjpWl0YnYMwOPNID9yPSuP1H7BqmoynUHjFnGSF3NgMR16fQ0kniB2M8UI8w7TkgdOK8zvLbVrsyx25maFcyEZxjuf50pSsNK7s2aPjXVNNhuoo/D37tlzveMnDjHHWuRuJZbpw8zPI2OD1NMiUNMqEhcuAc9ga9LvND0yxsYvsEQLg5ZmyevfrWNnM6m40NLXOO8MeHbrX7h0hQrDHhnbIGPpWp8RtKtdInsILQf8sdzEnk5JH9K2/Ajw6ZpNxO0pRlflfU4rA8f3p1jWJLq1Uvb26CNmHQHJP9aaSUfMzVRzne56b4AdrTwrYLPkFSQM+hY16Pat+5XkYx2ry7wTfRaj4ZtVlLCZX2gD0BBr0iwb9wozwBjmtovQyluzUUZXiud+INw1n4B8T3JODFpd0y/wC95Tbf1xW/E/FcF8fbo23wf8TyhgD5McePXfMiEfkxP4U5O0WVT1kj5m/ZqthcfGTQ2ZcpAtxK3tiBwv8A48Vr7G1a0t7qLaV+btXyv+yTaCb4jahO4GLfTJGUn+8ZIlH6Fvyr6xeM78jpWdFaGuJfvJHN2mgQ21+t1au0cn8QB4Nd1ZXe2BVchjWVFFnqBV9EQKAMVq433OdNrYtSzGTPv3qugx259aFlAPIqQN6ChK2xV7j4eOTU6HnNRRkMeKnSE9TxUSfcFrsOJ3DBFPVQo44FMTBPBzU+OBWbKjG4lFPK8dKKlMpxZ8I1veDtGj1rUmhnkKIiFsAdeCf6Vg1b0rd9ti2ymEA8yD+EdzURsddVe7dPU7W5ttR8A3AvbZ1ktZ15Tpt9M1QvNQ1nxNcWkptphamQfOpJXIP5V0Wk6fq/i6Xch22K/uTOw6gAEkfnXoejeHYNF0pLC2LmJSXJI6setbqJ5/Mnq1qZOn69FAXsdQBEgwkcgxggDgfkKkuNZ0/ypobhoXDqMq+MDitg2plcxmFWjAzk5yD+dVp9Kt7dY91oshdvv454q0I5bxB4U0XUfDETadHaQXe7cGjC5b8hXNfD3w1eXMD3MdwqozfdK9CvOevvXpF54biv0fyz5TFTgjqv0rmfhjZT6V/adpchljEoCE8dM7sfpU8tmPmewzU/Blzq8kUguhHIPkfg4Pf196IvA9pZhRJcea4JJwO2PrXoDx7AW9BkVnahbvJauYyVYoQCOvpVWQihpNhYRwH7PAACOWwMnmp7yIJGYoIRlxsJC9jUWilLaIW7biwPzMfU8/1rWmUl0RV4I5JpiPn/AMY6XJo+v3EL8qWJU9OvIrpPBl3NeWzFsSG3wrK/O5at/FGzWO6kll+Z2T5fbGBWL8NvKGpzm5cLCI+ckAZ4rH4WbN+0p3e6Kfiy5Nvq91DaqFgk5Cr2OT/jXW+DtLht9Auhdqu10O4sO4Xr+tcPO7ah4id4gHRXJXaONoOc10mq6i06LpWl5lM6kSnrsB4NMiV1FQW5Y+GLZW9jCkbJdygHp0/pXtGkvutU4IPPX615P4e0uTRYRIjkMc7z2P1969N0ORmtoy20llzkfWtI7EuScjo4h8o9a8j/AGpbs23wnljzhbq/ggOO5w8n/tM165buFClwGXuD3r5P/aa8V+JptVfwpr1lpsOnQXAvrO4tYpUa4jKsqMd8jDgMwIA4YHnFTVlZWNqEbyv2Nn9jqyD3fiu9I5ijtoQf98yH/wBp19PQkL1Ga+Tf2W9R8SQajfWmkWWm/wBiSSRyajf3scjGMKDhI9sigu2Tgc+p4FfUMl/ukYIgUHkYJOPxNFF6DxC969zSmmjiXOQKzpdQEjKqYyTiuU8e662mWINttlkb5ev3fevP/DWt6hqniNEluAsSRs52H0BNW5WMFqe4C9jLbSQGHHWtGCQSoAp5NeS6TNcS3/mu8gyxyD3r0jQSxCE9ad9ATudNbQhFycZpt7PsjOzr0qtNdtuaNV5AqOANL8z9ayUdbs059LIr6TeMdQlglB55Un8a3lGa5fUCbTULa4H3QwVvoa6eJwyhhjBGaVVWehVJj93FFMPSioLcj4SrsvhpHbS395Hd2bXSyQlQF6jKt0rja9M+Ba7tevCCoxFwcZxw1TBXZvW+E7z4dvJaabcabeW32crMzwqw5KHGM+/WurJYk4+6f0p7WqswkPzSY+8wwajfKHFdVjzhIYWWYuh47g025cbl3djnHahJQJdoY5qLUGITHHzHjPTp3pjGW91vckqAg4z71lW8cUymWAqdzkgg5zUOn6dqloGl1a4ie2kABSLPyse/Qeh707w7aQwmWO08wWynKlzn+vsKncC7Fei6doAQJk+VkJHWmXU0i7RHjA4/Wn/YLRpzMkQEhcOzr1qSa3Gw/Nt7gUCMm/uYo40UACeRwSAOw/8A1VrJMhEZcNtPrWXJbob/AMxgHZBkce3/ANetDyojED90AZPHQ0w9DgfjMsa6faTRkGR5dmO+3aT/AEFecLBPZaMZGBVbogDBwcd/6V3HiiO48QXkilR5Fu52sx6gHFVdX0h/EWpJZac5jgtYcZPQnj0rKauawmoqzIPh7of27TdQvBlphhU7Z4OcY/CpPh3bor6hPNtFykm0K55xj0rQ8IWmt6Nb3CWc8EixS5mhPUeoGR7VoLp+k+IZZHtWfStT+6wTjJ9eCPWmtCXJOTbNTSyZftttJGSrIXU44zjp+ldX4aw2nQMowACMevJrgPsfirRFdbW5iv4pPru54xyP61LpHje90qzS31DQ5TDExBkQjJJJJ649aq5mlY9WWZVIB+U+lcX8WPANj8RNBt7SadLK+tZQ9veMm4opx5iEDqCo6cfMq8jmsWf4q6QqsRa3pPZSq8H/AL6rldU+KOozSEWkZihzxvIyfrilKUWrM3hGafNFHpGk6bo/hjTrTQ9IiENjaqWKjlpH4zI57sfX6AYAAE3/AAkFmbUXAlPkHjhTn8uteMjxlfzTs7vslfgyZ4FW9Q8U21sIBYx+ainJTgKSKSmloiZRqN3aJ/iX4iW+ureGzkdEVCXG3GSSfUewqh4E1EWQuVVN8swaPJByuRjisXxFdm/vRdNEsKyjIUHIA/KoNIW6a4H2NysgGeD/AErNy1NnTTppdT2TR7pLYxRySqz4yTjvXf8AhbU1mlQZ+UDHFeEaFNc3GowWkszNOxPbGODXr3he1/s5drNufv8AWt46nLsd23FzI/RSMUml3XnJJ6KSKLaU3VswIwadZWot42C9zmhlIra6iy2Ew53bSV9jWpoc4uNLgkHJK4NQSxK+4EZyMc1BoD+VPc2eMKh3J9D/APqqZrQuD1NvNFJ0FFZobZ8KCvSPgnJbx6vfi7eRVaIBfL65w1ebivVvgBG8utaiFYDEQ6j2aog9TrrfCehajfXNhEGsJ5LhcZKSQEnr0BzVWbxHewoJZbC42kcgwnaPeute0uGz5d20eB1VQcfmKyL1dXjV1hulnkIxiZVx+gFdVjzzl38ZWcNxuuIXjUjkjOPyxXRabfwavbC7s3EkeNxA6r/hXOfbbmwm8vUtIhWUEkyxAurA9sAn1pINK0jUJpLmBprK+YE7on2/MfVWBwKNQOgv7rybViFLyN92PqSaXQ1htrJbYShp0Rd4XGA2OlcD9s8Q2erQQ3F7BLI5CRs+3aPXpjnpXWaBLZ6XbRW+pTRxXGSz4lDbuB1/WlcLI6PCKpC9DzUU8O/jnAGagfUNPLfuLqOVcZyO1VbnxDplnGwuJz5nZFHPtTArs8NlPdyXMjRqIg4LdCNwGBXOnWH16/Wz0xnMKn9465NVdZvL3xTqMEEMDR2BO0M/GSMn+ddVpNjaeG443T5TINjYIO447UrgZHiww+G/DTGIKJJmwvPLNzUGi2L3GiRRKjrJcclyOV74qn41sH1i5tY4oJWLzZj3HheDz/Kur0m6ma3hsJJVhv7dQoDrwccZoFa5FqmjadelvNVsD5TKq9R3zXnzeGbW919ItOy1tDKC8rEEScivRNVsr67uBZQzJbxkbnMa849859+lc1rdzF4RWDaf3jAtlSHx9cfSk0F2jVvIv7K1G0W1kcxP8zQuc4A5z+npWreXVvFbyz3QZbJQGJXsT/8ArrlrXxRYLaQyzvLc3E5KFUXBUEY6EZpdf1eLS/CLWxjuHubvhDsJwN3fj0Bo9A66nl3ia/i1HWJpINog3kRHH8NZHWrt9YPaQRyOcCQ8Aqen+RVRFLnAIBxxk4rmne56NJpR0GnoM+tPUS+U7IG255qxb6fcTTiNUx/tdRWwmg3xtyqybY8FjuGM/nTUXYmdaEXqzF08W7XQS6O2Mjhh2Oa7vwtosNqVvY7ngkr65FcHLZzxvsMbHBxlRkV1HheymS6C/bGjz8wIHH45FXBW3RhXcXqpHYNaWlnIsyovyneGAwSTx/Wuw8LzC7ZAOBnJrgJNSjuL2K0lkL4IBcKea9J8LWAhCSIxO4AjitkjnXkdvpieXlfarpzvOKq2gwMmrigE55oehSHbfl6ZNUXjMOpRXIACYKGtNVBNRX8Ia1kGOikis73dmWk1qh7XCbOCDRXnsutPayMty4jC/wB70orSMEZubZ8u16X8Dbq4ttX1A20LSs0QBCkDs3rXmYr0z4H6amo6rqKyTywhIlOY22k/ermgtT0K3wnsa396I2ZbZ1wMYyp5rPbVLtnb7TYMAP4twH8jUj6dBC5SPVNRXHJWORuP/HqqXmnxZJuL3UriP+6zE/1rrbPPKVx4u0zTnka+TcQOgXdisdNWg8W3QitEXT0HzFwm13Xp2+orSlvNEs45LSDTWlmPJ8yFdwB6nNZXh/U9Iu/EF1EuLdo08pHwOcED+lTqAzxB4TWHQpfs5nluITuWTzDuOc5PWt3RdG0i8sYLqG0EpcDLySOxz7ZNM17xEukWcrKj3EMZAkfsBWL4V1m203w3f3dteM0KzM4tnbtjjv8AWldLcDq7iDTtOh814Iol3YwB1zxXMwaK2t6o99MMR5CKu0AEfh9aqxXtx4t1a2umjZNNib5h7jn/AAr0a3KRwLtCKqjO0ccVT1AxXsUtLcIiKscRyvGPx/U1HJatf3EEk2fJiO9QO/GKtzh9TuyoysEQxkdG7/1q7BblIAgGMCi1hGapW4vXlfCCMBUGO44q3LYpOWkkCiY5xIowcelUribybgxSoAjZwffNDXcsE8hZS0IwBj1oApXKahZqzyTs5HyiUAdPU96wNd0xJBBcarKJbZ90KBerOehzx6ivRIStxa7XXKt61wPiK2DXK2kjbY7eZbhVb6//AGNIDDtPDcSa1bWtvNsuowZSzDgoMkD9DWx4i1C2vtJWOWBF2NtD5PBGaXTdRsJJZLnUZrcSZMauMblXHT9TWfqsVrqlla2+m3O+VrogAHPy85NJaA7tHJ+IHbVPs9lbwqHgTOR1z/k1zy6bOLowzqEYHOWPX8q9mg0C00xiIyr3AUM2Rn60aroVtqsGVhjjuByGVQDnHSpcL6lwqSirHEWaw6eiy3Nq204w+48frS6pqSX/ANlS2aSQZOY1JGRxwasnSrjz2t7y4k+QfKrZwf1pdO019GvkutgEQI3BhwRRZmb3uyWC1gl1iC1WykhZowxUtkHk+9T6kttpSyRrHt3qTgDp1/wqzLcSDUobsoDFOogV+yAk8/8Aj1XtS043cDAqsjJyCBnI61VmI5bwTcLcXbCVEbexCbgM56/yBr2zw8pWFDjbgY4FeceHfDMMGpQ3KqykPuKgdDjFeo2HyqFAwBTjoUjbjbIGKso+CKz4XxxVgE1VrjNONs0tyR5LemKpRSEEZpLyaR4mWOsuR3LUtLHAeMLCC5SRWzhh1zyKK3pdHNw4adjj0oreKJsfI1epfAeFZtU1TeeFiU/+hV5b2r1v9nmMSaprAP8AzwX+T1xQ3O6r8J6r9ojUupUKAOprnb3xja2ly1vBukuDwqKCSf0rqNT00zRbY2AzgEGobTQbCAo7W8bSjneRzXVY885yzfV9RaVZEe2gkX+IEN79a1IvD1hBbRAQ/Mighh645z+Nb0iKARj6dq5zxbrMei6b5u9Wlb5UjPOTijYdji/idK0FjDpljKvnXsmJE6nAGen41wl54FvrTUFtbmVFVk8zfx2/Gu88PeG9Rv8AUR4g1lkQHmOOQjgeuKwviDpV59uS7F+fskrFFG/oAeePxFZyRcZuOz/Ab4U8aR2mmf2NLAGYylVkQE9cDdx9K9KtHk1gBIFYWyjaX7t6/wA64j4daDb3lxLdRwr9iSUBZG6kYGf516vaRRWyBIkCKvHHeqgiZO5NY2UUFqEjAEYH60JgsyZ6VLJII02djyBUNmmS7Hv0q7COd8WaYbiETwu26E7yO2Kg0aSC601tQWeNYx98M46/SuqubUMGxyrDDA9xXGap4NhRllsDOqA7mhWTANIDXgvIhbrLE26N+jdv881zviySF73TLp9kkE2LaQqw6FuCf++jVxbq3eI2hU27jhUYECm2NpYubjTrmE+YwzGXJIB7Ec0hW1OW8f8AhzTbXSmubaNo3dlUBeRjIyf1rl9K05vD+vQ3EqsVQblOeoYYz+td7q120sX9lahbEnDIJP4SMZHOa5+KOG01ONNSJeKBdm48ghhwPw3D8qlpBdo7K18i8UXcaOX28E+hqa7SYW7fZwGZOcGsazuZ7Aj7NEXtRxyM5X2rodFnS68x0IPX5emBmqC9xtstvqVtGlwyfaduChODSXWjrJEFhU8DDZ61cvtMSXDxDyZQRh14+tXbbduO8gsDimBwN34VV7gxXUkiIVOzHQN2q3Yz/wBkN5cjF4hyWI/z6V215am4tZBGMyYJGezY4qnb6NHJCouIwCfvA9KLAQ6NeQTqZYSDnnGPwrcgmlLYC9e+KWz063gUeXGg4x8vpWhFHheQOOmKYx9uhxk9atjgVGv3acc4xTBEqknpTgKiXIFP5oKDHr0ooFFCEfFHavYf2chnVNZ/64p/7PXj3avX/wBnM/8AE01rBw3kpj3+/XHDc7qukT2yU4NVDgMQ7D86s3CrCpknZUTqS/GK868TazceIL86F4XkEkhGZbiM/dA5I/lXU3ocBe8V+NrLSS1npyNeaieFRQCFPvzWFoXh3UtVlfWfEaF5mO+GDnAPXpXR+EvDWmaEX8kJcahgGeRhznv6108huGB2AqSM57YxSSbG2cukL67HF58jwQ9XRTjafTiuC8RafB4l8Z2em2hlS2Xc0o3cDkZ7+1epSxfYbIrbqPPnJyemTXKeFNHji17ULgEC5iCquWxnJbP8qGriOksNHt7G1jt7JTDCg6D+L3qWWK8iLurB0ABIIqxDdIrosvBOAee9SXDsdpiJIPamtAGxSefbDact3J7Vct02oqjrXK3d1e2GqxNahDbyRnzFYcDr+vFdHpl+l3p0UqY3HOQPqadxFxn6g1FFt3kEjPvSCXMi5XIbpUUbFLh1lXqeDQBT1vSrbUF/fJuYD7wGKwJbdrS7R5sELwrjtzXZSDJAqnc2kc8bRTJuRxjFIDnb+2XUIjbnbJIB5ikdf88Vyh05btXeQB42baQw5BXj+ldTqUb6JGZImYZG2MdNzHov8qt29glxpSJMNsjffwOck5P6GgLHL2Vze2y/ZZLVniHyqVHVavQwtbTCbTnKbvvIx61YuLK/00oLedrm1jb5U2YcL1OTk1pRrbXpjljjCuDg+uaLBYfa3MkpVLhdjHqfWpLSdzdz288eGUKysPfP+FXTbKY/mGSD260WWmx28skqSSSeYFG5+emf8adgLKZ2cD8aVFL8HIq0igDFSJGp5oGRRp5a4zU0ZNLtweRxUioOo6U0gFVuKlAzUewCpE6U7DQtGeacozQEFAxFopcDPPWilcR8UCu9+Euk3mp396LLUGsPLRCzAgZHzeo9q4GvRfgrHb3Wv3VncSMhmiONpIJwGJ6Vxw+I7q3wm54osL1V+zRatqGqzuQPKXlR25IFdf8ADzQLvQ9HKtbpFcyksz5GcE9Pyrr9N0i2slItlCZ6sRljx6mrqRgNnb+p4rq5TguVrC1it0JSNVdzljjrU05AAUZyewGanIG3OeRWJrSyyLmCVkdTxtxn9arZCHJua+MrKuyPiMD17/0rE1u1mhdbmyQNID84UckZrY063+xwKhbc+0bmPU1O67eRx7ikByFxq9lezQLeyS2JhKtlhgkg5546cVrNrlosqCBzdRbwhkiBOCcf4irlzZWM25rm2SQkBRnOcfhXneombw545is9NG61nCytAuCSOh6/7tS9APS5TDNaSNMFwMk54p2lW8UdmpRdqkZA+tYU11a6jcwQ2ztFORmSGQEHaD0/lXUQlQqgYAAC4/Kq3Afs5x/D2qG4HK55OcZNXFwTgVBcplcjsc0WGSOhyOOlQSAquSCasQTLNGNpBPQ0kyjBLHao6luKAOX1RW1LXILB1CxRxfaVwOS4zjn/AICK1fKDkYG3jlew7Vi+KbiKZrX+xnM2ppKo+TO1UJ5J7dM1ZbVrjTLrZq0KNbcDzoicKT3IwP8AJpAT3No7FT0xnkGqNhGVdyy4G8kEd+TW1eTpJYO9s4lj2blZDkHvWPoeoRTxRJdFIpCMKGI5ppgbtv8AMDng5ogZYnCEAKOBjvTo1wORzUcsJYkg1QjRGCOMZpyEdqzrG5zlJBhhwPer0TKehqQLBwRilUYFM/GpUqkMBTgeaaxFJk0xkmfSlGc0xT60uaVguBAMm45zRSZyaKSQHxV2rofh9qf9jeMtJuycRi4RJP8AcZgG/QmueoHUZ6Dj864k7HpSV0faW9GCuhyrAMp9QRn+tNdgFNcx8NdTOteCdOunI82MGB8eq9P0Iro5FxnnOa607o82SsylNdyq+2NMioY45DKWl6HkCrxjCgGmN3xVElZ16sDn2oKs6Ain7SWx2qRRsHWgCCeFDGxJxxXnvi3Rprj7brVi7/bbORSpB/hUA/1Neh3bBYHeQ4VRnrWXpwMqEKAqsxJJ75GKloDAs7yPUdBTxNfBFlCFQwHIIJUV1OiXYv8ASbO7jKP5sYOQPTg/qDXm8Ntcw6tqHh4O32aSbzlDDhgwBOPxJr1HSraPT7KG2hAEcKbR+eT+poQF6I7cZp0hQehz2qAsz9BzUsVuTy5q9xmfJpzvNut5ZrcH+4SKo3ekGa7Ec97eTQheUeViM/ia6OZvKj461Xhhxlm5Lc5pcoFLT9Ot7GFfs0Koe7bRmp5rWGaGSOaNHVxghlzmrfHTtTWUgFhkUWA890y2fSdZ1Sw8+X7MVElvHk4AIXI/U1FLpscFzHdgGZVmJ2v/AAZJ5rpNdVYriO5KZHAbPvT4o1VD5Z+VienSpsI1LRhLCHU7g38XY1YRfSsm2kaJSEBwD0rSgnDLzwadwK18vlyK6D61YhkGBnNNlKs2CalRNw6UwLKEEcVIGqqCVqVX+XpVIZNnnmnbvSo1G7mpNo9KBibjQCc0d6F4PNADlORRSiigVj4qoPf9fajFBHUevWvPPUPW/gJ4i+y6hc6LO48q5JljX0fAB/RRXuW0g4bIOe/avkDQtSl0jV7O/hbDQSK3HUgHkfiK+tNL1OHWNIttSsjmGdcrkY5HDfkQa6KUtLHDWhZ3JiC1Js9Rin7WHNB+ZSDW7RiRkY6c1HKQAxBzim3EgQYzg+tQT3KW8EktxkKo4x3pCKWrbpnhtFyTIQW9hn/9dW5UjgtfLUDYOnrVLTmPmSXVwCZJD8o9FrSaHzkHp2pDON8XyR6X4n0LU2XMRRoDx1JV8frXW6a73EKNJwM5X3GawPGkYnn0WJ1DRi53MCOgwwrdiT7HcMjZ8ksdntSQNGzGAvamyzhDx8x9KhVsxrgnFTLGvBOKtARMjyHc5qwoyoHaiRhjA60ik4wKYxcAcVHK6hTzTwhJyaY0Q70mJmH4ghNxYuhyNwxmovDcQGnJHIxZo8J9ccVf1jcIgoHFVdPhMDBs/KwzUiND7OFckZNP8sAcjk1KpBQ5o2ZHBosBUkhyciprcvj5qkyF4NOU4FMY2RiAadG42jIprsCDipIh93iqQ7FlBhMilBzSL6Uq9aAsBwDzTSPSnN1peAKQCLRRniigD4qXleaU9KKK4D0xQBk8dj/KvpD4FMz/AA+t1YllEsmATkD5zRRWlLc5sRsd+Pu1BPxjFFFdbOMzbknzF571i6qS9xArHcueh5HWiikI3UUeY3A/KrsQGwfWiigDnvE4G2L/AHl/9CrXvAPsqnAziiigQqf6uL6VcP3KKKZS3FiAz0qZQN1FFBZJgbTUMn3TRRQQzM1LpSQAeQnHYUUUhFtANgqZO1FFMCvN/racvSiigGNNWoPuiiigksAcU0gegoooKW4rAelA6UUUFDT1ooopMfU//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right hypogastric angiogram on a 34-year-old woman with postpartum hemorrhage shows an area of extravasation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_25_1439=[""].join("\n");
var outline_f1_25_1439=null;
           